Consequences of Aryl Hydrocarbon Receptor Activation in Crohn\u27s Disease by Benson, Jenna Marie
University of Montana 
ScholarWorks at University of Montana 
Graduate Student Theses, Dissertations, & 
Professional Papers Graduate School 
2012 
Consequences of Aryl Hydrocarbon Receptor Activation in Crohn's 
Disease 
Jenna Marie Benson 
The University of Montana 
Follow this and additional works at: https://scholarworks.umt.edu/etd 
Let us know how access to this document benefits you. 
Recommended Citation 
Benson, Jenna Marie, "Consequences of Aryl Hydrocarbon Receptor Activation in Crohn's Disease" (2012). 
Graduate Student Theses, Dissertations, & Professional Papers. 234. 
https://scholarworks.umt.edu/etd/234 
This Dissertation is brought to you for free and open access by the Graduate School at ScholarWorks at University of 
Montana. It has been accepted for inclusion in Graduate Student Theses, Dissertations, & Professional Papers by an 
authorized administrator of ScholarWorks at University of Montana. For more information, please contact 
scholarworks@mso.umt.edu. 
i 
 
CONSEQUENCES OF ARYL HYDROCARBON RECEPTOR ACTIVATION  
IN CROHN’S DISEASE 
 
By 
 
Jenna M. Benson 
 
Bachelor of Arts in Chemistry and Biochemistry, University of Minnesota, Morris, 2007 
 
 
Dissertation 
 
Presented in partial fulfillment of the requirements 
 for the degree of 
 
Doctor of Philosophy 
 in Toxicology 
 
University of Montana 
Missoula, MT 
 
Fall 2011 
 
Approved by: 
 
Sandy Ross, Associate Dean of the Graduate School 
Graduate School 
 
Dr. David M. Shepherd, Chair 
Department of Biomedical and Pharmaceutical Sciences 
 
Dr. Howard Beall 
Department of Biomedical and Pharmaceutical Sciences 
 
Dr. Curtis Noonan 
Department of Biomedical and Pharmaceutical Sciences 
 
Dr. Keith Parker 
Department of Biomedical and Pharmaceutical Sciences 
 
Dr. Scott Wetzel 
Department of Biological Sciences 
 
Dr. Dori Germolec 
External Committee Member 
National Institute of Environmental Health Sciences 
ii 
 
Benson, Jenna M., Ph.D., Fall 2011      Toxicology 
 
 
 
CONSEQUENCES OF ARYL HYDROCARBON RECEPTOR ACTIVATION  
IN CROHN’S DISEASE 
 
 
Chairperson:  Dr. David M. Shepherd 
 
 
Activation of the aryl hydrocarbon (AhR), a ligand-activated transcription factor 
present in many immune cells, can trigger immunosuppressive responses through the 
generation of regulatory cells. Several AhR ligands exist in the diet including 
environmental contaminants, such as its prototypical ligand 2,3,7,8-tetrachlorodibenzo-p-
dioxin (TCDD), and natural sources, such as indole-3-carbinol (I3C) and indirubin. 
Crohn’s disease, a chronic inflammatory state of the gastrointestinal tract, affects millions 
worldwide; however, the exact cause is unknown and treatments do not cure the disease.  
The role of the AhR in mucosal immune responses is not well understood to date so we 
aimed to understand the consequences of AhR activation in gut inflammatory responses. 
The overall hypothesis of this project is that AhR agonists found in the diet have the 
potential to dampen inflammation associated with Crohn’s disease.  The first goal of this 
project was to examine the role of AhR activation in the development and progression of 
colitis using TCDD and the natural ligand I3C. TCDD suppressed TNBS-induced colitis, 
as demonstrated by the decreased disease severity and dampened inflammation in the gut. 
TCDD-treated mice exhibited decreased inflammatory mediator production and increased 
frequency of regulatory cells, both Foxp3+ Tregs and dendritic cells (DCs) in gut 
immune tissues.  In comparison, I3C suppressed disease severity in females but not 
males. Sex-specific effects on colonic cytokine production and gene expression were 
observed. The second goal of this project was to define the cellular mechanisms by which 
AhR ligands elicit their effects on important immune cell populations present in the gut. 
Therefore, we investigated the immunomodulatory effects of the dietary AhR ligands I3C 
and indirubin in bone marrow derived DCs (BMDCs). I3C- and indirubin-treated 
BMDCs upregulated the expression of immunoregulatory genes, such as ALDH1A, IDO, 
and TGFβ, and also drove the generation of Foxp3+ Tregs. Following LPS stimulation, 
I3C- and IO-treated BMDCs suppressed the LPS-induced production of TNF-α, IL-1β, 
IL-6 and IL-12. Anti-inflammatory effects were also observed in intestinal epithelial cells 
(IECs) treated with AhR ligands. Thus, I3C and indirubin possess immunosuppressive 
and anti-inflammatory effects in BMDCs and IECs. Taken together, our data demonstrate 
that the AhR is a therapeutic target that warrants further investigation, as natural AhR 
ligands may effectively prevent the onset of chronic inflammatory diseases or more 
effectively induce and maintain remission when combined with conventional medicine.   
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CHAPTER 1:  INTRODUCTION 
 
 This study describes the effects of aryl hydrocarbon receptor (AhR) activation on 
the initiation and progression of inflammation associated with Crohn’s disease.  The 
introductory chapter will:  1) describe the basic functions of the immune system with a 
focus on the gut mucosal immune system 2) provide information regarding the role of the 
AhR and its numerous ligands in immune responses 3) explain the immune dysregulation 
contributing to Crohn’s disease and 4) describe the potential role of dietary AhR ligands 
to modulate intestinal inflammation. 
 
Immune system 
Overview:  functions and components  
The immune system is a complex network of tissues, cells, and soluble mediators 
that work together to effectively protect the body against infection and disease.  There are 
four primary functions of immune responses:  proper recognition of infection, 
containment of infection, self-regulation to inactivate the robust protective response, and 
protection from recurring disease due to the same pathogen.  Successful immune 
responses typically involve both the innate and adaptive branches of the immune system.  
Innate responses occur within hours of pathogenic invasions via non-specific recognition 
of non-self molecules while the adaptive responses take days due to the recognition 
specificity of foreign antigens, which are substances capable of activating the immune 
system. Several factors contribute to the effectiveness of these immune responses 
including genetics, stress, diet, age, and medications among many others. 
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All cells involved in these immune responses arise from hematopoietic stem cells 
in the bone marrow and further differentiate into various populations of leukocytes.  
Innate cells, including neutrophils, macrophages, and dendritic cells (DCs), are the first 
responders to initiate immune and inflammatory responses.  T cells and B cells are the 
lymphocytes responsible for mounting antigen-specific adaptive immune responses.  
These leukocytes produce and secrete soluble mediators (such as cytokines, chemokines, 
antibodies, and cytotoxic granules) that influence surrounding cells and thus the ensuing 
immune response.  A more detailed discussion is provided below regarding two critical 
immune cell populations, DCs and T cells, and their specific roles in immunity and 
inflammation. 
 
Antigen presenting cells (APCs) 
APCs are essential to properly mounting innate and initiating adaptive immune 
responses that effectively fight infectious agents.  Although DCs, macrophages, and B 
cells all function as APCs, DCs are the professional APCs.  DCs are unique in that they 
are involved in the induction of both protective and regulatory responses, especially in 
the gut.  As shown in Figure 1.1, the life cycle of DCs involves antigen capture in the 
periphery, migration to lymph nodes, and presentation to T cells, which results in 
lymphocyte activation necessary to trigger adaptive responses (Banchereau et al., 2000).  
During this process, DCs change from immature DCs in the periphery to mature DCs in 
the lymphoid tissue.  Consequently, alterations in cell surface phenotype and functions of 
DCs also occur (Figure 1.2).   
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Figure 1.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1.  Life cycle of dendritic cells (DCs).  Immature DCs survey the periphery for 
foreign antigens that have penetrated mechanical barriers and entered tissues. Upon 
recognition, DCs take up antigen, process it, migrate to lymphoid organs, and present 
antigen to lymphocytes, which results in their activation.  Activated lymphocytes then 
return to the site of infection to clear it from the body (Banchereau et al., 2000). 
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 Figure 1.2 
 
 
 
 
 
Figure 1.2.  Stages of DC maturation.  Following antigen uptake, immature DCs 
undergo a maturation process to activated DCs, which results in several 
immunophenotypic and function changes. 
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Immature DCs are particularly efficient at antigen uptake but have poor abilities to 
migrate to lymph nodes and activate T cells.   Conversely, activated DCs do not take up 
antigen but are very effective T cell activators.  
Successful antigen processing and presentation by DCs first begins with proper 
uptake of antigens via receptor-mediated phagocytosis or macropinocytosis.  The 
recognition of pathogen associated molecular patterns (PAMPs) occurs through pattern 
recognition receptors (PRRs), such as Toll-like receptors (TLRs) and scavenger 
receptors, which are expressed on the surface of DCs.  The antigen is then internalized, 
processed, and displayed on the cell surface via major histocompatibility complexes 
(MHC). Finally, to successfully activate T cells, three signals are required between the 
APC and T cell (Figure 1.3).  Signal 1 is an activation signal involving the MHC:peptide 
complex with the T cell receptor (TCR) complex.  Signal 2 is a co-stimulatory signal 
between the B7 molecules on DCs with CD28 or CTLA4 on T cells.  Signal 3 involves 
cytokines and other secreted molecules that act as a differentiation signal.  However, if 
one of these signals is missing, T cells are not effectively activated. When T cells only 
receive signal 1 they become unresponsive (anergic), which allows for peripheral 
tolerance induction.  These unresponsive cells are particularly important in avoiding 
autoimmune responses to tissue-specific antigens. Furthermore, when signal 2 is received 
in the absence of an antigen, no effects occur on T cells. 
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Figure 1.3 
 
 
 
Figure 
1.3.   
 
 
 
 
 
 
Figure 1.3. Three signal hypothesis of T cell activation.  To effectively activate T cells 
APCs, such as DCs, deliver three signals including (1) binding of the MHC2:peptide 
complex to the TCR, (2) costimulation, and (3) cytokines (adapted from Cools et al., 
2007). 
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T cells  
 T cells are important adaptive immune cells that function to kill pathogens as well 
as to activate and regulate other cells in the body.  The two broad classes of T cells 
include CD4+ helper T cells (Th cells), which can activate APCs and B cells that 
ultimately produce antibodies, and CD8+ cytotoxic T cells (CTLs), which kill tumor cells 
or virus-infected cells. Following multiple signals from APCs, naïve T cells can 
differentiate into a variety of effector or regulatory cells (Figure 1.4).  In particular, naïve 
CD4+ T cells can become Th1, Th2, Th17, Th22, or regulatory T cells (Tregs), which 
each have distinct roles in the ensuing immune response. Each effector cell type is 
characterized by the cytokine profile that leads to differentiation of that subtype and the 
primary cytokines produced.  Th1, Th17, and Th22 cells are known for their roles in 
inflammatory and autoimmune responses whereas Th2 cells are best recognized for their 
involvement in allergic responses. Tregs are vital to regulating immune responses by 
suppressing effector cell proliferation and secretion of anti-inflammatory cytokines. 
Finally, since these are adaptive cells, memory cells are generated in the course of the 
immune response.  These memory T cells will rapidly differentiate into effector cells 
upon subsequent exposure to the same antigen.  
The balance of effector and Tregs is necessary to maintain homeostasis within the 
immune system. Defects leading to robust effector cell responses and/or weak regulatory 
cell responses contribute to the immune dysregulation found in numerous chronic 
inflammatory diseases, such as inflammatory bowel disease. 
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Figure 1.4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4.  Characterization of CD4+ T cell populations.  Upon activation, naïve 
CD4+ T cells (Th0) can differentiate into several subtypes based on cytokine production 
and function in immune responses.  Transcription factors necessary for each population is 
shown below the cell, and function is listed on the right (adapted from Jetten, 2009).
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 Inflammation 
 One of the essential steps in combating infection is inflammation.  Innate cells, 
such as the first responding neutrophils and macrophages, trigger the recruitment of other 
cells to the site of infection by releasing pro-inflammatory cytokines and chemokines 
(secreted mediators that direct cellular trafficking) through signaling cascades that 
activate transcription factors, such as nuclear factor kappa B (NF-kB). Furthermore, 
several acute response proteins are produced including C-reactive protein (CRP), serum 
amyloid A (SAA), cyclooxygenase (COX), and nitric oxide (NO). The local 
accumulation of cells and soluble mediators causes redness, swelling, heat, and pain, 
which are the hallmark clinical signs of an inflammation.  Later in the response, effectors 
of the adaptive branch, such as effector T cells and antibodies, contribute to the 
containment and clearance of infection.  
Inflammation is generally a beneficial immune response when it is localized and 
tightly regulated. Acute inflammation leads to resolution, healing, and priming of the 
adaptive responses. Signaling cascades are eventually inactivated to ensure that the attack 
does not spread to nearby tissues. Chronic inflammation and systemic inflammation 
(sepsis), however, are damaging conditions that can lead to many diseases including 
cancer and potentially death.  Under chronic inflammatory conditions, transcription 
factors, such as NF-kB, remain activated thereby promoting the transcription of many 
pro-inflammatory cytokine genes, such as IL-6, IL-12, and TNF-α. Tissues are often 
damaged as constant activation of inflammatory pathways leads to granulomas, fibrotic 
scar tissue, fluid accumulation, and abscesses.  Thus, moderation is essential to reaping 
the benefits of the inflammatory immune response.   
10 
 
Gut mucosal immunity 
Exposure to a diverse and extensive range of antigens and unusual effector and 
regulatory responses makes the mucosal immune system distinctly different than the rest 
of the immune system.  It must properly distinguish between pathogens and innocuous 
antigens including food particles and commensal bacteria, which are essential for the 
clearance of toxins, xenobiotic metabolism, nutrient absorption, and prevention of 
pathogenic bacteria colonizing the gut.  The gut associated lymphoid tissues (GALT), 
which include the Peyer’s patches of the small intestine, isolated lymphoid follicles, and 
the intraepithelial lymphocytes (IELs), are responsible for mounting the appropriate 
immune response to this vast array of antigens. 
 
Unique features 
There are two primary compartments of the intestines:  the epithelium and the 
lamina propria (Figure 1.5).  The epithelium is the first line of defense in the gut, as the 
tight junctions and mucus produced by Goblet cells are critical to preventing transfer of  
luminal contents into the underlying tissue.  Microfold cells (M cells) are another type of 
specialized epithelial cells unique to the gut.  These cells are the route by which antigen 
enters the Peyer’s patch from the lumen. Most of the immune cells are found in the 
lamina propria, which acts as the interface between the epithelium and lymphoid tissue 
below and is where most immune cells are found in the intestines.  In fact, large numbers 
of effector cells reside in the gut tissue even in the absence of infection. Furthermore, 
plasma cells (highly differentiated B cells) in the lamina propria that receive a 
transforming growth factor-beta (TGF-β) switch factor signal produce copious amounts  
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Figure 1.5 
 
 
 
Figure 1.5.  Components of the intestinal immune system.   The epithelium and lamina 
propria are the two major compartments in the intestines that contribute to protective and 
tolerant immune responses. Intraepithelial lymphocytes, intestinal epithelial cells (IECs), 
DCs, M cells, Paneth cells (not shown), and goblet cells (not shown) are found in the 
epithelial layer lymphocytes, whereas DCs, macrophages, and other innate cells reside in 
the lamina propria.  Following antigen uptake, APCs travel to the mesenteric lymph 
nodes to generate an adaptive response that includes IgA production by plasma cells 
(Macpherson and Harris, 2004).   
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of immunoglobulin A (IgA), which is present as a dimer and the predominant antibody 
isotype produced in the gut. In the periphery, the IgG isotype dominates, and IgA is 
present as a monomer.  There are several functions of IgA at the epithelial surface:  
neutralizing pathogens in the mucus layer to prevent penetration, neutralizing antigens 
internalized in endosomes in the epithelial layer, and exporting pathogens from the 
lamina propria. 
 
Important cellular players of intestinal immune responses 
As with the peripheral immune system, APCs play a critical role in mounting 
appropriate mucosal immune responses.  In the gut, both the intestinal epithelial cells 
(IECs) and DCs play important roles in antigen recognition, processing, and presentation.  
These cell populations sample luminal contents via pattern recognition receptors (PRRs) 
expressed on their surfaces. IECs sample antigens directly whereas DCs sample the 
luminal contents by projecting extensions through the epithelial layer (“snorkeling”) or 
indirectly via antigen processed by IECs.  Both of these cell populations secrete 
mediators, such as IL-10 and TGF-β, that can influence surrounding cells and the ensuing 
immune response.  Upon antigen uptake, DCs travel to the mesenteric lymph nodes 
(MLNs) to trigger subsequent adaptive responses.  The activated T cells then home back 
to the gut primarily via expression of the surface marker α4β7, an integrin that mediates 
the migration of cells to the intestines and associated immune tissues. 
Based on the antigen sampled, DCs and IECs produce mediators to generate 
either protective immunity, which is similar to peripheral responses, or oral tolerance, 
which is an unresponsiveness to harmless food, commensal bacteria, or non-pathogenic 
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bacteria.  In the presence of pathogenic organisms, DCs become activated and express 
strong costimulatory ligands that drive the differentiation of naïve CD4 T cells into Th1, 
Th2, Th17, or Th22 cells.  Alternatively, in the presence of commensal bacteria, which 
lack the virulence factors necessary for penetrating the epithelium, immature DCs give 
weak costimulatory signals and induce Tregs.  Furthermore, in the absence of infection, 
IECs produce prostaglandin-E2 (PGE-2), TGF-β, and thymic stromal lipoprotein (TSLP) 
that inhibit DC maturation.  These regulatory DCs express CD103 on the cell surface and 
produce protective mediators, such as TGF-β and IL-10.  Therefore, the activation state 
of local DCs determines either protective immunity or tolerance, which is the default 
immune status of the gut.   
As previously mentioned, effector T cells are prevalent in the gut immune tissues, 
which is typically indicative of an inflammatory phenotype; however, regulatory cells 
play a prominent role in preventing potentially harmful responses by effector cells.  
Following exposure to oral antigens, several classes of Tregs are induced including 
thymic-derived Foxp3+ Tregs, mucosally-induced Foxp3+ Tregs, Tr1 cells, and Th3 cells 
(reviewed in Weiner et al., 2011). These different classes likely differ in antigen 
specificity, development, and mechanism of immune regulation. Interestingly, the 
frequency of these Treg populations changes along the gastrointestinal tract due to the 
nature of the different microenvironments, as the colon carries a significantly greater 
bacteria load than the small intestine where the primary function is nutrient absorption.  
Most IL-10 producing Tregs in the colon lamina propria are Foxp3+ Tregs while Foxp3- 
Tr1 cells are more prevalent in the small intestine (Maynard et al., 2007).  Although there 
are several classes of Tregs responding, in general the primary function of Tregs is to 
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induce/maintain tolerance and decrease inflammation in the gut. Therefore, perturbations 
in this regulatory state can lead to disease involving intestinal inflammation including 
inflammatory bowel diseases. 
 
Factors that alter mucosal immune responses 
 Several factors including age, stress, and medications can modulate immune 
responsiveness. Perhaps one of the most influential factors in the mucosal immune 
system is the diet since dietary compounds directly contact the tissues in the 
gastrointestinal tract. Numerous studies have identified dietary constituents that can 
either promote or suppress inflammation in the gut.  These compounds or their metabolite 
can act directly on cells and tissues to alter inflammatory mediator production or 
indirectly by altering the intestinal microbial communities. 
More specifically, intake of certain fats and carbohydrates drastically affects 
immune responses by promoting inflammation while intake of other nutrients suppresses 
inflammatory responses. For example, fatty diets promote inflammation in the intestine 
as well as in other peripheral tissues because they change the intestinal microflora such 
that Gram negative bacteria, which contain endotoxin, predominate instead of Gram 
positive bacteria (Cani et al., 2007).  This increased presence of lipopolysaccharide (LPS) 
in the gut is recognized by immune cells, such as DCs and IECs, which triggers 
inflammation not only in the gut but also in other tissues and contributes to the 
development of metabolic disease. Moreover, increased intake of linoleic acid, an omega-
6 fatty acid, alters the balance between omega-3 fatty acids and omega-6 fatty acids such 
that omega-6 fatty acids dominate and promote inflammation (Wall et al., 2009).  Finally, 
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refined carbohydrates, from which fiber and essential nutrients have been removed, have 
been shown to increase circulating levels of pro-inflammatory cytokines including IL-6 
and TNF-α (Esposito et al., 2002). 
In contrast, many dietary supplements including probiotics, fiber, fish oil, and 
vitamins have the potential to dampen inflammation in the gut.  Probiotics, or the 
beneficial bacteria found in many commercial food products, alter intestinal immune 
responses in several ways (extensively reviewed in Sanders, 2011).  They decrease 
pathogen binding, produce antibacterial substances, and decrease pro-inflammatory 
cytokine production.  Additionally, barrier integrity is improved with increased 
production of mucins and defensins.  When this “good” bacteria is recognized by DCs, 
they produce regulatory signals, such as IL-10, that drive the proliferation of Tregs, 
which ultimately promotes tolerance and suppresses gut inflammation.  Soluble fiber, 
also known as the prebiotic non-starch carbohydrate, is also anti-inflammatory in nature.  
Its main fermentation byproduct, butyrate, inhibits NF-kB signaling and therefore the 
production of pro-inflammatory cytokines (Segain et al., 2000; Luhrs et al., 2002). 
Omega-3 fatty acids, especially eicosapentaenoic acid (EPA) and docosahexaenoic acid 
(DHA), also inhibit the production of several inflammatory mediators including pro-
inflammatory cytokines and eicosanoids (Issa and Saeian, 2011).  Foods also contain 
many vitamins that can generate an immunoregulatory environment.  Vitamin A is 
metabolized into retinoic acid (RA) by CD103+ regulatory DCs in the gut.  In turn, RA 
can contribute to the differentiation of naïve T cells into Tregs while also inhibiting the 
generation of Th17 cells.  Vitamin D has also been shown to increase Foxp3+ regulatory 
T cells (Hardenberg et al., 2011). 
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Clearly there are several sensitive pathways critical to maintaining mucosal 
immune homeostasis, and the commensal bacteria play an important role in this process.  
It is essential to understand the factors that are necessary to maintain a properly 
functioning intestinal immune system.  A better understanding of these mechanisms will 
help us better understand intestinal immune disorders and how to effectively treat them. 
Aryl hydrocarbon receptor 
Many factors contribute to the immune responsiveness of cells.  The aryl 
hydrocarbon receptor (AhR) is a cytosolic, ligand-activated transcription factor that is a 
member of the basic helix-loop-helix/Per-Arnt-Sim (bHLH/PAS) protein family and 
binds a variety of natural and synthetic compounds.  The AhR is present and inducible in 
immune cells but is constitutively expressed in DCs.  Furthermore, AhR expression is 
dramatically increased in Th17 cells compared to other subsets of Th cells, such as Th1 
and Th2 cells (Veldhoen et al., 2008). 
As shown in Figure 1.6, the canonical pathway involves ligand binding to the 
AhR in the cytosol to activate the receptor.  Following binding, accessory proteins (hsp90 
and XAP2) dissociate and reveal the nuclear localization signal (nls) allowing the 
ligand:AhR complex to translocate into the nucleus.  There it complexes with the AhR 
nuclear translocator (ARNT), binds to dioxin response elements (DREs), and modulates 
transcription of several genes, including Phase I drug metabolizing enzymes, such as 
CYP1A1. AhR activation is believed to modulate immune and inflammatory responses 
via transcriptional regulation as there exist multiple (putative) DREs in the promoter 
regions of several cytokine genes, such as those implicated in Tregs (TGF- and IL-10), 
Th1 cells (IL-12), as well as Th17 cells (IL-21 and IL-23) (Kerkvliet, 2009).  A non- 
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Figure 1.6  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6. Canonical and non-canonical AhR signaling pathways. In the canonical 
AhR signaling pathway, a ligand diffuses into the cell and binds cytosolic AhR complex, 
which triggers dissociation of chaperone proteins. Upon entering the nucleus, the ligand-
bound AhR binds ARNT before binding DREs thereby triggering transcription of the 
AhR gene battery.  In the non-canonical signaling pathway, the ligand-bound AhR binds 
RelB in the nucleus thereby allowing binding to NF-kB response elements (adapted from 
Tian et al., 2002).  
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canonical AhR signaling pathway also exists, and involves binding of the ligand-bound 
AhR to the nuclear factor-B (NF-B) family member, RelB, which subsequently 
activates transcription of genes controlled by both the AhR and NF-B (Tian et al., 1999; 
Tian et al., 2002; Vogel and Matsumura, 2009). Therefore, both of these AhR signaling 
pathways have the potential to elicit immunomodulatory effects following AhR 
activation. 
 The prototypical ligand of the AhR is 2,3,7,8-tetrachlorodibenzo-p-dioxin 
(TCDD), a byproduct of various industrial processes. TCDD is the most popular chemical 
to study the effects of AhR activation because it is the highest affinity ligand for this 
receptor and is resistant to metabolism (Ward, 1985; Davila et al., 1995; Mann et al., 
1999).  Several adverse effects, including those on the immune system, are observed 
following exposure to TCDD. Studies show that AhR null animals do not experience the 
immunotoxic effects associated with administration of TCDD thereby indicating that the 
AhR is necessary to mediate the immunosuppressive effects of TCDD and many TCDD-
like chemicals. Since many immune cells express the AhR and many immune genes 
contain DREs (Kerkvliet, 2009), it is critical to understand how AhR activation can affect 
the function of the immune system.  
 
Effects of the AhR on inflammatory responsiveness 
Prior to discussing the role of the AhR in mediating the effects of various ligands, 
it must be acknowledged that, independent of exogenous ligands, the AhR plays an 
important role in controlling several physiological processes including inflammatory 
responses.  Recently, several studies have revealed that mice lacking the AhR are more 
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sensitive to inflammatory responses.  AhR null mice display increased sensitivity to LPS-
induced septic shock, which was primarily due to macrophage dysfunction (Sekine et al., 
2009).  Furthermore, these investigators found that LPS-stimulated bone marrow-derived 
macrophages secreted more pro-inflammatory cytokines than the wildtype AhR cells.  
Kimura and colleagues extended these results by demonstrating that AhR forms a 
complex with Stat1 and NF-kB in macrophages to ultimately inhibit IL-6 activity 
(Kimura et al., 2009).  Similar effects have been observed in disease models.  In murine 
models of inflammatory bowel diseases, several investigators have revealed that AhR 
deficiency results in a more severe disease phenotype (Arsenescu et al., 2011; Furumatsu 
et al., 2011; Monteleone et al., 2011).  These data suggest that the AhR plays an 
important role in regulating inflammation so intentional and targeted activation of the 
AhR may be a promising therapeutic approach for the treatment chronic inflammatory 
diseases, such as inflammatory bowel disease. 
 
Immunoregulatory effects of TCDD 
Although early reports suggested that TCDD exacerbates some inflammatory 
responses, more recent studies have defined cellular mechanisms for its potent 
immunosuppressive effects on both humoral and cell-mediated responses. TCDD affects 
humoral immunity by suppressing CD40L-activated B cell proliferation (Ito et al., 2002; 
Allan and Sherr, 2005).  T cells were initially believed to be the primary target of TCDD 
in the immune system due to thymic involution, which results in thymocyte loss, arrest of 
T cell proliferation, and premature emigration of T cell progenitors (Laiosa et al., 2003; 
Temchura et al., 2005; McMillan et al., 2007). In addition to suppressing CD4+ Th cell 
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differentiation, TCDD also enhances the development of Tregs, as it has been 
demonstrated that CD4+CD25+ Tregs producing suppressive cytokines are induced 
following TCDD exposure (Funatake et al., 2005; Marshall et al., 2008).  There are 
several mechanisms by which the AhR can influence the differentiation and expansion of 
Tregs: (1) the AhR can directly regulate Foxp3 expression due to the DREs present in the 
Foxp3 promoter (Hauben et al., 2008; Kimura et al., 2008; Quintana et al., 2008);   (2) 
the AhR signaling pathway can affect TGF-β production via cross-talk with the TGF-β 
signaling pathway (Guo et al., 2004; Santiago-Josefat et al., 2004; Gomez-Duran et al., 
2006; Thomae et al., 2006); and (Miller) cell-cell interactions and cytokine milieu 
produced by DCs drastically alter the fate of naïve Th cells (Thorstenson and Khoruts, 
2001; Akbari et al., 2002; Yamazaki et al., 2006; Bankoti et al., 2010a; Bankoti et al., 
2010b; Benson and Shepherd, 2011; Simones and Shepherd, 2011). In particular, AhR 
activation in DCs triggers the induction of IL-10, TGF-β, aldehyde dehydrogenase, and 
indoleamine-2,3-dioxygenase (IDO), an enzyme that catalyzes the essential amino acid 
tryptophan via the kynurenine pathway.  
 
Immunomodulatory effects of other AhR ligands 
Being a promiscuous orphan receptor, the AhR can bind a structurally diverse 
range of compounds including various environmental contaminants, endogenous 
compounds, dietary components, and therapeutic agents.  Many of these compounds act 
as AhR agonists and have been shown to alter immune responses (Table 1.1).  These 
ligands, however, do not typically bind the AhR as strongly as TCDD and are usually 
quickly metabolized, which can alter their effects on the immune system.  
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Table 1.1.  AhR ligands and their role in immunity
a 
 
 
a
A diverse range of compounds that bind the AhR and exert a variety of effects on 
immune cells to modulate immune responsiveness. 
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It has been suggested that by binding to the AhR in CD4+ T cells, tryptophan 
metabolites can elicit their immunosuppressive effects by inducing a Treg phenotype 
(Fallarino et al., 2002; Frumento et al., 2002; Terness et al., 2002; Belladonna et al., 
2006; Fallarino et al., 2006). One of the most studied metabolites is 6-formylindolo[3,2-
b]carbazole (FICZ) due to its potent AhR agonistic activity.  It has been suggested that 
AhR activation occurs in a ligand-specific manner as activation via TCDD results in Treg 
production while activation via FICZ results in the production of Th17 cells, which may 
be due to differences in the timing and duration of AhR activation (Ho and Steinman, 
2008).  Quintana and colleagues recently reported that prolonged activation of AhR via 
TCDD resulted in the production of suppressive Treg cells while brief AhR activation via 
FICZ generated inflammatory Th17 cells in a murine model of autoimmune encephalitis 
(Quintana et al., 2008; Veldhoen et al., 2008). It could be hypothesized that significant 
upregulation of the AhR in Th17 cells makes these cells more susceptible to endogenous 
AhR ligands that could subsequently mount immunosuppressive Treg responses to 
dampen the Th17-mediated responses. 
In contrast to exacerbating autoimmunity, FICZ was recently reported to suppress 
the severity of several models of murine colitis, which was partly dependent on IL-22 
(Monteleone et al., 2011).  FICZ-treated mice experienced decreased production of IFN-
γ, IL-17A, and TNF-α and increased IL-22 production. As previously mentioned, IL-22 is 
a cytokine produced by Th22 and Th17 cells in an AhR-dependent manner (Veldhoen et 
al., 2008; Trifari et al., 2009; Veldhoen et al., 2009).  This cytokine is often associated 
with autoimmunity since it promotes inflammation by acting synergistically with IL-17, 
INF-γ, and TNF-α. In the gut, however, IL-22 exhibits a protective role because it 
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induces antimicrobial peptides that help maintain mucosal barrier integrity.  Thus, the 
effects of IL-22 production induced by AhR activation seem to be dependent on the 
microenvironment of the inflammatory response. 
It must be emphasized that, to date, it is not well understood why some AhR 
ligands have the potential to promote the development of a Th17-mediated inflammatory 
response while others promote the development of a Treg-mediated suppressive response.  
Due to the critical role that these T cell populations play in the generation of immune and 
inflammatory responses in the gut mucosa, it is necessary to examine the effects of AhR 
activation in this compartment. 
 
Crohn’s disease  
Inflammatory bowel disease (IBD), comprised of Crohn's disease and ulcerative 
colitis, is a chronic inflammatory state of the gastrointestinal tract.  This disease typically 
affects young Caucasians aging from 15 to 35 years old that live in urbanized, developed 
countries (Head and Jurenka, 2004).  It is estimated that the average number of cases 
currently ranges from 100-200 cases per 100,000 individuals in North America, northern 
Europe, and the United Kingdom (Loftus et al., 1998; Bernstein et al., 1999; Loftus et al., 
2000; Loftus, 2004; Cho, 2008).  Unlike ulcerative colitis, Crohn’s disease affects all 
layers of the intestinal wall anywhere along the gastrointestinal tract, but especially in the 
ileum and colon.  Due to a severe inflammatory response, Crohn’s disease patients 
experience many unpleasant symptoms, such as frequent diarrhea, abdominal pain, and 
rectal bleeding.  Many painful and potentially life-threatening intestinal and 
extraintestinal complications can also affect patients.  Since the exact cause of Crohn’s 
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disease remains unknown, conventional treatments typically consist of a combination of 
corticosteroids and immunomodulatory agents, azathioprine and 6-mercaptopurine, to 
diminish flare-ups and induce remission.  In addition to these conventional therapies, 
many patients use various complementary and alternative therapies to enhance the effects 
of conventional therapies or reduce the side effects caused by conventional medicine. 
 
Intestinal immune dysregulation 
As previously described, epithelial and immune cells sample antigens in the lumen of the 
gut to induce a state of tolerance such that an immune response is not elicited towards 
commensal bacteria under homeostatic conditions.  There is a balanced differentiation of 
Th0 cells into effector cells (Th1, Th2, Th17, Th22) and regulatory cells (Tregs).  In 
Crohn’s disease, this state of oral tolerance appears to be disrupted, as demonstrated in 
Figure 1.7 (Sanchez-Munoz et al., 2008).  Several factors have been implicated in the 
pathogenesis of the disease, including a defective mucosal epithelium, imbalance 
between effector T cells and Tregs, oxidative stress, and the hygiene hypothesis, which 
suggests that lack of antigen exposure at a young age triggers the onset of Crohn’s 
disease (Head and Jurenka, 2004).  In the mucosal immune system, the epithelium is the 
first line of defense, and defects in this barrier have been implicated in the pathogenesis 
of Crohn’s disease (Baumgart and Dignass, 2002).  Moreover, altered innate immune 
mechanisms, including genetic polymorphisms associated with intracellular bacterial 
processing and autophagy, could also lead to an inappropriate immune response to 
commensal bacteria (Hugot et al., 2001; Ogura et al., 2001; Baumgart and Carding, 2007; 
Cho, 2008).  These environmental and genetic factors shift the balance between effector  
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Figure 1.7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7.  Immune dysregulation contributing to Crohn’s disease (CD) and 
ulcerative colitis (UC). In IBD, the balance between effector T cells and Tregs is 
disrupted.  Th1 and Th17 cells drive the immune dysregulation in CD whereas UC is a 
Th2-mediated response.  
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and regulatory cells such that Th1 inflammatory cells predominate over Tregs. Th1-
mediated immune responses are implicated in the development of colitis as Crohn’s 
disease patients show elevated levels of IL-12 (Monteleone et al., 1997; Parronchi et al., 
1997; Liu et al., 1999).  Furthermore, decreased levels of IL-10, a potent 
immunoregulatory cytokine, also play a role in this disease.  It should be noted that 
recently, Th17 cells, in addition to Th1 cells, have been implicated in the development of 
Crohn’s disease.  The differentiation, expansion, and stabilization of Th17 cells involves 
the cytokine IL-23, which numerous genome-wide association studies have linked to the 
development of Crohn’s (Abraham and Cho, 2008). Clearly the pathogenesis of Crohn’s 
disease is very complex as it involves a combination of genetic and environmental factors 
that alter multiple populations of innate and adaptive immune cells. 
 
Complementary therapies for Crohn’s disease management  
Numerous Crohn’s disease patients seek complementary therapies to alleviate 
symptoms of the disease not relieved by conventional medicine and/or to reduce the side 
effects from conventional medicines.  Many of these therapies include dietary 
supplements, such as omega-3-fatty acids and probiotics, which have the potential to alter 
inflammation.  Since AhR activation can result in suppression of Th1-mediated immune 
responses, dietary components that are AhR ligands would be expected to alter the 
inflammatory response associated with Crohn’s disease.  Cruciferous vegetables, such as 
broccoli, brussel sprouts, and cabbage, contain glucosinolates, which are sulfur-
containing compounds that possess chemoprotective effects (Hayes et al., 2008). The 
hydrolysis of glucobrassican forms indole-3-carbinol (I3C), which is sold as a 
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commercially available dietary supplement.  In the acidic environment of the stomach, 
I3C forms a condensation product, diindolomethane (DIM).  The oral consumption of 
I3C has been shown to induce Phase I and Phase II enzymes similar to TCDD (Higdon et 
al., 2007; Hayes et al., 2008).  Additionally, the beneficial effects of this supplement may 
also involve NF-kB as DIM has been shown to inhibit the activation of NF-B (Hayes et 
al., 2008).  Most recently, Kim and colleagues revealed that DIM decreased 
inflammatory damage and inflammatory mediator production induced by the dextran 
sodium sulfate model of colitis in Balb/c mice (Kim et al., 2009).  However, the cellular 
signaling events responsible for this effect were not examined.  In addition to dietary 
supplements, traditional Chinese medicines (TCMs) may also alter AhR signaling.  
Indirubin, a TCM used to treat chronic myelocytic leukemia and other inflammatory 
conditions, increased CD4+CD25+Foxp3+ T cells in indirubin-treated mice (Zhang et al., 
2007).  Collectively, these results suggest that common dietary constituents may 
modulate inflammation and immunity via activation of the AhR. 
 Since CD affects millions of Americans, it is important to study the mechanisms 
underlying this disease so that new and more effective therapeutics can be developed.  
Moreover, because AhR activation can effectively modulate both immune and 
inflammatory responsiveness, studying the effects of both synthetic and natural AhR 
ligands on the generation of Crohn’s disease is warranted. Therefore, the goal of the 
studies described in this dissertation is to elucidate the role of AhR activation by dietary 
supplements and TCM in the development and progression of inflammation associated 
with Crohn’s disease.  The results of this project will provide novel information about gut 
mucosal immunity.  
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Hypothesis and specific aims 
 
The goal of the proposed research is to elucidate the role of aryl 
hydrocarbon receptor activation (AhR) in the development and 
progression of inflammation associated with Crohn’s disease. 
This proposal is novel in that the role of AhR activation in 
mucosal immunity has not been investigated. Ultimately this 
research will lead to a better understanding of Crohn’s disease, 
how dietary factors can affect it, and potential therapeutic 
modalities that may be useful for humans. 
 
Crohn's disease, one of the conditions encompassing inflammatory bowel disease (IBD), 
is a chronic inflammatory disorder of the gastrointestinal tract typically affecting younger 
patients of European descent.  There is no known cause; however, it is suspected that the 
disease likely results from various genetic and environmental factors triggering an 
inappropriate immune response to normal gut bacteria. Currently, the most common 
therapies for Crohn’s disease include a combination of corticosteroids and 
immunomodulatory drugs.  Since these drugs are often accompanied by unpleasant and 
severe side effects, it is important to investigate the potential prophylactic and therapeutic 
effects of natural products since it has been suggested that dietary components can alter 
the inflammatory state of the gut. The AhR is a ligand-activated transcription factor most 
recognized for its involvement in the toxicity of the prototypical AhR ligand TCDD, an 
environmental contaminant that typically affects people through the diet.  Activation of 
the AhR by TCDD results in the regulation of transcription, an effect that is primarily 
mediated via Dioxin Response Elements (DREs) in the promotor/enhancer regions of 
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specific target genes, such as CYP1A1 (a xenobiotic metabolizing enzyme) and IL-2 (an 
important immune cytokine).  Moroever, TCDD is an extremely potent chemical that has 
recently been shown to suppress immune responses via the generation of regulatory T 
cells. In addition to TCDD, other potent dietary AhR ligands have the potential to 
modulate the immune system presumably via activation of the AhR and DRE-mediated 
gene regulation. Crohn’s disease patients often seek natural, complementary therapies in 
addition to the conventional therapeutics.  Importantly, some compounds present in 
dietary supplements are also potent AhR ligands. Therefore, the potential exists for these 
chemicals to alter the generation of immune responses and inflammation associated with 
Crohn’s disease. Common dietary supplements, such as indole-3-carbinol (I3C), a 
compound found in cruciferous vegetables, and tryptophan, an essential amino acid, can 
be potent natural AhR ligands.  Moreover, tryptophan and its metabolites, such as 6-
formylindolo[3,2-b]carbazole (FICZ), have been shown to have immunomodulatory 
effects following AhR activation. Furthermore, plants used in traditional Chinese 
medicine, such as indirubin, also have a critical role in influencing inflammatory 
responses.  We hypothesize that AhR agonists found in the diet have the potential to 
dampen inflammation associated with Crohn’s disease.  This central hypothesis will 
be tested by the following specific aims: 
 
Specific Aim 1: Examine the role of AhR activation in development and progression 
of inflammation associated with Crohn’s disease. 
 
Specific Aim 2: Investigate the cell-specific mechanism(s) by which dietary AhR 
ligands exert their effects inflammatory responses.   
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Specific Aim 1 
The purpose of these studies is to specifically investigate the role of AhR 
activation by various ligands during the inflammatory response associated with Crohn’s.  
Since the murine model of TNBS-induced colitis (described below) resembles human 
Crohn’s disease in the histological outcome as well as the cytokine profile, we will utilize 
this model.  The approach to this Specific Aim involves 3 key experiments.  To fully 
characterize the role of AhR activation in Crohn’s, we will first examine the readouts of 
inflammation using the prototypical AhR ligand, TCDD, in AhR
+/+
 mice.  Secondly, we 
will definitively show that the AhR is involved in this response by using AhR
-/- 
mice.  
Finally, we will then examine the effects of other dietary AhR ligands throughout the 
development of Crohn’s disease.  Overall, the results of Specific Aim 1 will define the 
immunomodulatory effects of TCDD and other dietary AhR ligands in mucosal 
immunity.  Chapters 2-4 describe the results of this Aim. 
 
Experimental approach:  murine colitis models 
Completion of Specific Aim 1 requires use of a murine model of Crohn’s disease. 
There exist many animal models to investigate the development, progression and 
maintenance of colitis (Bouma and Strober, 2003).  Although none of these animal 
models perfectly represent human Crohn’s disease, each model has its own advantages 
for studying various aspects of inflammation in the gut (Pizarro et al., 2003).  For 
example, the CD4+CD45RB
high
 SCID transfer model elicits a chronic Th1 transmural 
response and defines specific effector and regulatory cell populations while the IL-10 
knock out model elicits an acute Th1 transmural response and defines the role of pro-
31 
 
inflammatory and regulatory cytokines as well as specific cell populations in intestinal 
inflammation.  Perhaps the most commonly used animal model to study Crohn’s disease 
is the TNBS-induced model of colitis that was first described by Neurath and colleagues 
in 1995 (Neurath et al., 1995). This model shares similar immunological pathways as 
human Crohn’s disease and is useful for testing new potential therapeutic interventions 
(Pizarro et al., 2003).   More specifically, in this model the use of an ethanolic vehicle 
disrupts the mucosal barrier, allowing TNBS to haptenate colonic proteins and leading to 
a Th1-mediated immune response driven by IL-12 and other pro-inflammatory cytokines 
including TNF-, IL-6, IFN-, and IL-17 (Kawada et al., 2007).  Deficiencies in 
regulatory cytokines, including IL-10, and TGF-, have also been reported. Therefore, 
we have chosen the TNBS-induced model of colitis primarily because the innate immune 
response induced by this chemical most closely resembles the effects observed in people, 
which is useful for investigating potential prophylactic therapeutics. Furthermore, in the 
TNBS model, a sensitization step can be added such that T cells are primed and 
subsequently elicit a more potent T cell response upon a secondary exposure during the 
TNBS enema. Therefore, based on the potential for TCDD and other AhR ligands to 
modulate inflammatory and immune responses by altering the differentiation of T cells, 
the effects of AhR activation may be more pronounced in this model of colitis that 
involves greater contributions from T cells.   
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Specific Aim 2 
The toxicity of TCDD is primarily due to binding of ligand:AhR:ARNT complex 
to the DRE in the regulatory region of various target genes, including those involved in 
innate and adaptive immune responses. However, it has also been suggested that the 
effects of AhR activation may be due to DRE-independent events.  It has been reported 
that the ligand-bound AhR can interact with the Rel component of NF-B, which would 
allow for altered transcription of immune genes that are under the control of the DRE or 
NF-B. It is therefore important to evaluate the potential DRE-dependent and 
independent events leading to the immunosuppressive effects of various AhR ligands.  
The results obtained from this Specific Aim will provide data that will mechanistically 
define the role of AhR activation by various ligands in immunity and inflammation.  
Chapter 5 describes the results of this Aim. 
 
Experimental approach 
 For this Aim, murine BMDCs were generated from the bone marrow of AhR+/+ 
and AhR-/- mice (both on a C57Bl/6 background) using the growth factor GM-CSF in the 
presence of the DMSO vehicle or the AhR ligands, I3C and indirubin.  Serveral endpoints 
were evaluated in these studies including cell surface molecule expression via flow 
cytometry, cytokine production via ELISAs, and gene transcription via qRT-PCR.  The 
role of NF-kB was determined with the TransAM NF-kB colorimetric assay, and co-
cultures with naïve antigen-specific T cells were generated to evaluate the 
immuneregulatory potential of the ligand-treated DCs.   
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ABSTRACT 
Crohn's disease results from a combination of genetic and environmental factors 
that trigger an inappropriate immune response to commensal gut bacteria.  The aryl 
hydrocarbon receptor (AhR) is well known for its involvement in the toxicity of 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD), an environmental contaminant that affects people 
primarily through the diet. Recently, TCDD was shown to suppress immune responses by 
generating regulatory T cells (Tregs). We hypothesized that AhR activation dampens 
inflammation associated with Crohn’s disease. To test this hypothesis, we utilized the 
2,4,6-trinitrobenzenesulfonic acid (TNBS) murine model of colitis. Mice were gavaged 
with TCDD prior to colitis induction with TNBS. Several parameters were examined 
including colonic inflammation via histological and flow cytometric analyses. TCDD-
treated mice recovered body weight faster and experienced significantly less colonic 
damage. Reduced levels of IL-6, IL-12, IFN-γ, and TNF-α demonstrated suppression of 
inflammation in the gut following TCDD exposure. Foxp3
egfp
 mice revealed that TCDD 
increased the Foxp3+ Treg population in gut immune tissue following TNBS exposure.  
Collectively, these results suggest that activation of the AhR by TCDD decreases colonic 
inflammation in a murine model of colitis in part by generating regulatory immune cells. 
Ultimately, this work may lead to the development of more effective therapeutics for the 
treatment of Crohn’s disease.  
 
KEY WORDS 
 Aryl hydrocarbon receptor (AhR); 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD); Crohn’s 
disease; inflammation; regulatory T cells (Tregs) 
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INTRODUCTION 
Crohn’s disease, one of the conditions encompassed by inflammatory bowel 
disease, is a chronic inflammatory disease of the gastrointestinal tract that primarily 
affects younger European Americans (Head and Jurenka, 2004). The exact cause of 
Crohn’s disease remains unknown; however, it is suspected that both genetics and 
environmental factors contribute to an inappropriate immune response to commensal 
bacteria. Normally there exists a state of tolerance in the gut such that effector and 
regulatory cell differentiation is balanced and immune responses are not mounted against 
commensal bacteria or food substances. In Crohn’s disease, however, imbalanced 
differentiation of T effector cells (Teffs) and T regulatory cells (Tregs) results in Th1- 
and Th17-dominated inflammatory responses (Sanchez-Munoz et al., 2008). Since 
current medical treatment can be associated with severe side effects and life-threatening 
complications, it is essential to better understand this immune dysfunction so that novel 
and more effective therapeutics can be developed. 
The aryl hydrocarbon receptor (AhR) is a member of the bHLH/PAS protein 
family and acts as a cytosolic, ligand-activated transcription factor that binds a variety of 
synthetic and natural compounds. The AhR is perhaps most recognized in the immune 
system for its role in mediating the immunotoxic effects of the prototypical ligand 
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD).  Cannonical signaling involves ligand-
activated AhR interaction with dioxin response elements to modulate gene transcription. 
Many immune cells express the AhR and several cytokine genes possess dioxin response 
elements so AhR activation can significantly impact immune responses. Recently, it has 
been shown that the generation of CD4+CD25+ Tregs is the likely mechanism 
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responsible for the immunosuppressive effects following TCDD exposure (Funatake et 
al., 2005; Marshall et al., 2008). Moreover, AhR-deficient mice do not experience 
immunosuppression following exposure to TCDD and TCDD-like compounds, thus 
demonstrating that the effects of these chemicals are AhR-mediated.  
To examine the potential of new therapeutic agents to treat Crohn’s disease, the 
2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced mouse model resembles 
inflammatory responses in human Crohn’s disease so it is commonly used for this 
purpose (Neurath et al., 1995; Pizarro et al., 2003). In this model, TNBS binds colonic 
proteins to trigger a Th1-mediated response primarily driven by the pro-inflammatory 
cytokine IL-12 as well as a Th17-mediated response driven by IL-17. Excessive amounts 
of TNF- and IFN- along with deficiencies in the regulatory cytokines IL-10 and TGF- 
have also been observed (Kawada et al., 2007). Based on the potential for TCDD and 
other AhR ligands to modulate inflammatory and immune responses by altering the 
differentiation of T cells, the effects of AhR activation may be quite pronounced in this 
model of colitis involving Th1 and Th17 cells.  
Since Crohn’s disease affects millions of people worldwide, it is essential to 
investigate the underlying mechanisms of pathogenesis so that new and more effective 
therapeutics can be developed. Additionally, activation of the AhR modulates immune 
and inflammatory responses so studying the effects of AhR activation on the 
pathogenesis of Crohn’s disease is warranted. Therefore, we explored the effects of 
TCDD on the generation of TNBS-induced colitis in mice. We hypothesized that AhR 
activation reduces the inflammation generated in a murine model of Crohn’s disease by 
promoting an immunosuppressive environment in the gut. Collectively, our data 
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demonstrate for the first time that AhR activation by TCDD in the gut suppresses 
inflammation and generates regulatory cells in the TNBS model of colitis in mice. These 
results also provide novel information regarding gut mucosal immunity and suggest the 
AhR may be a potential therapeutic target for Crohn’s disease. 
 
MATERIALS AND METHODS 
Laboratory animals.  Six to eight week old male and female AhR
+/+
, AhR
-/-
, and 
Foxp3
egfp
 mice (all on the C57Bl/6 background) were bred and maintained in the animal 
research facility at the University of Montana. C57Bl/6 AhR
+/+ 
were originally obtained 
from The Jackson Laboratories (Bar Harbor, ME) and bred in-house. C57Bl/6 AhR
-/- 
(B6.AhR
tm1Bra
) mice were obtained from Dr. Paige Lawrence (University of Rochester 
Medical College, Rochester, NY) and bred as previously described (Schmidt and 
Bradfield, 1996). Foxp3
egfp 
mice were kindly provided by Dr. R. Noelle (Dartmouth 
Medical School, Lebanon, NH) who originally obtained these mice from Dr. A. 
Rudensky (University of Washington School of Medicine, Seattle, WA). All mice were 
housed under specific pathogen-free conditions and maintained on 12 h dark/light cycles. 
Throughout each experiment animals were individually caged, and standard laboratory 
food and water were provided ad libitum. All protocols for the use of animals were 
approved by the University of Montana Institutional Animal Care and Use Committee 
and adhered to the current NIH guidelines for animal usage. 
 
Chemicals for in vivo use.  2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) was obtained 
from Cambridge Isotope Laboratories Inc., (Woburn, MA), initially dissolved in anisole 
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(Sigma-Aldrich, St. Louis, MO), and further diluted in peanut oil, which was used as a 
vehicle control for gavages. 2,4,6-trinitrobenzenesulfonic acid (TNBS) was also obtained 
from Sigma-Aldrich and dissolved in acetone/olive oil for pre-sensitization or 40% 
ethanol for enema administration. 
 
Colitis induction.  As described in Figure 2.1, mice were gavaged on day -1 and day 6 
with 15 μg TCDD per kg body weight (~200-250 μl total volume) or a comparable 
volume of peanut oil vehicle control prior to pre-sensitization and colitis induction. Pre-
sensitization on day 0 involved an application of 150 μl 5% TNBS in a 4:1 acetone:olive 
oil solution between the shoulder blades such that mice were not orally exposed to 
TNBS. Colitis was then induced via an intrarectal injection with TNBS on day 7, as 
previously described with modifications (Wirtz et al., 2007). Briefly, mice were 
anesthetized with isoflurane and received an enema of 2.5 mg TNBS in 40% ethanol (50 
l total volume) via a 3.5 F catheter inserted 3 cm into the colon. To ensure distribution 
of TNBS in the colon, mice were held in a vertical position for 90 s before being returned 
to their cages. Body weight loss and the severity of clinical symptoms (overall body 
condition, stool consistency, and dehydration state via a skin pinch test) was monitored 
daily, as fully described in Table 2.1A. Briefly, the severity of each clinical sign was 
scored on a scale 0-3 and combined to determine the total severity score. On days 10-12, 
mice were euthanized via CO2 asphyxiation followed by cervical dislocation. 
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Figure 2.1 
 
 
 
 
 
 
 
 
Figure 2.1.  Experimental design. This schematic represents the experimental design 
utilized for the studies in which animals were gavaged with 15 μg/kg TCDD, peripherally 
sensitized with 5% TNBS, intrarectally injected with 2.5 mg TNBS, and subsequently 
harvested for evaluation. 
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Table 2.1. Scoring criteria for severity of clinical symptoms and microscopic damage 
  
A. Clinical severity  
Score I.  Stool Consistency II.  Dehydration III.  Body Condition 
0 Well-formed None Normal 
1 Semi-formed Mild Slower movements 
2 Loose Moderate 
Significant weight loss or 
abdominal distension 
3 Liquid  Severe 
Emaciated and very slow 
movements 
 
B.  Microscopic damage 
 
(A) Clinical severity in terms of stool consistency, dehydration, and overall body 
condition was documented during disease progression. Total severity score represents a 
combination of all three categories (I-III) such that clinical severity scores range from 0 
to 9. (B) Hematoxylin and eosin (H&E)-stained tissue sections were scored 
microscopically based on inflammatory cell infiltration and tissue lesions. The total 
damage score represents a combination of scores from both categories (I and II) such that 
damage scores range from 0 to 6. 
Score I.  Inflammatory Cell Infiltration II.  Tissue Lesions 
0 Normal Normal 
1 
Increased numbers of inflammatory 
cells in the lamina propria 
Surface epithelial degeneration and/or 
mucosal hyperplasia 
2 
Inflammatory cells extending into  
the submucosa 
Focal/multifocal ulcer and/or crypt loss 
3 Transmural extension of infiltrate 
Extensive mucosal damage and 
ulceration 
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Colon processing and histology. Colons were excised from each mouse and washed with 
PBS to remove debris. For histological analysis, a 1 cm section from the distal colon was 
fixed in 2% paraformaldehyde, processed in the Shandon Citadel 2000 Automated Tissue 
Processor (Thermo Fisher Scientific, Waltham, MA) with vacuum unit, embedded using 
the Shandon Histocentre 2 Embedding unit, sectioned at 7 μm using the Thermo Shandon 
Finesse 325 microtome, and stained with hematoxylin and eosin (H&E) in the Shandon 
Veristain 24-4 Slide Stainer. Colons were assessed microscopically by a blinded 
individual to determine the severity of inflammation based on the modified scale shown 
in Table 2.1B (Hartmann et al., 2000). Briefly, the extent of inflammatory cell infiltration 
and tissue lesions was scored on a scale 0-3 and combined to determine a total damage 
score. Slides were imaged using the Nikon E800 Microscope with Cambridge Research 
Instrumentation, Inc. and Nuance camera software version 1.62 at 4X magnification. The 
remaining colon was divided into two sections for cell isolation, as described below, and 
homogenization in lysis buffer from which the supernatants were analyzed for cytokine 
production using commercially available ELISA kits. 
 
Cytokine assays.  Supernatants from homogenized colon tissue were examined for the 
levels of IL-6, IL-10, IL-12, IL-17, IFN-γ, and TNF-α via enzyme-linked immunosorbent 
assay (ELISA).  Samples were analyzed according to the manufacturer’s instructions 
using mouse cytokine-specific BD OptEIA ELISA kits (BD Biosciences, San Diego, CA) 
or R&D ELISA kits (Minneapolis, MN). 
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Antibody production.  IgA production was assessed in the colon, feces, and serum. Five 
days after colitis induction, colons were harvested and homogenized in lysis buffer, and 
supernatants from tissue were collected. Fecal pellets were collected from the distal colon 
and homogenized in 0.01% NaN3 (1 μl 0.01% NaN3 per 1 mg feces), as previously 
described (Kato et al., 2001). Supernatants were collected for antibody production 
analysis. Finally, immediately after euthanization, a cardiac puncture was performed to 
collect serum. All samples were stored at -20°C until subsequent evaluation of antibody 
levels using a commercially available ELISA kit per the manufacturer’s instructions 
(SouthernBiotech, Birmingham, AL). 
 
qRT-PCR. RNA was isolated from colon tissue with Trizol reagent (Invitrogen, Carlsbad, 
CA) followed by RNA clean-up using the Total RNA Kit with optional DNase treatment 
(Omega Bio-Tek, Norcross, GA) according to the manufacturers’ instructions. First 
strand cDNA synthesis was performed using qScript cDNA Supermix (Quanta 
Biosciences, Gaithersburg, MD). Resulting cDNA was subjected to qRT-PCR using 
commercially obtained primers (SABiosciences, Frederick, MD) including aryl 
hydrocarbon receptor repressor (AhRR), aldehyde dehydrogenase family 1, subfamily A2 
(Aldh1a2), a proliferation-inducing ligand (APRIL), B cell activating factor (BAFF), 
cytochrome P450, family 1, subfamily a, polypeptide 1 (Cyp1a1), forkhead box P3 
(Foxp3), indoleamine-2,3-dioxygenase 1 (IDO1), indoleamine-2,3-dioxygenase 2 
(IDO2), interleukin 17A (IL17A), interleukin 17F (IL17F), RAR-related orphan receptor 
gamma (Rorc), transforming growth factor, beta 1 (Tgfb1), transforming growth factor, 
beta 2 (Tgfb2), and transforming growth factor, beta 3 (Tgfb3). Reactions were performed 
 49 
with PerfeCTa SYBR Green Supermix for iQ (Quanta Biosciences) on a Bio-Rad iQ™5 
Multicolor RT-PCR Detection System. Resulting data were normalized to -actin, and 
fold changes were calculated using the ∆∆Ct method, which compares threshold values 
of the samples of interest for a particular gene relative to a housekeeping gene. 
 
Preparation of cells from mesenteric lymph nodes (MLNs) and colon.  Mesenteric 
lymph nodes (MLNs) were removed, washed in media, homogenized using the end of a 
syringe plunger, and subsequently filtered through a 40 m nylon cell strainer, as 
previously described (Bankoti et al., 2010a). Lamina propria mononuclear cells were also 
isolated from the colon tissue, as previously described (Weigmann et al., 2007). Briefly, 
colons were excised and washed with PBS, digested with collagenase/DNase (Sigma-
Aldrich/Invitrogen), filtered, and subjected to Percoll (GE Healthcare, Pittsburg, PA) 
density centrifugation. Cells from both tissues were counted via Trypan blue exclusion on 
a hemacytometer, and 2x10
6
 cells were subsequently washed with buffer prior to cell 
staining. 
 
Flow cytometry.  Expression of accessory molecules on isolated cells was determined by 
flow cytometry, as previously described (Shepherd et al., 2001). Briefly, cells were 
washed with PAB (1% bovine serum albumin and 0.1% sodum azide in PBS). To 
eliminate non-specific staining, cells were blocked with 30 μg purified rat and/or hamster 
IgG (Jackson ImmunoResearch, West Grove, PA).  Optimal concentrations of 
fluorochrome-conjugated monoclonal antibodies were used to stain cells for an additional 
10 min.  Antibodies used in these experiments included CD4-AlexaFluor 700 (GK1.5), 
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CD25-PerCP/Cy5.5 (PC61), CTLA4-APC (UC10-4B9), GITR-PECy7 (YGITR), α4β7-
PE (DATK32), CD103-Pacific Blue (2E7), CD11c-PE (HL3), MHC2-PECy7 
(M5/114.15.2), CD86-APC (GL-1), and their corresponding isotype controls, all of which 
were purchased from BioLegend (San Diego, CA) or BD Biosciences (San Jose, CA). 
One to five hundred thousand events were collected using a BD FACSAria flow 
cytometer and analyzed using FACSDiva (Version 6.1.2, BD Biosciences, San Jose, CA) 
and FlowJo (Version 8.7.1, TreeStar, Inc., Ashland, OR) software programs. 
 
Immunohistochemistry. Using the embedded colon tissue prepared as described above, 5 
μm sections were mounted on slides and allowed to air dry prior to being deparaffinized 
and coverslipped using the ProLong Gold anti-fade reagent with DAPI mounting media 
(Invitrogen Molecular Probes). Slides were imaged at 40X magnification using the 
Olympus FluoView 1000 LSC on an inverted 1x81 microscope with spectral detection 
and TIRF module (Version 2.1b software with 405, 458, 488, 515, 559, and 635 laser 
lines available). 
 
Chemicals for cell culture. TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin) in DMSO was 
obtained from Cambridge Isotope Laboratories Inc. (Woburn, MA). For in vitro cultures, 
TCDD was used at a final concentration of 1 nM, and the vehicle control DMSO (Sigma-
Aldrich) was used at a final concentration of 0.01%.  These concentrations of TCDD and 
DMSO were not cytotoxic. 
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Cell culture.  CMT-93 cells (ATCC, Manassas, VA) were cultured in complete RPMI 
media (cRPMI) consisting of RPMI (GibcoBRL, Grand Island, NY) supplemented with 
10% FBS (Hyclone, Logan, UT), 50 μM mercaptoethanol, 20 mM HEPES, 10 mM 
sodium pyruvate, and 50 μg/ml gentamicin (GibcoBRL). Cells were maintained at 37°C 
and 5% CO2 with weekly passage and utilized for experimentation at 80-90% confluency. 
 
Cell activation and treatment. CMT-93 cells were incubated overnight in T25 flasks to 
facilitate attachment prior to experimentation. Prior to activation, cells were 80% 
confluent. Cells were then concomitantly stimulated with 1 μg/ml LPS (Escherichia coli 
(055:B5), Sigma-Aldrich) and treated with 1 nM TCDD or the DMSO (0.01%) vehicle 
control. After 24 h, cells were harvested for qRT-PCR analysis and supernatants were 
collected for analysis of IL-6, IL-10, IL-12, IFN-γ, and TNF-α levels.  
 
Statistics. All statistical analyses were performed using GraphPad Prism 4.0a for 
Macintosh (GraphPad Software, San Diego, CA). Student’s t-test was used to compare 
vehicle-treated groups and TCDD-treated groups while 2-way analysis of variance 
(ANOVA) with Bonferroni’s post-hoc test was used to compare multiple groups. Values 
p≤0.05 were determined to be significant. 
 
RESULTS 
AhR activation by TCDD decreases the severity of clinical symptoms in TNBS-treated 
mice.  In order to characterize the effects of TCDD on the progression of TNBS-induced 
colitis in C57Bl/6 AhR
+/+
 mice, clinical symptoms were monitored throughout the course 
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of the experiment. Crohn’s disease is a progressive wasting disease so body weight loss is 
a hallmark indicator of clinical severity. As shown in Figure 2.2A, vehicle-treated mice 
rapidly lost approximately 17% of their initial body weights following TNBS exposure 
and did not recover by the end of the study. Conversely, TCDD-treated mice lost only 8% 
of their initial weights and recovered weight rapidly. The protective effect of TCDD was 
also observed in the clinical severity of colitis, as measured by stool consistency, 
dehydration, and body condition (Table 2.1A). Vehicle-treated mice typically had loose 
stools, mild dehydration, and slower body movements while the TCDD-treated mice had 
semi-formed stools initially but recovered quite rapidly (Figure 2.2B). Thus, TCDD 
decreases the severity of clinical symptoms of mice in the TNBS-induced model of 
Crohn’s disease. 
 
Inflammation and tissue damage in the colon decreases following treatment with 
TCDD.  Crohn’s disease results in transmural inflammation and ulceration of the colon 
tissue. To examine the degree of inflammatory cell infiltration and tissue lesions, cross 
sections of the distal colon were stained with H&E and assessed microscopically to 
determine damage (Table 2.1B and Figure 2.3A). Transmural infiltration of inflammatory 
cells and extensive mucosal damage was frequently observed in vehicle-treated mice 
following TNBS exposure, which resulted in an average damage score of 5.5. However, 
the extent of inflammatory cell infiltration and lesions was significantly less in TCDD-
treated mice, as represented by an average damage score of 3.2. Representative images of 
each treatment group are shown in Figure 2.3B. These results demonstrate that TCDD  
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Figure 2.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2. TCDD reduces wasting disease and clinical symptoms associated with 
TNBS-induced colitis.  Animals were monitored daily after disease induction for body 
weight loss (A) and other clinical symptoms including body condition, dehydration state, 
and stool consistency (B). Clinical severity was determined by combining the symptom 
scores for a total possible severity score of 9, as described in Table 2.1A. Results are 
shown as mean ± SEM (n=6) and representative of three separate experiments. *indicates 
significances of p≤0.05, **indicates significance of p≤0.01, and ***indicates significance 
of p≤0.0001. 
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 exposure prior to colitis induction significantly suppress colonic inflammation following 
TNBS insult. 
 
AhR activation decreases the production of inflammatory mediators in colitis.  
TNBS-induced colitis is driven by pro-inflammatory cytokines including IL-6, IL-
12, and IL-17 (Kawada et al., 2007). Accordingly, cytokine production in supernatants 
from homogenized colon tissue was evaluated.  As shown in Figure 2.4, TCDD decreased 
the production of IL-6, IFN-γ, and TNF-α by approximately 45% each as well as the 
production of IL-12 by 18%. In a separate preliminary experiment, neither IL-6 
(TCDD=36318 pg/ml; vehicle=38222 pg/ml) nor IL-12 (TCDD=2763141 pg/ml; 
vehicle=2633190 pg/ml) colonic levels were significantly reduced in TCDD-treated 
AhR null mice when compared to the vehicle-treated wild-type controls.  Furthermore, 
production of IL-10 and IL-17 in the colon was unaffected by TCDD in TNBS-treated 
animals. Together, these results suggest that TCDD can alter the gut immune 
environment by suppressing pro-inflammatory cytokines in an AhR-dependent manner 
and decrease inflammation associated with TNBS-induced colitis.   
The effects of TCDD on antibody production were also assessed because IgA 
plays an important role in regulating immune responses in the gut. Following TCDD 
treatment, IgA levels in the supernatants from homogenized colon tissue and feces 
increased from 38.89 μg/ml to 54.99 μg/ml and from 5.85 μg/ml to 15.46 μg/ml, 
respectively (Table 2.2), an effect that was not observed in AhR null mice treated with 
TCDD (data not shown). While a trend was observed for a TCDD-induced increase in  
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Figure 2.3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3. Colonic inflammation is reduced following exposure to TCDD. Animals 
were harvested five days after disease induction, and a section of the distal colon assessed 
microscopically. Damage score (A) was determined by combining the scores for 
inflammatory cell infiltration (0-3) and tissue damage (0-3), as described in Supplemental 
Table 1B. Representative images of H&E-stained tissues sections of vehicle-treated and 
TCDD-treated animals are shown in B. Results are shown as mean ± SEM (n=6) and are 
representative of three separate experiments. **indicates significance of p≤0.01. 
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Figure 2.4 
 
 
Figure 2.4.  Modulation of cytokine production by TCDD in colon tissue. On day five 
following disease induction, colons were excised, washed, and homogenized. The 
supernatants were assessed for cytokine production, as described in the Materials and 
Methods. Results are shown as mean ± SEM (n=6) and representative of three separate 
experiments. *indicates significance of p≤0.05 and **indicates significance of p≤0.01. 
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IgA in the serum of TNBS-exposed mice, this effect was not statistically significant. 
TCDD also increased total Ig production in the colon from 48.67 μg/ml to 113.1 μg/ml 
but did not alter total Ig levels in the feces or serum. Interestingly, without the TNBS-
triggered inflammatory response, TCDD did not induce significant increases in IgA 
production in the gut (data not shown). Thus, TCDD modulates humoral immune 
responses in the gut of TNBS-treated mice. 
We also examined the potential for intestinal epithelial cells (IECs) to contribute to the 
suppression of inflammation following TCDD treatment since these cells are important in 
maintaining the mucosal barrier against gut flora and mounting immune responses by 
acting as antigen presenting cells. CMT-93 cells, a murine intestinal epithelial cell line, 
were stimulated with 1 μg/ml LPS and concurrently treated with TCDD. The LPS-
induced production of IL-6, as determined by ELISA, was suppressed by TCDD 
treatment (Table 2.3A). Similar effects were observed when cells were stimulated with 
CpG and concomitantly treated with TCDD (data not shown). IL-10, IL-12, and IFN-γ 
were not detected in either of these experiments (data not shown). 
 
TCDD alters transcription of immunoregulatory genes in colonic tissue of TNBS-
treated mice.  To gain further insight into factors that may be responsible for the 
immunomodulatory effects of TCDD in colitis, intestinal tissue was evaluated by qRT-
PCR to assess changes in gene transcription. Three days after colitis induction, which 
was the peak of clinical disease severity, TCDD enhanced the expression of AhRR, 
Cyp1a1, and IDO1 by 6.74, 216.40, and 2.91 fold, respectively (Table 2.4). Conversely, 
mRNA levels of APRIL, IDO2, and IL17A were decreased. Five days after enema 
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Table 2.2.  Effects of TCDD on antibody production in TNBS-exposed mice
a 
 
 
a
Supernatants from colon tissue, feces, and blood were obtained five days after colitis 
induction from vehicle- and TCDD-treated mice, as described in Supplemental Materials 
and Methods, and subsequently analyzed for IgA and total Ig production. Data is shown 
as mean ± SEM, which is representative of three separate experiments (n=6). *indicates 
significance of p≤0.05 when compared to vehicle-treated controls and ***indicates 
significance of p≤0.0001. 
§
indicates mg/ml. 
 IgA (μg/ml) Total Ig (μg/ml) 
 Vehicle TCDD Vehicle TCDD 
Colon 39.89 ± 3.75 54.99 ± 8.39* 48.67 ± 4.52 113.1 ± 16.43*** 
Feces 5.85 ± 1.40 15.46 ± 3.31*** 8.38 ± 1.52 9.51 ± 1.80 
Serum 147.20 ± 7.11 173.70 ± 14.53 3.056 ± 0.28
§
 2.43 ± 0.35
§
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Table 2.3. Effects of TCDD on cytokine production and gene transcription in cultured 
IECs 
A. TCDD decreases the LPS-induced production of IL-6  
 
 
 
 
 
 
 
 B. TCDD alters gene transcription in IECs 
 
(A) Supernatants were harvested 24 h after concurrent treatment of LPS and TCDD and 
subsequently assessed for cytokine production, as fully described in the Supplemental 
Materials and Methods. ***indicates significance of p≤0.0001 when compared to the 
LPS-stimulated samples. BD represents below detection. (B) Cells were treated as 
described in A and lysed in Trizol for qRT-PCR analysis. Fold change is relevant to 
vehicle-treated mice and normalized to β-actin. Genes analyzed include: a proliferation-
inducing ligand (APRIL), B cell activating factor (BAFF), cytochrome P450, family 1, 
subfamily a, polypeptide 1 (Cyp1a1), indoleamine-2,3-dioxygenase 1 (IDO1), 
indoleamine-2,3-dioxygenase 2 (IDO2), interleukin 6 (IL6), transforming growth factor, 
beta 1 (Tgfb1), transforming growth factor, beta 2 (Tgfb2), and transforming growth 
factor, beta 3 (Tgfb3). Data shown are representative of one experiment (n=6).  Bolded p-
values indicate significance of p≤0.05.   
 
Treatment IL-6 (pg/ml) 
DMSO BD 
1 nM TCDD BD 
LPS 485.6 ± 15.8 
1 nM TCDD + LPS 133.2 ± 6.9*** 
 LPS 1nM TCDD 1nM TCDD + LPS 
Gene Fold Change p-value Fold Change p-value Fold Change p-value 
APRIL 4.53 0.045 2.83 0.006 6.85 0.001 
BAFF 3.12 0.092 1.04 0.397 2.45 0.002 
Cyp1a1 -1.10 0.237 124.80 <0.0001 195.80 <0.0001 
IL6 11.90 0.0003 -3.15 0.0009 2.68 0.015 
IDO1 -1.76 0.274 -1.00 0.495 -1.06 0.454 
IDO2 1.92 0.035 1.27 0.102 2.00 0.053 
Tgfb1 1.27 0.058 1.01 0.466 1.98 0.017 
Tgfb2 2.00 0.013 -1.91 0.006 1.48 0.070 
Tgfb3 -1.09 0.322 -1.26 0.105 1.27 0.175 
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administration, a significant upregulation of AhRR, Cyp1a1, and IDO was observed; 
however, mRNA levels of IL17A and IL17F were unaffected by TCDD, which was 
consistent with the results obtained from the ELISA. Although not significant, a modest 
trend for increased TGFβ3 mRNA following AhR activation by TCDD was observed in 
wild type animals. These effects, with the exception of Cyp1a1 and AhRR induction, 
were specific to the inflamed colonic tissue and did not affect tissue from the small 
intestine.  
The ability of TCDD to also alter inflammatory responses by IECs was assessed 
via qRT-PCR. TCDD induced Cyp1a1 mRNA and downregulated the LPS-induced 
expression of IL6 (Table 2.3B). Moreover, TCDD treatment of LPS-stimulated IECs 
resulted in a 6.85- and 2.45-fold upregulation in APRIL and BAFF, respectively. Thus, 
IECs may be directly affected by TCDD to help mount immunosuppressive responses in 
the inflamed gut by decreasing the production of pro- inflammatory cytokines and 
enhancing the activity of B cells and their subsequent IgA responses. 
 
Immunoregulatory cells in the MLNs and colon are induced following AhR activation. 
AhR activation by TCDD promotes the generation of Tregs in several disease models so 
we hypothesized that TCDD dampened inflammation in TNBS-treated mice by 
increasing regulatory cell populations in the gut. Therefore, Foxp3
egfp
 mice that contain a 
knock-in allele encoding a green fluorescent protein (GFP)-Foxp3 fusion protein were 
utilized to specifically assess the presence of Foxp3+ Tregs. Initial experiments with 
these mice revealed no significant changes in regulatory cell populations when mice were 
harvested five days after TNBS enema administration (data not shown). Since the 
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Table 2.4. TCDD alters gene transcription in the intestinal tissue of TNBS-exposed mice
a
 
 
 
 
a
Three or five days following colitis induction, colon tissue from wild type mice treated 
with TCDD was homogenized in Trizol and subjected to qRT-PCR to assess alterations 
in gene transcription.  Fold change is relevant to vehicle-treated mice and normalized to 
β-actin. Genes analyzed include: aryl hydrocarbon receptor repressor (AhRR), aldehyde 
dehydrogenase family 1, subfamily A2 (Aldh1a2), a proliferation-inducing ligand 
(APRIL), B cell activating factor (BAFF), cytochrome P450, family 1, subfamily a, 
polypeptide 1 (Cyp1a1), forkhead box P3 (Foxp3), indoleamine 2,3-dioxygenase (IDO1), 
1 indoleamine 2,3-dioxygenase 2 (IDO2), interleukin 17A (IL17A), interleukin 17F 
(IL17F), RAR-related orphan receptor gamma (Rorc), transforming growth factor, beta 1 
(Tgfb1), transforming growth factor, beta 2 (Tgfb2), and transforming growth factor, beta 
3 (Tgfb3). Bolded values indicate significance of p≤0.05. Data are representative of a 
single experiment with n=6 mice per treatment group. 
 
Small Intestine 
Day 3 
Colon 
Day 3  
Colon 
Day 5 
Gene 
Fold 
Change 
p-value 
Fold 
Change 
p-value 
Fold 
Change 
p-value 
AhRR 2.17 0.026 6.74 0.009 25.49 <0.0001 
Aldh1a2 1.01 0.494 1.42 0.088 1.43 0.179 
APRIL -1.01 0.475 -2.05 0.024 -1.29 0.179 
BAFF -1.06 0.413 -1.62 0.115 -1.22 0.191 
Cyp1a1 50.56 0.0009 216.40 0.0002 1807 <0.0001 
Foxp3 1.26 0.331 -1.07 0.450 -1.17 0.366 
IDO1 1.65 0.109 2.91 0.006 2.15 0.026 
IDO2 -1.27 0.271 -1.67 0.067 -1.05 0.440 
IL17A 2.89 0.255 -9.40 0.009 -1.47 0.265 
IL17F 1.64 0.165 1.46 0.220 1.25 0.337 
Rorc 1.24 0.143 1.23 0.198 -1.38 0.236 
Tgfb1 1.08 0.328 1.36 0.116 -1.19 0.299 
Tgfb2 -1.25 0.270 1.00 0.495 1.16 0.335 
Tgfb3 -1.05 0.400 1.16 0.274 1.71 0.051 
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 peak of clinical disease severity occurred three days after disease induction, Foxp3
egfp
 
mice were evaluated three days following the TNBS enema. Populations of regulatory 
cells, both Tregs and dendritic cells (DCs), following TCDD treatment were analyzed in 
the colon tissue and MLNs (Table 2.5). Several markers were used to define regulatory 
cell populations: Tregs were characterized by the expression of CD4, CD25, Foxp3, 
CTLA4, GITR, CD103, and α4β7 while DCs were characterized by the expression of 
CD11c, MHC class II, CD86, and CD103.  
In the MLNs, TCDD increased the percentage of CD4+CD25+Foxp3+ cells from 
6.34% to 7.74%, and the percentage of these Tregs that expressed CD103 increased by 
6.5% (Table 2.5A), an effect that did not occur in AhR null mice treated with TCDD 
(data not shown). Additionally, the CD4+CD25-Foxp3+ Tregs were also evaluated since 
it has recently been shown that TCDD-induced CD25- Tregs can effectively suppress 
immune responses (Funatake et al., 2009). The percentage of CD103+ and α4β7+ cells 
increased in the CD4+CD25-Foxp3+ Treg population by approximately 10% and 3%, 
respectively. In the colon, TCDD increased the number of cells expressing CTLA4 from 
4.05% to 13.80% as well as the relative expression (MFI) of GITR from 386 to 710 in the 
CD4+CD25+Foxp3+ Tregs, even though this population was significantly decreased 
following TCDD exposure. Additionally, this population of Tregs also exhibited a 12% 
increase in cells expressing α4β7. AhR activation by TCDD also increased the percentage 
of CD4+CD25-Foxp3+ cells expressing CTLA4 as well as the relative expression of 
GITR from 325 to 458, CD103 from 1639 to 1915, and α4β7 from 155 to 185. 
Immunohistochemistry performed on the colon tissue revealed an increased Treg 
population in TNBS-treated mice, as more Foxp3+ expression was observed in mice 
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treated with TCDD (Figure 2.8). It should be noted that TCDD treatment in the absence 
of the TNBS enema did not induce an increased frequency of Foxp3+ cells in the gut 
(data not shown).  
Regulatory DCs were also examined in these experiments because these cells can 
promote the generation of Tregs. TCDD increased the percentage of 
CD11c+MHC2+CD103+ DCs in the MLNs from 8.673% to 11.88% (Table 2.5B), an 
effect that was also not observed in AhR null mice (data not shown). However, a greater 
frequency of CD11c+ DCs isolated from the colon expressed decreased levels of MHC 
class 2. Collectively, these results suggest that AhR activation by TCDD induces 
regulatory immune cells in the gut that may reduce the inflammation in mice 
experiencing TNBS-induced colitis. 
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Table 2.5.  Effects of TCDD on immune cells and their regulatory cell surface marker 
expression during TNBS-induced colitis in Foxp3
egfp
 mice
a 
 
A.  Tregs in the gut 
 
 
B.  DCs in the gut 
 
 
a
Leukocytes from colon tissue and mesenteric lymph nodes (MLNs) were isolated three 
days after disease induction and immunophenotypically evaluated by flow cytometry to 
determine the presence of regulatory T cells (Tregs) and dendritic cells (DCs). Values are 
listed as the percent of the bolded parent population indicated in the table, except for 
GITR, CD103, and α4β7 expression on colon T cells and CD86 expression on DCs, 
which indicate the Median Fluorescence Intensity (MFI) values. Bolded p-values indicate 
significance of p≤0.05. Data are representative of a single experiment (n=6). 
Representative histograms are shown in Figures 2.5-2.7. 
  MLNs   Colon  
 Vehicle TCDD p-value Vehicle TCDD p-value 
CD4+CD25+Foxp3+ 6.34 7.74 0.036 26.8 15.98 0.017 
CTLA4 11.78 12.30 0.411 4.05 13.80 0.001 
GITR 83.86 85.52 0.274 386 710 <0.0001 
CD103 45.36 51.90 0.008 1945 2072 0.104 
47 18.12 20.04 0.263 235 263 0.029 
CD4+CD25-Foxp3+ 3.90 3.98 0.444 16.78 17.02 0.445 
CTLA4 2.20 2.94 0.151 0.62 1.42 0.033 
GITR 78.66 78.88 0.472 325 458 0.005 
CD103 32.90 42.74 <0.0001 1639 1915 0.007 
47 5.60 8.36 0.009 155 185 0.013 
  MLNs   Colon  
 Vehicle TCDD p-value Vehicle TCDD  p-value 
CD11c+ 3.43 2.74 0.036 9.56 11.65 0.030 
MHC2 81.73 82.4 0.369 20.56 11.07 0.001 
CD86 652 592 0.228 338 364 0.288 
CD103 24.43 33.14 0.005 88.54 92.43 0.160 
MHC2+CD103+ 8.673 11.88 0.024 6.595 4.910 0.089 
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Figure 2.5 
 
 
Figure 2.5. Representative histograms for T cells isolated from the MLNs.  
Leukocytes were harvested from MLNs three days after disease induction, as described in 
Materials and Methods. Gating strategy is displayed in a linear manner to define 
regulatory characteristics of CD4+ T cells. 
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Figure 2.6 
 
 
Figure 2.6. Representative histograms for T cells isolated from colonic tissue. 
Leukocytes were harvested from the colon three days after disease induction, as 
described in Materials and Methods. Gating strategy is displayed in a linear manner to 
define regulatory characteristics of CD4+ T cells. 
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Figure 2.7 
 
 
 
Figure 2.7. Representative histograms for DC isolated from the MLNs and colonic 
tissue. Leukocytes were harvested from MLNs and the colon three days after disease 
induction, as described in Materials and Methods. Gating strategy is displayed in a linear 
manner to define surface phenotype of CD11c+ DCs. 
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Figure 2.8 
 
 
 
 
Figure 2.8. TCDD increases Foxp3 expression in colon tissue. Colons were harvested 
from Foxp3
egfp
 mice three days after disease induction. Tissues were sectioned, mounted 
on slides, and stained with DAPI to visualize the nucleus. Slides were imaged at 40X 
magnification using the Olympus FluoView 1000 LSC on an inverted 1x81 microscope 
with spectral detection and TIRF module.  Images are representative of a single 
experiment (n=6). 
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DISCUSSION  
Crohn’s disease arises from a combination of genetic and environmental factors 
that trigger an inappropriate immune response against commensal bacteria. This disease 
is characterized by progressive weight loss, transmural inflammation in the intestines, 
and infiltration of inflammatory cells that produce inflammatory mediators. More 
specifically, many pro-inflammatory cytokines, such as IL-12, are upregulated in the 
inflamed intestinal mucosa of Crohn’s disease patients (Monteleone et al., 1997; 
Parronchi et al., 1997; Liu et al., 1999; Abraham and Cho, 2008; Eastaff-Leung et al., 
2010). Thus, the first goal of this study was to characterize the effects of TCDD treatment 
in gut mucosal inflammation associated with TNBS-induced colitis. When compared to 
vehicle-treated mice, TCDD treatment significantly reduced disease severity, as indicated 
by decreased body weight loss, recovery periods, and colonic inflammation. TCDD also 
altered the cytokine environment by decreasing production of the inflammatory mediators 
IL-6, IL-12, IFN-γ, and TNF-α. Notably, five days after colitis induction, TCDD did not 
appear to affect IL-10 or IL-17 protein levels, which have both been implicated in human 
IBD. Although the TNBS-induced colitic response in mice is mediated primarily by Th1 
cells and may not correlate exactly with the human condition that involves both Th17 and 
Th1 cells, no animal model perfectly represents human IBD. However, TNBS-induced 
colitis in mice does induce many of the inflammatory sequelae that contribute to human 
IBD, and thus this model is very useful for assessment of these early events.  
Recently, Takamura and colleagues utilized the dextran sodium sulfate (DSS) 
model of ulcerative colitis, another type of inflammatory bowel disease, to study the 
effects of TCDD on gut inflammation (Takamura et al., 2010). In their model, pre-
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treatment with TCDD ameliorated disease severity, inflammation, and TNF-α production 
in colonic tissue of DSS-treated mice. Although these results were obtained in a model 
that elicits a slightly different immune response, our results are consistent with those 
obtained in this independent study. Thus, TCDD treatment suppresses pro-inflammatory 
cytokine production that may be responsible for propagating inappropriate effector T cell 
responses in the gut. Interestingly, the TCDD dose (15 ug/kg) that was used in our studies 
was slightly higher than the TCDD dose (5 μg/kg) used by Takamura and colleagues. 
Selection of the dose of TCDD in our experiments was based on the reproducible, but not 
overtly toxic, effects of 15 ug/kg in many models of immunity performed in C57Bl/6 
mice. To date, we have not performed dose-response studies; however, it would be of 
interest to evaluate the potential for both higher and lower doses to affect inflammation 
associated with the colitic response in TNBS-treated mice. 
The intestinal immune system is comprised of organized lymph tissue, various 
innate and adaptive immune cells, and intestinal epithelial cells (IECs). In addition to the 
cells located in the lamina propria, the mesenteric lymph nodes (MLNs) are essential sites 
for mounting successful adaptive immune responses against pathogens in the gut. In the 
healthy gut, there is a balance between effector and regulatory cells such that no response 
is elicited against commensal organisms. In Crohn’s disease, this balance is disrupted and 
many cellular components contribute to the exaggerated immune and inflammatory 
responses. In the inflamed mucosa of Crohn’s disease patients, there is a significant 
decrease in Foxp3 expression in CD4+CD25+ cells along with decreased numbers of 
CD4+CD25+Foxp3+ cells, which may contribute to enhanced Th1- and Th17-mediated 
immune responses (Eastaff-Leung et al., 2010). Moreover, TCDD has been reported to 
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induce CD4+CD25+ T cells that express elevated levels of GITR and CTLA4 and 
suppress proliferation of effector T cells (Funatake et al., 2005). Thus, we investigated 
potential alterations in several key immune cell populations in the context of gut mucosal 
immunity. Pre-treatment of Foxp3
egfp
 mice with TCDD increased Foxp3+ cells in the gut 
of TNBS-treated mice. These cells displayed increased levels of GITR, CTLA4, and 
CD103, which indicate a regulatory potential for these cells. It must be acknowledged 
that our flow cytometry data revealed a decreased frequency of Foxp3+ cells while the 
immunohistochemistry images revealed increased Foxp3+ expression in the colonic 
tissue. This discrepancy is potentially due to the fact that the colon section removed for 
histology was at the site of TNBS administration, and therefore possessed the most severe 
inflammation, while surrounding tissue was used to isolate leukocytes for flow 
cytometric analyses. Even though the GFP fluorescence was not quantified in these 
images, the increase of Foxp3+ Tregs at the site of inflammation in TCDD-treated mice 
most likely contributes to decreased inflammation. Furthermore, Treg induction by 
TCDD may primarily occur in the context of an inflammatory environment since we did 
not observe increased Foxp3 expression with TCDD treatment alone. Regulatory DCs 
were also present in the MLNs, as indicated by increased frequencies of CD103+ DCs. 
Although not directly assessed by flow cytometry, downregulation of IL17A mRNA in 
the colon suggests that TCDD may decrease Th17 cells; however, no corresponding 
changes in IL-17 protein levels were observed. We expect that performing these studies 
in Rorγt reporter mice will fully define the contribution of Th17 cells in this model and 
how TCDD might affect this population of inflammatory T cells. Taken together, our 
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results demonstrate that TCDD generates regulatory cells that may contribute to 
decreased inflammation in the gut of TNBS-treated mice.  
Successful antibody responses in the gut are essential to limiting inappropriate 
responses against commensal bacteria. IgA is the primary antibody responsible for 
limiting bacterial penetration in the gut (Macpherson and Uhr, 2004), and its production 
is promoted by TGF-β. In the normal intestinal immune environment DCs maintain a 
tolerogenic environment, as they are conditioned by TGF-β and PGE-2 to secrete IL-10 
and/or TGF-β (Iwasaki and Kelsall, 1999; Chirdo et al., 2005). In addition, IECs play an 
important role in the innate and adaptive immune responses in the gut. The epithelium is 
not only the first line of defense against bacteria, but IECs can also act as antigen 
presenting cells capable of influencing intestinal immune function. Defects in the 
epithelial barrier have been associated with CD pathogenesis (Baumgart and Dignass, 
2002). In our experiments, IgA production was increased in the colon tissue and feces 
suggesting that TCDD may be acting on DCs and/or IECs to produce switch factors 
necessary to induce IgA production by B cells in the gut. Additionally, BAFF and APRIL 
are expressed in many immune cells and play important roles in lymphocyte homeostasis 
(Ng et al., 2005). Although BAFF transcript levels were reduced in the colon, TGFβ 
upregulation was observed, which may be responsible in part for the increased IgA 
production in the gut following TCDD treatment in TNBS-exposed mice. Moreover, 
stimulated IECs upregulated BAFF and APRIL mRNA levels following TCDD exposure. 
Thus, IECs may contribute to the amelioration of disease severity in the TNBS-induced 
colitis model by contributing to increased production of IgA. Additional studies focused 
on further defining the effects of TCDD on IgA production in the gut and the 
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mechanisms responsible for these effects are warranted. It must be emphasized that 
TCDD may be acting on T cells, B cells and other immune and non-immune cells to 
reduce inflammation in the gut, and we believe that these events need not be mutually 
exclusive. Indeed, it is very likely that the effects of TCDD on all of these cells 
collectively may be necessary to generate a regulatory environment during TNBS-
induced colonic inflammation. Thus, to definitively determine if TCDD is acting directly 
on T cells or indirectly on B cells, DCs or IECs to mount protective immune responses 
during the generation of colitis, it would be necessary to perform adoptive transfer 
experiments or generate TNBS-induced colitis in AhR conditional knockout mice. Our 
laboratory is currently pursuing these experimental possibilities. 
The effects of TCDD notably occur via activation of the AhR, which is a ligand-
activated transcription factor present in many immune cells including T cells, B cells, 
DCs, and macrophages (Marshall and Kerkvliet, 2010). As such, activation of the AhR 
by TCDD results in the suppression of immune and inflammatory responses. Since it has 
been demonstrated in AhR-deficient mice that the immunosuppressive effects of TCDD 
are AhR-dependent, we anticipate that TCDD is also acting through the AhR to suppress 
colitis. Although our preliminary study using AhR null mice suggested that many of our 
observed TCDD-induced effects are dependent on the AhR, additional studies are 
currently underway in our laboratory to fully examine the role of the AhR in mediating 
the effects of TCDD as well as endogenous AhR ligands in TNBS-induced colitis.  
Indoleamine-2,3-dioxygenase (IDO) has been implicated in promoting the 
generation of Tregs. Tryptophan, an essential amino acid, is primarily catabolized via 
induction of IDO, an enzyme that has been linked to immune tolerance. Furthermore, 
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tryptophan metabolites can activate the AhR (Fallarino et al., 2002; Frumento et al., 
2002; Terness et al., 2002; Denison and Nagy, 2003; Belladonna et al., 2006; Fallarino et 
al., 2006). It has been suggested that by binding to the AhR in activated CD4+ T cells, 
tryptophan metabolites can elicit their immunosuppressive effects by inducing a Treg 
phenotype. Moreover, Bankoti and colleagues recently demonstrated that TCDD 
upregulated IDO1, IDO2, TGFβ1, and TGFβ2 in LPS-stimulated inflammatory bone 
marrow-derived DCs (Bankoti et al., 2010b). In our study, TCDD treatment increased 
IDO1 transcript levels in the colon of TNBS-treated mice. It is therefore possible that 
TCDD induces IDO in the intestinal DCs and/or CD4+ T cells subsequently leading to a 
significant induction of Tregs in mice exposed to TNBS. Furthermore, tolerogenic DCs 
capable of promoting Treg differentiation can be generated following the interaction of 
ligand-activated AhR with RelB via the non-canonical NF-kB signaling pathway, an 
effect that is mediated via IDO induction in DCs and subsequent Foxp3 expression in T 
cells (Mellor et al., 2004; Belladonna et al., 2007; Curti et al., 2007; Tas et al., 2007; 
Vogel et al., 2008; Bankoti et al., 2010b).  
Current therapeutic strategies for Crohn’s disease involve a combination of 
corticosteroids and immunomodulatory drugs to rapidly reduce inflammation and induce 
remission. These therapeutics, however, often possess severe adverse effects. Although 
TCDD suppressed colonic inflammation in this model, it is recognized that TCDD would 
not serve as a useful therapeutic agent for Crohn’s disease patients due to its potential 
toxic side effects. There are numerous other AhR ligands present in the diet, such as 
indole-3-carbinol in cruciferous vegetables and resveratrol in grapes that have 
documented anti-inflammatory properties and have little or no associated toxicity (Leibelt 
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et al., 2003; Aggarwal and Shishodia, 2006; Cottart et al., 2010). Thus, it is possible that 
AhR agonists found naturally in the diet can activate the AhR to reduce disease severity 
similar to TCDD. Recent studies have suggested a potential protective effect in the colitic 
response for 3,3’-diindolylmethane, the acid condensation product of indole-3-carbinol 
(Kim et al., 2009) and resveratrol (Martin et al., 2006; Larrosa et al., 2009; Cui et al., 
2010). Although these studies were not performed in TNBS-treated mice, they 
demonstrated decreased disease severity and gut inflammation during a colitic response; 
however, the role of the AhR in mediating the effects in each of these studies was not 
evaluated. Conversely, AhR activation by 6-formylindolo[3,2-b]carbazole (FICZ), a 
typtophan metabolite, exacerbated inflammatory responses by promoting Th17 
differentiation in some murine disease models, such as experimental autoimmune 
encephalitis (Martin et al., 2006; Ho and Steinman, 2008; Quintana et al., 2008; 
Veldhoen et al., 2008). Although ligand-specific effects may be due to the timing and 
duration of AhR activation, it must be emphasized that, to date, it is not well understood 
why some AhR ligands, such as FICZ, have the potential to promote the development of 
Th17-mediated inflammatory responses while others, such as TCDD, promote the 
development of Treg-mediated suppressive responses. Therefore, it is critical to continue 
to evaluate the effects of AhR activation by multiple ligands in the context of gut 
inflammation.  
Collectively, our results demonstrate for the first time that the potent AhR ligand 
TCDD suppresses gut inflammation and disease severity in the murine model of TNBS-
induced colitis, an effect that correlates with an induction of Tregs. Further investigations 
are needed to elucidate the signaling events responsible for Treg generation in the gut, as 
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TCDD may induce Tregs directly or alternatively via the generation of regulatory DCs. It 
would also be interesting to evaluate other AhR ligands, as these compounds may prove 
to represent a new class of therapeutics to treat Crohn’s disease in humans.  
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ABSTRACT 
Due to the severe adverse effects that can accompany conventional therapies for 
Crohn’s disease, the search for natural complementary therapies has increased 
dramatically in recent years. Indole-3-carbinol (I3C), a constituent of cruciferous 
vegetables, possesses anti-inflammatory properties; however, its effects on intestinal 
inflammation have yet to be evaluated.   To test the hypothesis that I3C dampens 
intestinal inflammation, C57Bl/6 mice were treated with I3C and exposed to 2,4,6-
trinitrobenzenesulfonic acid (TNBS) to induce colitis. Several parameters of disease 
severity and inflammation were subsequently evaluated.  I3C dampened the disease 
severity, as indicated by decreased body weight loss and decreased severity of clinical 
signs.  Interestingly, this effect was observed in female but not male mice, which 
displayed a trend towards exacerbated colitis.  Differential effects were observed in the 
profiles of cytokine production, as the production of pro-inflammatory cytokines was 
increased in males.   The sex-specific effect of I3C in TNBS-induced colitis is a novel 
finding and warrants further investigation since this is a common dietary compound and 
is also available commercially.  
 
 
KEY WORDS  
 Indole-3-carbinol (I3C); inflammation; Crohn’s disease 
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INTRODUCTION 
 The desire to identify natural products to treat and prevent various diseases has 
increased dramatically in recent years due to the decreased satisfaction with conventional 
therapeutics. One compound of interest is indole-3-carbinol (I3C), a prevalent constituent 
of cruciferous vegetables including broccoli, brussel sprouts, and cabbage.  I3C is 
primarily recognized for its potent anti-cancer properties since it has the unique ability to 
eliminate tumor cells while being protective in normal cells.  Importantly, no immediate 
or long-term severe adverse effects have been documented following human consumption 
in several cancer clinical trials (Bradlow et al., 1994; Reed et al., 2005; Rosen and 
Bryson, 2004; Wong et al., 1997) thereby emphasizing its usefulness as a therapeutic 
agent. 
Several molecular targets have been identified for I3C and its metabolites, such as 
the primary acid condensation product diindolylmethane (DIM). Activities contributing 
the observed effects of I3C include decreased proliferation, increased apoptosis, and 
decreased metastasis (reviewed in Aggarwal and Ichikawa, 2005). Furthermore, I3C can 
bind several cytosolic receptors and alter several important signaling pathways including 
aryl hydrocarbon receptor (AhR), estrogen receptor (ER), androgen receptor (AR), and 
nuclear factor-kappa B (NF-κB). A complex signaling cascade is likely induced 
following I3C exposure due to crosstalk between these pathways including physical 
interaction of the ligand-bound AhR with NF-κB (Vogel et al., 2007a; Vogel et al., 
2007b) and the ER (Matthews et al., 2005; Ohtake et al., 2003; Wormke et al., 2003). 
While I3C has been primarily investigated for its anti-cancer properties, there has 
been increased interest in evaluating its immunomodulatory properties.  It has been 
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documented that I3C can suppresses inflammation in vitro and in vivo in part by 
inhibiting NF-κB activation and decreasing production of inflammatory mediators 
(Benson and Shepherd, 2011b; Chang et al., 2011; Takada et al., 2005; Tsai et al., 2010). 
Therefore, the potential exists for this compound to be effective in reducing the severity 
of chronic inflammatory diseases including Crohn’s disease and ulcerative colitis, which 
are inflammatory bowel diseases.  In fact, the I3C acid condensation product DIM 
suppressed disease severity of dextran sodium sulfate (DSS)-induced colitis, which is an 
animal model of ulcerative colitis (Kim et al., 2009). However, the potential beneficial 
effects of its parent compound, I3C, on intestinal inflammation have yet to be 
investigated.   
In this study we assessed the potential of I3C to suppress inflammation in a 
murine model of Crohn’s disease.  We hypothesized that I3C would exert anti-
inflammatory effects in the 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colitis.  
Our results demonstrate for the first time that I3C exerts sex-specific effects in TNBS 
colitis, as it ameliorates disease severity and inflammation in female, but not male, mice. 
I3C clearly has potential to be a useful therapeutic for intestinal inflammation; however, 
future studies are necessary to further define the sex-specific effects of this compound in 
the gut.  
 
MATERIALS AND METHODS 
Laboratory animals.  Six to eight week old male and female C57Bl/6 mice, originally 
obtained from The Jackson Laboratories (Bar Harbor, ME), were bred and maintained in 
the animal research facility at the University of Montana. All mice were housed under 
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specific pathogen-free conditions and maintained on 12 h dark/light cycles. Throughout 
each experiment animals were individually caged, and standard laboratory food and water 
were provided ad libitum.  All protocols for the use of animals were approved by the 
University of Montana Institutional Animal Care and Use Committee and adhered to the 
current NIH guidelines for animal usage. 
 
Chemicals.  Indole-3-carbinol (I3C) was obtained from Sigma-Aldrich (St. Louis, MO), 
and suspended in peanut oil, which was used as a vehicle control for gavages, at 10 
mg/ml.  The purity and stability of I3C was verified in house via NMR.  2,4,6-
trinitrobenzenesulfonic acid (TNBS) was also obtained from Sigma-Aldrich and 
dissolved in acetone/olive oil for pre-sensitization or 40% ethanol for enema 
administration. 
 
Colitis induction.  As described in Figure 3.1, mice were gavaged daily starting on day -1 
and ending on day 6 with 100 mg I3C per kg body weight (~200-250 μl total volume) or 
a comparable volume of peanut oil vehicle control prior TNBS exposures. Pre-
sensitization on day 0 included an application of 150 μl 5% TNBS in a 4:1 acetone:olive 
oil solution between the shoulder blades. Colitis was then induced via an enema 
containing TNBS on day 7, as previously described (Benson and Shepherd, 2011). Body 
weight loss and the severity of clinical symptoms (overall body condition, stool 
consistency, and dehydration state) was monitored daily and scored as previously 
described in detail (Benson and Shepherd, 2011a). On day 12, mice were euthanized via 
CO2 asphyxiation followed by cervical dislocation. 
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Figure 3.1 
 
 
 
 
 
Figure 3.1.  Experimental design.  This schematic represents the experimental design 
utilized for the studies in which animals were gavaged daily with 100 mg/kg I3C, 
peripherally sensitized with 5% TNBS, intrarectally injected with 2.5 mg TNBS, and 
subsequently harvested on day 12 for evaluation. 
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Colon processing and histology. Colons were excised from each mouse and washed with 
PBS to remove debris. For histological analysis, a 1 cm section from the distal colon was 
fixed in 2% paraformaldehyde, processed in the Shandon Citadel 2000 Automated Tissue 
Processor (Thermo Fisher Scientific, Waltham, MA) with vacuum unit, embedded using 
the Shandon Histocentre 2 Embedding unit, sectioned at 7 μm using the Thermo Shandon 
Finesse 325 microtome, and stained with hematoxylin and eosin (H&E) in the Shandon 
Veristain 24-4 Slide Stainer. Colons were assessed microscopically by a blinded 
individual to determine the severity of inflammation based on an established scoring table 
(Benson and Shepherd, 2011a).  Slides were imaged using the Nikon E800 Microscope 
with Cambridge Research Instrumentation, Inc. and Nuance camera software version 
1.62 at 10X magnification. The remaining colon was divided into two sections for cell 
isolation, as described in Supplemental Material and Methods, and homogenization in 
lysis buffer from which the supernatants were analyzed for cytokine production, as 
described below. 
 
Cytokine assays.  Supernatants from homogenized colon tissue were examined for the 
levels of IL-1β, IL-6, IL-10, IL-12, IL-17, and IFN-γ via enzyme-linked immunosorbent 
assay (ELISA).  Samples were analyzed according to the manufacturer’s instructions 
using mouse cytokine-specific BD OptEIA ELISA kits (BD Biosciences, San Diego, CA) 
or R&D ELISA kits (Minneapolis, MN). 
 
qRT-PCR. RNA was isolated from colon tissue with Trizol reagent (Invitrogen, Carlsbad, 
CA) and subjected to RNA clean-up using the Total RNA Kit with optional DNase 
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treatment (Omega Bio-Tek, Norcross, GA) according to the manufacturers’ instructions. 
First strand cDNA synthesis was performed using qScript cDNA Supermix (Quanta 
Biosciences, Gaithersburg, MD). Resulting cDNA was subjected to qRT-PCR using 
commercially obtained primers (SABiosciences, Frederick, MD or Integrated DNA 
Technology, Coralville, IA) including aryl hydrocarbon receptor (AHR), aldehyde 
dehydrogenase family 1, subfamily A1 (ALDH1A1), aldehyde dehydrogenase family 1, 
subfamily A2 (ALDH1A2), estrogen receptor alpha (ESR1), estrogen receptor beta 
(ESR2), indoleamine-2,3-dioxygenase 1 (IDO1), indoleamine-2,3-dioxygenase 2 (IDO2), 
interleukin 6 (IL6), interleukin 10 (IL10), interleukin 17A (IL17A), interleukin 17F 
(IL17F), interleukin 22 (IL22), transforming growth factor, beta 1 (TGFB1), transforming 
growth factor, beta 2 (TGFB2), and transforming growth factor, beta 3 (TGFB3). 
Reactions were performed with PerfeCTa SYBR Green Supermix (Quanta Biosciences) 
on an Agilent Technologies Stratagene Mx3005P QPCR System (Santa Clara, CA). 
 
Flow cytometry.  Lamina propria mononuclear cells from colonic tissue and cells from 
the mesenteric lymph nodes (MLNs) were isolated and evaluated for expression of 
accessory molecules by flow cytometry, as previously described (Benson and Shepherd, 
2011).  Briefly, after cells were washed with PAB (1% bovine serum albumin and 0.1% 
sodum azide in PBS), they were blocked with Fc block (BioLegend, San Diego, CA) to 
eliminate non-specific staining.  Subsequently, cells were stained for 10 min using 
optimal concentrations of fluorochrome-conjugated monoclonal antibodies.  Antibodies 
used in these experiments included CD4-PE (GK1.5), CD25-PerCP/Cy5.5 (PC61), 
CD11c-APC (HL3), MHC2-FITC (M5/114.15.2), CD103-Pacific Blue (2E7), and their 
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corresponding isotype controls, all of which were purchased from BioLegend or BD 
Biosciences (San Jose, CA). Two hundred thousand events were collected using a BD 
FACSAria flow cytometer and analyzed using FACSDiva (Version 6.1.2, BD 
Biosciences, San Jose, CA) and FlowJo (Version 8.7.1, TreeStar, Inc., Ashland, OR) 
software programs. 
 
Statistics. All statistical analyses were performed using GraphPad Prism 4.0a for 
Macintosh (GraphPad Software, San Diego, CA). Student’s t-test was used to compare 
vehicle-treated groups and I3C-treated groups while 2-way analysis of variance 
(ANOVA) with Bonferroni’s post-hoc test was used to compare multiple groups. Values 
p≤0.05 were determined to be significant. 
 
RESULTS 
Severity of TNBS-induced colitis is reduced with I3C treatment in females but not 
males.  I3C is a prevalent dietary compound with anti-inflammatory properties so its 
potential to decrease inflammation in a murine model of colitis was evaluated.  This 
compound has been used extensively in clinical trials with no serious long-term adverse 
effects reported.  Therefore, the dose used in this study is comparable to a dose in humans 
taking I3C supplements (Minich et al., 2007). In order to assess the potential for I3C to 
ameliorate colitis, key indicators that mark the onset of Crohn’s disease, including 
significant body weight loss, loose stools, and dehydration, were evaluated first.  Female 
mice treated with I3C did not lose as much weight and recovered more rapidly than 
vehicle-treated mice (Figure 3.2A).  The clinical severity, as determined by the overall  
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Figure 3.2 
 
 
Figure 3.2. I3C ameliorates colitis in female, but not male, mice exposed to TNBS.  Mice 
were monitored daily after disease induction for body weight loss and other clinical signs 
including body condition, dehydration state, and stool consistency. Clinical severity was 
determined by combining the symptom scores for a total possible severity score of 9. 
Closed circles represent vehicle-treated mice, and open circles represent I3C-treated 
mice. Results are shown as mean ± SEM (n=5) and representative of three separate 
experiments. *indicates significance of p≤0.05. 
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body condition, stool consistency, and dehydration state, was also significantly less 
severe in female I3C-treated mice.  Conversely, when compared to vehicle-treated mice, 
male mice treated with I3C lost weight, regained that weight more slowly, and 
experienced a trend towards more severe clinical signs (Figure 3.2B). 
 
Inflammation and tissue damage in the colon decreases following treatment with I3C 
in females. Since intestinal inflammation associated with Crohn’s disease is transmural in 
nature, inflammatory cell infiltration and tissue lesions were evaluated in the colon.  In 
line with the clinical signs, female I3C-treated mice colon inflammation decreased from 
4.0 in vehicle-treated mice to 1.4 with I3C treatment (Figure 3.3A).  Conversely, the 
damage score increased from 4.0 to 5.3 in male vehicle- and I3C-treated mice, 
respectively (Figure 3.3B).  This increase, however, was not statistically significant. 
 
I3C exerts differential effects on cytokine production in colonic tissue of TNBS-
exposed mice.  Colitis is associated with significant production of pro-inflammatory 
cytokines. To better understand how I3C may alter the onset of Crohn’s disease, cytokine 
production in colonic tissue was measured.  In I3C-treated female mice, IFN-γ levels 
decreased from 337 pg/ml to 174 pg/ml (Figure 3.4).  IL-10 increased from 591 pg/ml to 
680 pg/ml, but this was not statistically significant.   It should be noted that IL-10 was 
significantly increased in one of the three experiments while just a trend towards 
increased IL-10 was observed in the other experiments.  I3C did not alter the production 
of IL-1β, IL-6, IL-12, or IL-17 in female mice.  In I3C-treated male mice, IL-1β and IL-6 
were both increased from 332 pg/ml to 817 pg/ml and from 66 pg/ml to 154 pg/ml, 
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Figure 3.3 
 
 
 
 
Figure 3.3.  Sex-specific effects of I3C on colon damage. Colon tissue was removed on 
day 5 post-enema and evaluated histologically to determine tissue damage. The final 
damage score was based on the severity inflammatory cell infiltration and mucosal 
lesions, both of which were scored on a scale of 0-3. Representative images are displayed 
to the right of the graph. Results are shown as mean ± SEM (n=5) and representative of 
three separate experiments. *indicates significance of p≤0.05. 
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Figure 3.4 
 
 
 
Figure 3.4.  I3C induces production of anti-inflammatory and pro-inflammatory 
mediators in colonic tissue of TNBS-treated mice. Colon tissue was harvested five 
days after TNBS enema delivery, homogenized, and assessed for cytokine production. 
Results are shown as mean ± SEM (n=5) and representative of three separate 
experiments. *indicates significance of p≤0.05. 
 94 
respectively.  IFN-γ levels decreased from 296 pg/ml to 167 pg/ml. As with female mice, 
I3C did not alter the production of IL-12 or IL-17. 
 
Differential regulation of gene expression by I3C in TNBS-induced colitis.  Since 
exposure to other dietary chemicals leads to the induction of regulatory genes that 
correlates to decreased colitis, gene expression was evaluated in vehicle- and I3C-treated 
mice five days after the TNBS enema (Table 3.1).  Interestingly, I3C-treated female mice 
downregulated IL17A expression by 3.5 fold while male mice treated with I3C 
upregulated IL17A expression by 8.1 fold.  A similar trend was observed with IL6 
expression with decreased levels in females and increased levels in males treated with 
I3C.  There was also a trend of increased expression of ALDHA1 and TGFB families of 
genes in females and decreased levels in male mice.  More specifically, in female I3C-
treated mice, there was a 2.3 fold decrease in ALDH1A2 levels and a 2.2 fold decrease in 
TGFB1 transcript levels. Conversely, in male I3C-treated mice, TGFB3 expression was 
increased by 6.6 fold while increases in other TGFB family members and the ALDH1A 
genes were not statistically significant. Notably, IL10 expression was decreased by 2.4 
fold in male mice but not significantly altered in female mice. Expression levels of AHR, 
ESR1, and ESR2 were unchanged in both female and male mice five days post-enema. 
 
Alterations in gut cell populations were not observed five days after TNBS enema.  T 
cells and dendritic cells (DCs) are particularly important for maintaining homeostasis in 
the intestinal immune system.  Therefore, cells were isolated from the colon tissue and 
the mesenteric lymph nodes (MLNs) and evaluated for phenotypic changes that could 
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Table 3.1.  Differential regulation of gene expression by I3C in TNBS-induced colitis
a 
 
 
 
 
 
 
 
 
 
 
 
 
 
a
Colon tissue was harvested, homogenized in Trizol, and subjected to qRT-PCR to assess 
alterations in gene transcription.  Fold change is relevant to vehicle-treated mice and 
normalized to β-actin. Data are representative of a single experiment with n=5 mice per 
treatment group. *indicates significance of p≤0.05.  
 
Gene 
Female Male 
Fold change p-value Fold change p-value 
AHR -1.1 0.4 4.3 0.2 
ALDH1A1 -1.2 0.4 1.2 0.4 
ALDH1A2 -1.5 0.2 1.7 0.3 
ESR1 1.1 0.4 2.7 0.3 
ESR2 1.1 0.4 4.3 0.2 
IDO1 1.2 0.4 -1.3 0.3 
IDO2 1.4 0.3 1.3 0.4 
IL6 -2.4 0.08 4.1 0.2 
IL10 -2.2 0.2 -2.4* 0.02 
IL17A -3.5* 0.05 8.1* 0.05 
IL17F -2.3 0.06 -1.2 0.5 
IL22 -1.7 0.3 1.3 0.4 
TGFB1 -2.2* 0.03 2.7 0.2 
TGFB2 -1.6 0.06 1.8 0.2 
TGFB3 -1.1 0.4 6.6* 0.05 
 96 
Table 3.2.  I3C does not significantly alter critical immune cells in colon
a
  
 
A.  Colon (Percent Population) 
 
 
 
 
 
 
 
 
B.  Colon (Mean Fluorescence Intensity) 
 
 
 
 
 
 
 
 
C.  MLNs  (Percent Population) 
 
 
 
 
 
 
 
 
D.  MLNs (Mean Fluorescence Intensity) 
 
 
 
 
 
 
 
 
 
a
Leukocytes were isolated from colonic tissue and mesenteric lymph nodes (MLNs) five 
days after enema administration. For T cells, CD25+ cells were gated out of the CD4+ 
population, and for dendritic cells MHC2+ and CD103+ cells were gated out of the 
CD11c+ population. Results are representative of three independent experiments (n=5).
Immune cell 
markers 
Female Male 
Vehicle I3C Vehicle I3C 
CD4 2.4 ± 0.4 2.8 ± 0.6 3.1 ± 0.2 4.9 ± 1.5 
CD25 77.9 ± 7.6 70.4 ± 5.5 67.5 ± 5.1 67.1 ± 15.4 
CD11c 2.7 ± 0.5 3.4 ± 0.8 3.9 ± 0.2 4.1 ± 0.6 
MHC2 35.1 ± 10.3 40.1 ± 6.8 48.7 ± 6.2 36.8 ± 13.9 
CD103 73.1 ± 6.0 68.9 ± 4.6 64.2 ± 3.4 65.3 ± 11.2 
Immune cell 
markers 
Female Male 
Vehicle I3C Vehicle I3C 
CD4 536 ± 51 492 ± 18 512 ± 21 520 ± 21 
CD25 426 ± 4 433 ±15 443 ± 25 417 ± 26 
CD11c 570 ± 73 620 ± 78 651 ± 21 559 ± 102 
MHC2 3039 ± 159 3072 ± 153 2780 ± 167 3166 ± 405 
CD103 340 ± 38 290 ± 14 368 ± 26 326 ± 28 
Immune cell 
markers 
Female Male 
Vehicle I3C Vehicle I3C 
CD4 18.3 ± 0.9 21.8 ± 1.4 26.1 ± 3.1 20.2 ± 4.4 
CD25 8.1 ± 0.7 6.9 ± 0.4 6.1 ± 0.6 8.2 ± 1.6 
CD11c 1.4 ± 0.1 1.9 ± 0.2 1.6 ± 0.3 1.3 ± 0.3 
MHC2 82.5 ± 1.6 81.1 ± 2.3 81.5 ± 1.5 83.5 ± 0.7 
CD103 18.3 ± 2.6 14.2 ± 1.0 11.7 ± 1.0 17.4 ± 4.9 
Immune cell 
markers 
Female Male 
Vehicle I3C Vehicle I3C 
CD4 1115 ± 21 1183 ± 24 1176 ± 37 1254 ± 59 
CD25 296 ± 23 472 ± 17 465 ±14 488 ± 23 
CD11c 1208 ± 70 1114 ± 77 916 ± 62 1042 ±160 
MHC2 5440 ± 132 5196 ± 273 5050 ±153 5009 ± 257 
CD103 2094 ± 235 2230 ± 363 1819 ± 308 1637 ± 713 
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indicate the presence of regulatory cells following exposure to I3C.  Five days after 
administration of the TNBS enema, no significant changes in T cells or DCs were 
observed (Table 3.2). 
 
DISCUSSION  
The cruciferous vegetable constituent I3C is a potent anti-cancer agent, but its 
effects on inflammatory responses, especially in the gut, are not well documented. Since 
I3C and its primary metabolite DIM recently have been shown to produce anti-
inflammatory and immunoregulatory effects in vitro (Benson and Shepherd, 2011b; 
Chang et al., 2011; Cho et al., 2008; Tsai et al., 2010), these compounds have the 
potential to elicit protective effects in diseases characterized by chronic inflammation.  
The current conventional medicines for Crohn’s disease, a chronic inflammatory disease 
of the gastrointestinal tract, can be accompanied by severe adverse effects so many 
patients have turned towards natural and complementary therapies as part of their 
treatment regimens.  Consequently, we evaluated the potential of I3C to decrease the 
severity of Crohn’s disease using a murine model of colitis. 
To characterize the effects of I3C on colitis, we evaluated the hallmark signs of 
disease onset:  significant body weight loss, clinical severity, damage to colonic tissue, 
and inflammatory mediator production.  I3C suppressed the body weight loss and the 
severity of clinical signs, but   this effect was surprisingly only observed in female mice 
while male mice displayed a trend to a more severe disease phenotype.  Furthermore, 
inflammatory cell infiltration and tissue lesions were decreased in the colons of female, 
but not male, mice.  The acid condensation product DIM has been reported to ameliorate 
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the DSS model of colitis in terms of clinical signs and histological scoring of the tissue.  
In this report, however, Balb/c mice of an unspecified sex were used in the experiments 
(Kim et al., 2009). Using the prototypical AhR ligand TCDD, our laboratory previously 
reported that TCDD dampened disease severity in TNBS-induced colitis (Benson and 
Shepherd, 2011a).  In those studies we used male and female mice, and both sexes 
benefited from TCDD administration. 
Colitis induction is characterized by increased production of inflammatory 
mediators.  Thus, an important aspect of potential therapeutic would be to decrease the 
production of these damaging mediators.  Interestingly the profile of cytokines produced 
in the gut was quite surprising. As expected, the exacerbated disease state in males was 
associated with increased production of pro-inflammatory cytokines following I3C 
treatment.  In female mice, only IFN-γ production was reduced.  With DIM treatment in 
DSS-induced colitis, decreased levels of IL-6, IFN-γ, TNF-α, PGE-2, and NO were 
observed (Kim et al., 2009).  Additionally, there was a trend towards decreased IL-10 
production at highest dose evaluated (20 mg/kg).  The authors concluded that decreased 
inflammation was likely due to decreased NF-κB binding activity in colon tissue.  
In contrast to I3C, following TCDD treatment of both female and male mice we 
observed decreases in the pro-inflammatory cytokines and no change in IL-10 (Benson 
and Shepherd, 2011a).  Furthermore, TCDD treatment resulted in significant increases in 
the expression of AHRR, CYP1A1, and IDO in the colons of mice five days after enema 
delivery.  I3C primarily affected ALDH1A2, IL17A, IL10 and the TGFB family members.  
Importantly, I3C did not have lasting effects on AHRR or CYP1A1 gene expression (data 
not shown), which suggests that the AhR is not the sole or primary factor responsible for 
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the suppression of TNBS-induced colitis in females.  These differences suggest that 
different mechanisms of action are responsible for mediating the effects of the dietary 
AhR ligands TCDD and I3C.  Since I3C possesses anti-estrogenic properties, the 
estrogen receptor (ER) may also play a role, especially since the AhR and the ER have 
been demonstrated to physically interact (Matthews et al., 2005; Ohtake et al., 2003; 
Wormke et al., 2003). Although we did not observe changes in ER expression five days 
after colitis induction, additional studies assessing the role of the ER in mediating the 
effects of I3C in TNBS colitis would be worthwhile. 
Even though there was not an overwhelming decrease in pro-inflammatory 
cytokines in female mice, I3C may be acting on several important immune cells in the gut 
to ameliorate colitis.  Dendritic cells (DCs) play important role in maintaining intestinal 
immune homeostasis. In a recent report from our laboratory, we demonstrated that bone 
marrow-derived DCs grown in the presence of I3C and cultured with antigen-specific 
naïve CD4+ T cells generated Foxp3+ regulatory T cells (Tregs) (Benson and Shepherd, 
2011b).  Therefore, it is possible that DCs increased Tregs in the gut consequently 
leading to the decreased gut inflammation observed in I3C-exposed mice.  This would be 
consistent with what we observed in TNBS-treated mice exposed to TCDD (Benson and 
Shepherd, 2011a).  Although we did not observe any significant alterations in cell 
populations on day five post-enema, it is possible that the functions of DCs and T cells in 
the mesenteric lymph nodes and colon tissue were altered earlier in the inflammatory 
response. Thus, there may be direct and/or indirect effects of I3C on T cells in the gut, 
and this possibility must be further evaluated. 
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Taken together, our results demonstrate the novel finding that I3C imparts sex-
specific effects in the TNBS colitis model. Since these findings could have significant 
implications for Crohn’s disease patients consuming increased amounts of cruciferous 
vegetables and/or I3C dietary supplements, additional studies are warranted to define the 
specific mechanisms responsible for the divergent effects on colonic inflammation 
induced by I3C.  
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ABSTRACT 
 The aryl hydrocarbon receptor (AhR) has been identified as a potential 
therapeutic target for chronic inflammatory diseases, as activation of the AhR by various 
ligands can suppress disease severity.  In the process of confirming the role of the 
receptor in mediating the effects in murine colitis, several investigators demonstrated that 
AhR knockout (KO) mice were more sensitive to inflammatory stimuli and consequently 
developed a more severe disease phenotype.  Similarly we set out to further evaluate the 
role of the receptor in TNBS-induced colitis in our laboratory. In contrast to published 
results, our AhR KO mice exposed to TNBS developed a less severe disease state, as 
demonstrated by decreased weight loss, decreased colonic inflammation, and decreased 
expression of pro-inflammatory cytokine genes. However, by using the AhR antagonist 
CH223191 in AhR wild-type (WT) exposed to TNBS, we generated the anticipated 
results in that CH223191-treated mice developed colitis and also displayed increased 
colonic inflammatory mediator production as well as increased expression of 
inflammatory genes, which are indicative of a more severe disease state. Taken together, 
our results demonstrated that AhR KO mice in this animal facility are less sensitive to 
intestinal inflammation induced by TNBS.  Since there was no definitive explanation for 
the decreased responsiveness to TNBS in AhR KO mice, additional studies are necessary 
to better understand the gut mucosal immune responses in these mice. 
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INTRODUCTION 
 The aryl hydrocarbon receptor (AhR) is critical in modulating immune responses 
and other physiological processes, as evident by the potentially adverse effects exerted by 
its prototypical ligand, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD).  Importantly, these 
effects induced by TCDD are not usually observed in AhR knockout (KO) mice thereby 
emphasizing the role of this receptor in the documented pathologies.  The AhR also plays 
important roles in normal cellular and developmental processes, as abnormalities in AhR 
KO mice have been observed including hypertrophy and fibrosis of cardiac and hepatic 
tissues, lymphocyte depletion in the spleen, skin lesion, and rectal prolapses in aging 
AhR KO mice (Schmidt et al., 1996; Fernandez-Salguero et al., 1997).  Notably, the AhR 
is critical in regulating inflammatory responses.  AhR KO mice are more susceptible to 
inflammatory stimuli, such as lipopolysaccharide, as increased production of 
inflammatory mediators and increased mortality due to sepsis have been documented 
(Kimura et al., 2009; Sekine et al., 2009).   
Since the AhR has critical roles in immune and inflammatory responsiveness, 
numerous studies in recent years have targeted the AhR via TCDD and other ligands for 
the treatment of chronic inflammatory disorders.  While performing our studies using the 
TNBS colitis model, reports emerged regarding the role of the AhR in the dextran sodium 
sulfate (DSS) colitis model, a chemically induced colitis model that primarily triggers a 
Th2-mediated immune response in the gut.  AhR activation by TCDD was also protective 
in these studies, as decreased disease severity and decreased production of inflammatory 
mediators was decreased (Takamura et al., 2010).  The role of the receptor in this model 
was also investigated independent of ligand treatment.  AhR KO mice exposed to DSS 
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developed a more severe colitis phenotype that resulted in the death of several mice 
(Arsenescu et al., 2011; Furumatsu et al., 2011). 
Our laboratory has previously demonstrated the beneficial effects of the AhR 
ligands TCDD and I3C against 2,4,6-trinitrobenzenesulphonic acid (TNBS)-induced 
colitis (Benson and Shepherd, 2011).  In line with other investigators, we wanted to use 
AhR KO mice to definitively demonstrate that the receptor is indeed involved in 
mediating the effects of various ligands that dampened disease severity.  Therefore, in 
this study we first aimed to reproduce the results generated in AhR KO mice independent 
of ligand treatment and hypothesized that TNBS-exposed AhR KO mice should 
experience a more severe disease phenotype compared to AhR wild-type (WT) mice. Our 
results surprisingly revealed that AhR KO mice were less sensitive to the intestinal 
inflammation induced by TNBS. When AhR WT mice were exposed to an AhR 
antagonist prior to TNBS, however, colitis was successfully induced. Thus, distinctly 
different outcomes were observed in our animal facility in mice lacking receptor versus 
blocking receptor activity in wild-type mice. 
  
MATERIALS AND METHODS 
Laboratory animals.  Six to eight week old AhR WT and AhR KO female mice (both on 
the C57Bl/6 background) were bred and maintained in the animal research facility at the 
University of Montana. C57Bl/6 AhR WT mice were originally obtained from The 
Jackson Laboratories (Bar Harbor, ME) and bred in-house. C57Bl/6 AhR KO 
(B6.AhRtm1Bra) mice were obtained from Dr. Paige Lawrence (University of Rochester 
Medical College, Rochester, NY) and bred as previously described (Schmidt and 
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Bradfield, 1996). All mice were housed under specific pathogen-free conditions and 
maintained on 12 h dark/light cycles. Throughout each experiment animals were 
individually caged, and standard laboratory food and water were provided ad libitum. All 
protocols for the use of animals were approved by the University of Montana Institutional 
Animal Care and Use Committee and adhered to the current NIH guidelines for animal 
usage. 
 
Chemicals. 2,4,6-trinitrobenzenesulfonic acid (TNBS) was obtained from Sigma-Aldrich 
and dissolved in 4:1 acetone:olive oil for pre-sensitization or 40% ethanol (EtOH) for 
enema administration. The acetone/olive oil solution was used for the vehicle in the 
antagonist experiment. The AhR antagonist CH223191 (Sigma-Aldrich) was dissolved in 
DMSO (final concentration 0.07%) and further diluted in PBS for i.p. delivery.   
 
Colitis induction.  Colitis was induced with TNBS, as previously described (Benson and 
Shepherd, 2011). As shown in Figure 4.1, pre-sensitization was conducted on day 0, as 
previously described (Benson and Shepherd, 2011).  For experiments utilizing an AhR 
antagonist, 10 µg CH223191 in PBS was delivered via i.p. injection on day 6. The dose 
as well as the delivery and timing were based on the study conducted by Monteleone and 
colleagues (2011). Body weight loss and clinical signs were monitored daily. Briefly, the 
severity of each clinical sign was scored on a scale 0-3 and combined to determine the 
total severity score. On day 12, mice were euthanized via CO2 asphyxiation followed by 
cervical dislocation. 
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Figure 4.1 
 
 
 
 
 
 
 
 
 
Figure 4.1.  Experimental design.   AhR WT and KO mice were peripherally sensitized 
with TNBS and subsequently received an enema containing TNBS to induce colitis on 
day 7.  In experiments utilizing the AhR antagonist in AhR WT mice, CH223191 was 
delivered via i.p. injection on day 6.  Tissues were harvested 5 days after disease 
induction for evaluation. 
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Colon processing and histology. Colons were excised from each mouse and washed with 
PBS to remove debris. For histological analysis, a 1 cm section from the distal colon was 
fixed in 2% paraformaldehyde, processed in the Shandon Citadel 2000 Automated Tissue 
Processor (Thermo Fisher Scientific, Waltham, MA) with vacuum unit, embedded using 
the Shandon Histocentre 2 Embedding unit, sectioned at 7 µm using the Thermo Shandon 
Finesse 325 microtome, and stained with hematoxylin and eosin (H&E) in the Shandon 
Veristain 24-4 Slide Stainer. Colons were assessed microscopically by a blinded 
individual to determine the severity of inflammation based on the scale developed by our 
laboratory (Benson and Shepherd, 2011).  Briefly, the extent of inflammatory cell 
infiltration and tissue lesions was scored on a scale 0-3 and combined to determine a total 
damage score. Slides were imaged using the Nikon E800 Microscope with Cambridge 
Research Instrumentation, Inc. and Nuance camera software version 1.62 at 10X 
magnification. Another section of the colon was homogenized in lysis buffer from which 
the supernatants were analyzed for cytokine production using commercially available 
ELISA kits.  The last section of the colon was homogenized in Trizol for gene expression 
analysis. 
 
Cytokine assays.  Supernatants from homogenized colon tissue were examined for the 
levels of IL-6, IL-10, IL-12, IL-17, IL-22, IFN-γ, and TNF-α via enzyme-linked 
immunosorbent assay (ELISA).  Samples were analyzed according to the manufacturer’s 
instructions using mouse cytokine-specific BD OptEIA ELISA kits (BD Biosciences, San 
Diego, CA) or R&D ELISA kits (Minneapolis, MN). 
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qRT-PCR. RNA was isolated from colon tissue with Trizol reagent (Invitrogen, Carlsbad, 
CA) followed by RNA clean-up using the Total RNA Kit with optional DNase treatment 
(Omega Bio-Tek, Norcross, GA) according to the manufacturers’ instructions. First 
strand cDNA synthesis was performed using 500 ng RNA and qScript cDNA Supermix 
(Quanta Biosciences, Gaithersburg, MD). Resulting cDNA was subjected to qRT-PCR 
using commercially obtained primers (SABiosciences, Frederick, MD) including aryl 
hydrocarbon receptor (AHR), cytochrome P450 A1 (CYP1A1), interferon gamma (IFNG), 
interleukin 6 (IL6), IL10, IL12, IL17A, IL22, and tumor necrosis factor alpha (TNFA). 
Reactions were performed with PerfeCTa SYBR Green Supermix (Quanta Biosciences) 
on an Agilent Technologies Stratagene Mx3005P® QPCR System (Santa Clara, CA). 
Resulting data were normalized to β-actin, and fold changes were calculated using the 
∆∆Ct method, which compares threshold values of the samples of interest for a particular 
gene relative to a housekeeping gene. 
 
Statistics. All statistical analyses were performed using GraphPad Prism 4.0a for 
Macintosh (GraphPad Software, San Diego, CA). Student’s t-test was used to compare 
WT versus KO groups while 2-way analysis of variance (ANOVA) with Bonferroni’s 
post-hoc test was used to compare multiple groups. Values p≤0.05 were determined to be 
significant. 
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RESULTS 
TNBS colitis is less severe in AhR KO mice.  In order to investigate the role of the AhR 
in colitis, the clinical signs of colitis were first monitored in AhR WT and KO mice that 
were not treated with an AhR ligand.  As shown in Figure 4.2, both WT mice and KO 
mice rapidly lost more than 10% of their initial body weights following TNBS exposure. 
Surprisingly, the AhR KO mice were less sensitive than AhR WT mice, as they lost less 
body weight (Figure 4.2A) and recovered more rapidly from clinical signs (Figure 4.2B). 
Furthermore, the degree of inflammatory cell infiltration and tissue lesions was also 
lower in KO mice compared to WT mice, as the average damage score was 4.7 in AhR 
WT mice and 2.5 in AhR KO mice (Figure 4.2C). 
 
Inflammatory and protective mediator production in mice experiencing colitis.  To 
further evaluate how AhR KO mice respond to TNBS-induced colitis, the production of 
cytokines critical to potentiating colonic inflammation were assessed.  In AhR KO mice, 
IL-10 production increased from 1096 pg/ml in AhR WT mice to 1252 pg/ml, and IL-12 
production decreased from 1628 pg/ml in WT mice to 1342 pg/ml in AhR KO mice 
(Figure 4.3).  No significant changes were observed in IL-6, IL-17, IL-22, IFN-γ, or 
TNF-α levels in the colon.  
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Figure 4.2 
 
A.      B. 
 
 
 
 
 
 
 
 
 
C. 
 
 
Figure 4.2.  TNBS colitis is less severe in AhR KO mice.  AhR WT mice (•) and AhR 
KO mice (°) were monitored daily after disease induction for body weight loss (A) and 
other clinical symptoms including body condition, dehydration state, and stool 
consistency (B).  Damage in colonic tissue was also evaluated for inflammatory cell 
infiltration and tissue lesions (C).  Results are shown as mean ± SEM (n=5) and 
representative of three separate experiments. *indicates significances of p≤0.05.   
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Figure 4.3  
 
 
 
 
Figure 4.3. Inflammatory and protective mediator production during colitis.  
Colonic tissues from AhR WT and KO mice were homogenized, and cytokine levels in 
the supernatants were measured by ELISAs.  Results are shown as mean ± SEM (n=5) 
and representative of three separate experiments. *indicates significances of p≤0.05. 
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Altered gene expression in AhR KO mice exposed to TNBS.  Modifications in colonic 
gene expression were evaluated next to better understand the unexpected results in 
TNBS-exposed AhR KO mice.  In contrast to the relatively unchanged protein 
expression, several genes were down-regulated in TNBS-exposed AhR KO mice 
compared to AhR WT mice (Table 4.1).  Notably, decreased mRNA expression was 
observed in AHR by 154-fold, IFNG by 46.7-fold, IL6 by 10.9-fold, IL10 by 5.9-fold, 
IL12 by 8.7-fold, IL17A by 13.9-fold, and TNFA by 12.0-fold. No significant changes 
were observed in CYP1A1 or IL22 expression. 
 
AhR WT mice exposed to the AhR antagonist CH223191 develop colitis. Recently it 
was demonstrated that the AhR antagonist CH223191 generated results similar to studies 
using AhR KO mice (i.e. more severe disease phenotype) in mice exposed to TNBS 
(Monteleone et al., 2011). Since we did not observe a more severe outcome in 
conventional AhR KO mice treated with TNBS, this AhR antagonist was used to block 
AhR activity in wild-type mice during TNBS-induced colitis. As expected, mice exposed 
to the EtOH control only (with no TNBS enema and with/without CH223191) did not 
develop disease, as demonstrated by no decrease in body weight or increase in severity of 
clinical signs (Figure 4.4A).  While both groups of mice exposed to TNBS developed 
colitis, the difference between CH223191 and its PBS vehicle was not statistically 
significant. Histological evaluation revealed significant inflammatory cell infiltration and 
tissue lesions following TNBS exposure (Figure 4.4B).  However, CH223191-treated 
mice experienced a trend towards increased colonic damage, as indicated with a score of 
5.0 with CH223191 treatment compared to the score of 4.38 with vehicle treatment.   
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Table 4.1.  Gene expression is decreased in the gut of AhR KO mice during colitis 
 
 
 
 
 
 
 
Colon tissue was harvested on day 5 post-enema, homogenized in Trizol, and 
subsequently subjected to qRT-PCR to assess changes in gene expression.  Fold change is 
relevant to AhR WT mice and normalized to β-actin.  Data are representative of one 
experiment (n=5). *indicates significances of p≤0.05. 
 
 
 
 
Gene Fold change p-value 
AHR -154* 0.02 
CYP1A1 -1.7 0.4 
IFNG -46.7* 0.007 
IL6 -10.9* 0.006 
IL10 -5.9* 0.008 
IL12 -8.7* 0.03 
IL17A -13.9* 0.02 
IL22 -1.6 0.3 
TNFA -12.0* 0.03 
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Figure 4.4 
A. 
 
B. 
 
 
 
 
 
 
 
Figure 4.4.  TNBS colitis is induced in CH223191-treated WT mice.  Mice were 
monitored daily after disease induction for body weight loss and other clinical symptoms 
including body condition, dehydration state, and stool consistency (A).  Damage in 
colonic tissue was also evaluated for inflammatory cell infiltration and tissue lesions (B). 
Results are representative of one experiment (n=3-6). *indicates significances of p≤0.05.  
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CH223191 treatment alters inflammatory mediator and gene expression profiles. 
Treatment with the AhR antagonist CH223191 significantly altered cytokine production 
in the colon of TNBS- and vehicle-exposed mice (Figure 4.5).  In TNBS-exposed mice, 
CH223191 increased IL-6 from 411 to 1462 pg/ml, IL-10 from 287 to 340 pg/ml, IL-17 
from 158 to 196 pg/ml, and IFN-γ from 117 to 176 pg/ml. Conversely, IL-12 and TNF-α 
production was significantly decreased.  In absence of the TNBS inflammatory stimulus, 
mice exposed to CH223191 exhibited increased IL-10 production from 319 to 410 pg/ml 
and increased IL-22 production from 99 to 142 pg/ml.  
CH223191 also induced several changes in colonic gene expression on day 5 
post-enema (Table 4.2).  In TNBS-exposed mice, CH223191 significantly increased the 
expression of several inflammatory mediators including IFNG by 12.5-fold, IL6 by 3.2-
fold, IL10 by 9.9-fold, IL12 by 9.5-fold, and IL17A by 6.2-fold.  Although CH223191 
had no effect on AHR gene expression, CYP1A1 expression was not increased, which is a 
hallmark indicator of AhR activation by an agonist. In line with other investigators, AHR 
expression was significantly upregulated by 636-fold in TNBS-exposed mice compared 
to the ethanol vehicle control (data not shown). Finally, in the absence of TNBS, 
CH223191 did not induce changes in colonic gene expression at the time of harvest.  
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Figure 4.5 
 
 
 
Figure 4.5. CH223191 alters cytokine production in AhR WT mice during colitis.  
Colonic tissues were collected on day 5 post-TNBS enema, homogenized, and cytokine 
levels in the supernatants measured by ELISA.  Results are shown as mean ± SEM (n=5) 
and representative of one experiment (n=3-6). *indicates significances of p≤0.05. 
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Table 4.2.  Gene expression is altered in the gut of CH223191-treated mice 
 
 
 
 
 
 
 
 
Colon tissue was harvested on day 5 post-enema, homogenized in Trizol, and 
subsequently subjected to qRT-PCR to assess changes in gene expression.  Fold change is 
relevant to vehicle-treated mice and normalized to β-actin.  Data are representative of one 
experiment (n=3-6). *indicates significances of p≤0.05. 
TNBS EtOH Gene Fold change p-value Fold change p-value 
AHR 2.3 0.2 -1.3 0.4 
CYP1A1 1.2 0.4 -1.7 0.3 
IFNG 12.5* 0.02 -1.5 0.3 
IL6 3.2* 0.05 1.5 0.3 
IL10 9.9* 0.04 -1.0 0.5 
IL12 9.5* 0.02 1.3 0.4 
IL17A 6.2* 0.04 -1.1 0.5 
IL22 1.0 0.5 -1.2 0.4 
TNFA 1.2 0.4 1.4 0.3 
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 DISCUSSION 
Since immune suppression is a classic response following activation of the AhR, 
this signaling pathway has been investigated as a new therapeutic target for chronic 
inflammatory diseases, such as Crohn’s disease and multiple sclerosis. In fact, numerous 
studies have been published recently regarding the beneficial effects of AhR activation by 
TCDD to reduce disease severity (Quintana et al., 2008; Kerkvliet et al., 2009; Takamura 
et al., 2010; Benson and Shepherd, 2011).  Recently several laboratories have focused 
their studies on the role of the AhR in intestinal inflammation. As such, AhR KO mice 
have been used to confirm the role of the AhR in mediating the effects of various ligands.  
In addition to demonstrating that the AhR was responsible for mediating the protective 
effects against colitis, it has also been shown that AhR KO mice were more sensitive to 
inflammation (Arsenescu et al., 2011). Similarly, in this study we also aimed to 
definitively demonstrate the role of the AhR by using conventional AhR KO mice in the 
TNBS-induced colitis model.   
We first evaluated the role of the AhR in TNBS-induced colitis independent of 
AhR ligand treatment in AhR WT and KO mice.  Surprisingly, AhR KO mice appeared 
to be less sensitive to disease severity and colonic inflammation.  Furthermore, there was 
a significant decrease in the expression of several pro-inflammatory genes in the colon 
including IFNG, IL6, IL12, IL17A, and TNFA. Thus, decreased inflammatory mediator 
production may be partially responsible for reduced inflammation in the gut of our AhR 
KO mice.  This finding is in complete contrast to a previously published report that was 
conducted in WT and AhR KO mice using DSS-induced colitis, as it was revealed that 
AhR KO mice exposed to DSS died within 7 days of the beginning of treatment whereas 
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the AhR WT mice developed colitis as expected (Arsenescu et al., 2011).  Furumatsu and 
colleagues also confirmed increased mortality in AhR KO mice exposed to DSS and 
consequently suggested that the endogenous ligands that regulate homeostasis in AhR 
WT mice cannot do so in AhR KO mice thereby resulting in exacerbated DSS-induced 
colitis (Furumatsu et al., 2011). Although this hypothesis is plausible for their results, it is 
not consistent with the ameliorated disease state we observed in AhR KO mice treated 
with TNBS to induce colitis.  
Instead of using AhR KO mice, several laboratories use chemical antagonists to 
block AhR receptor activity to specifically evaluate the role of the AhR in mediating 
various physiologic responses. One such antagonist is CH223191, which was first 
identified as an antagonist by Kim and colleagues because this compound blocked 
TCDD-induced gene transcription responsible for mediating the toxic effects of TCDD 
(Kim et al., 2006).  However, CH223191 is a ligand-selective antagonist as it inhibits 
some AhR agonists, such as TCDD and related halogenated aromatic hydrocarbons, but 
not others, such as polycyclic aromatic hydrocarbons, flavonoids, and indirubin (Zhao et 
al., 2010). Moreover, it is currently unknown if this antagonist blocks the binding of 
endogenous ligands. Nevertheless, using an antagonist such as CH223191 can be 
advantageous over AhR KO mice since it is used in WT mice that develop normally and 
do not have other physiological defects that have been reported in conventional AhR KO 
mice.   
Accordingly, the AhR antagonist CH223191 was administered to AhR WT mice 
prior to inducing colitis with TNBS (Monteleone et al., 2011).  In this study, the authors 
observed increased disease severity and inflammation in mice co-treated with TNBS and 
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CH223191, which is consistent with the observations in AhR KO mice exposed to DSS.  
Since our results in the TNBS-induced colitis model using AhR KO mice were not 
consistent with previously published reports using either TNBS or DSS, we performed an 
additional study using CH223191 in an experimental approach (i.e. dose and regimen) 
similar to Monteleone and colleagues (2011).  We found that administration of 
CH223191 to AhR WT mice resulted in the induction of colitis by TNBS.  This outcome 
was distinctly different than what we previously observed with AhR KO mice in which 
colitis disease severity was attenuated in AhR WT mice.  Interestingly, although the 
differences were not statistically significant, there was also a trend towards increased 
colonic damage and more severe clinical signs in mice exposed to CH223191.  
In addition to the effects on disease severity observed in TNBS-treated mice, 
CH223191 also significantly altered the production of several pro-inflammatory 
cytokines.  There was increased production of IL-6, IL-17, and IFN-γ, which is 
supportive of the anticipated exacerbated disease phenotype.  Interestingly, CH223191 
decreased IL-12 and TNF-α production, which was not observed by Monteleone and 
colleagues (2011).  The expression of several inflammatory genes was also increased in 
CH223191-treated mice with the TNBS inflammatory stimulus, which is suggestive of a 
more severe disease phenotype. However, we did not detect a decrease in AHR gene 
expression induced by CH223191 at the time of harvest, an effect that was observed by 
Monteleone and colleagues (2011).  It is possible that AhR protein levels decreased in 
colonic tissue even though gene expression was unchanged; however, this possibility has 
yet to be evaluated. Nevertheless, the trend toward an anticipated increased disease 
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severity and increased inflammation was observed in our AhR WT mice exposed to 
CH223191. 
While we could not replicate the published results of colitis in AhR KO mice, we 
were able to generate results that were more consistent with published observations using 
an AhR antagonist in AhR WT mice. Thus, several factors may be affecting the immune 
responsiveness in the gut of our AhR KO mice.  First of all, it must be noted that there 
are multiple conventional AhR KO mice commercially available on the C57Bl/6 
background.  One strain was generated by the Gonzalez laboratory by targeting exon 1 
for deletion (Fernandez-Salguero et al., 1997) whereas another strain was generated by 
the Bradfield laboratory by targeting exon 2 for deletion (Schmidt et al., 1996).  
Although several similar pathologies are observed in both AhR KO mice, there are 
numerous discrepancies between the two null alleles (reviewed in (Lahvis and Bradfield, 
1998).  This may be due to different targeting strategies that can alter the function of 
neighboring genes, different genetic backgrounds used to generate AhR KO mice, and/or 
the variability of housing environments. In our studies we used the mice generated from 
the Bradfield laboratory; however, other conventional AhR KO mice were used in other 
studies.  Furumatsu and colleagues used another null mouse generated by the Fujii-
Kuriyama laboratory (Shimizu et al., 2000), while Arsenescu and colleagues (2011) did 
not specify which AhR KO mice strain they obtained from Jackson Laboratories.  
Therefore, it is very possible that the differences in the AhR null alleles contribute to the 
inconsistencies observed in our studies compared to the current literature.   
Additionally, we observed sex-specific effects on colitis severity when dietary 
AhR ligand indole-3-carbinol was administered to mice. Although not previously 
 124 
documented, male and female AhR KO mice in our facility could respond differently to 
absence of the AhR.  In our studies, we used female mice, as at the time of the study we 
had a greater availability of female AhR KO mice.  Arsenescu and colleagues (2011) 
used male AhR KO mice while Furumatsu and colleagues (2011) did not specify the sex 
of mice utilized.  Thus, a combination of sex differences and difference in null alleles 
could be contributing to the decreased disease severity observed in our studies. 
Finally, it is also possible that the microbiome and/or various environmental 
conditions (i.e. bedding, food, etc…) in this facility have significantly impacted the 
inflammatory responsiveness of AhR KO mice making them less susceptible to TNBS-
induced colitis. Accordingly, AhR KO fecal samples were sent to Charles River for a 
PCR Rodent Infectious Agent (PRIA) panel analysis to assess the presence of parasites, 
viruses, bacteria, and fungi that may be affecting gut mucosal immune responses (data 
not shown). Results revealed that our AhR KO mice tested positive for mouse norovirus 
(MNV), Pasturella pneumotropica-Heyl and Helicobacter hepaticus.  MNV and P. 
pneumotropica are very common in many animal facilities, and MNV has been present in 
our animal facility for several years. AhR KO mice are known to have Helicobacter 
present in the gut, which is a contributing factor to rectal prolapses in mice greater than 9 
months (Schmidt et al., 1996; Fernandez-Salguero et al., 1997), an effect that we have 
observed over the last several years in our AhR KO colony. MNV has been attributed to 
worsened intestinal inflammation in a bacteria-induced model of colitis (Lencioni et al., 
2008).  Although some pathogens are present in the gut of AhR KO mice, these 
pathogens are not necessarily supportive of making these mice less sensitive to colitis 
induction by TNBS.  However, there could be a shift in commensal bacteria in this 
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facility that alters immune responsiveness to TNBS, which has yet to be investigated. 
Furthermore, preliminary microarray and proteomics analyses (Appendix 1) conducted 
on naïve AhR KO mice did not provide a definitive answer to explain the discrepancies, 
but the data suggested that decreased NF-kB signaling and decreased apoptosis in the 
AhR KO gut may contribute to the decreased disease severity in AhR KO mice. Future 
studies evaluating the importance of these signaling pathways in the gut of AhR KO mice 
in this facility may help elucidate the mechanisms responsible for their decreased 
sensitivity to TNBS. 
Collectively, our results demonstrate that AhR KO mice in the University of 
Montana Laboratory Animal Facility are less sensitive to intestinal inflammation induced 
by TNBS whereas AhR WT mice treated with an antagonist develop colitis as expected. 
By achieving the documented trend towards increased disease severity using the AhR 
antagonist in AhR WT mice, this strongly suggests that a complex set of factors is 
drastically impacting the ability of these mice to respond to the TNBS inflammatory 
stimulus.  Additional studies are warranted to better understand the gut mucosal immune 
responses in our AhR KO mice. 
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CHAPTER 5 
 
Dietary ligands of the aryl hydrocarbon receptor induce anti-inflammatory and 
immunoregulatory effects on murine dendritic cells 
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ABSTRACT  
Activation of the aryl hydrocarbon receptor (AhR) in immune cells, such as 
dendritic cells (DCs), can lead to suppressed immune responses.  Although AhR 
activation is most recognized for mediating the effects of its prototypical ligand 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD), many compounds existing in dietary sources can 
also bind the AhR. Since the immunomodulatory effects of indole-3-carbinol (I3C) and 
indirubin-3’-oxime (IO) have yet to be investigated in DCs, we evaluated the potential 
immunomodulatory effects of these compounds on murine DCs. We hypothesized that 
I3C and IO suppress immune and inflammatory responses in DCs. We found that both 
I3C and IO decreased the expression of CD11c, CD40, and CD54 while they increased 
expression of MHC2 and CD80.  Following LPS-activation, I3C and IO suppressed the 
production of pro-inflammatory mediators including TNF-, IL-1, IL-6, IL-12, and 
nitric oxide but increased IL-10 levels. These effects of I3C and IO were partially 
mediated by the AhR. Additionally, immunoregulatory genes, such as ALDH1A, IDO and 
TGFB, were upregulated following treatment with I3C or IO. Both I3C and IO decreased 
basal levels of NF-B p65 but only I3C suppressed the LPS-induced activity of RelB. 
Finally, when cultured with naïve T cells, BMDCs treated with the dietary AhR ligands 
increased the frequency of Foxp3+ Tregs in an antigen-specific manner.  Taken together, 
these results indicate that I3C and IO exhibit immunosuppressive and anti-inflammatory 
effects on DCs. Since I3C and IO are significantly less toxic than TCDD, these natural 
products may ultimately become useful therapeutics for the treatment of autoimmune and 
inflammatory diseases. 
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INTRODUCTION 
 Dendritic cells (DCs) are professional antigen presenting cells (APCs) that bridge 
the innate and adaptive branches of the immune system.  As such, these cells are critical 
to mounting successful immune and inflammatory responses against antigens as well as 
promoting tolerance.  Following antigen uptake in the periphery, DCs mature and migrate 
to lymph nodes where they present processed antigen to naïve T cells.  Many factors 
contribute to the ensuing adaptive immune response.  One of these involves activation of 
the aryl hydrocarbon receptor (AhR), the cytosolic ligand-activated transcription factor 
responsible for the toxic and immunomodulatory effects of its prototypical ligand, 
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD).  The AhR is expressed in immune cells and 
is involved in many important physiological processes, as AhR deficient mice have 
numerous defects including slowed early growth, anal prolapses, and hepatic 
abnormalities (Schmidt et al., 1996).  Importantly, AhR activation by TCDD in DCs 
results in immune suppression via induction of indoleamine-2,3-dioxygenase (IDO) and 
subsequent generation of regulatory T cells (Tregs) (Vogel et al., 2008; Mezrich et al., 
2010; Nguyen et al., 2010; Simones and Shepherd, 2011). 
 Besides environmental contaminants, additional compounds present in the diet 
have the potential to bind and activate the AhR.  One of these dietary constituents is 
indole-3-carbinol (I3C), which is found in cruciferous vegetables, and another is 
indirubin, which is a component in the traditional Chinese medicine Danggui Longhui 
Wan.  However, neither of these compounds binds the AhR as potently as TCDD.  Both 
I3C and indirubin have well-documented anti-cancer properties, as they both work in part 
by inhibiting cyclin dependent kinases that leads to cell cycle arrest in various cell lines.  
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More specifically, I3C has been evaluated for the treatment of both breast and prostate 
cancer (Weng et al., 2008) while indirubin has been used traditionally for the treatment of 
chronic myelocytic leukemia (Eisenbrand et al., 2004). 
Despite these known effects on cancerous cells, the effects of I3C and indirubin 
on immune cells have not yet been investigated in depth.  I3C suppresses the production 
of pro-inflammatory cytokines in macrophages (Chen et al., 2003; Tsai et al., 2010; 
Chang et al., 2011) while indirubin has been demonstrated to suppress these mediators in 
splenocytes and microglial cells (Kunikata et al., 2000; Jung et al., 2011).  Therefore, 
studies evaluating the effects of these dietary AhR ligands on additional immune cell 
populations, such as DCs that constitutively express the AhR, are warranted since these 
compounds are present in the diet or readily consumed supplements and have great 
potential as complementary therapies in chronic inflammatory diseases.  
In this study we aimed to define the specific immunomodulatory effects of I3C 
and indirubin on murine bone marrow-derived DCs (BMDCs).  We hypothesized that 
these natural AhR ligands alter DC maturation such that they suppress immune and 
inflammatory responses in DCs.  To test this hypothesis, we conducted an array of in 
vitro experiments to assess changes in BMDC fate and function following exposure to 
I3C and indirubin. The results obtained in this study suggest that both I3C and indirubin 
generate immunosuppressive effects on DCs that may promote a regulatory environment, 
which may be useful to suppress chronic inflammatory diseases and/or autoimmunity in 
vivo.  
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MATERIALS AND METHODS 
Chemicals and reagents. Indole-3-carbinol (I3C) and indirubin-3’-oxime (IO), a 
commercially available indirubin derivative that is also an AhR agonist (Guengerich et 
al., 2004), were obtained from Sigma-Aldrich (St. Louis, MO) and dissolved in DMSO 
(Sigma-Aldrich). Both compounds were >99% pure when purchased, and the purities of 
I3C and IO were also confirmed in house prior to use via NMR and HPLC, respectively 
(data not shown).  For initial concentration-response studies, I3C was used at 
concentrations of 25, 50, 100, and 200 μM and IO was used at 0.01, 0.1, 1.0, and 5.0 μM.  
For all other experiments, I3C and IO were used at final concentrations of 50 μM and 1 
μM, respectively. The final concentration of solvent used in cell culture was below 0.1% 
and did not induce DC cytotoxicity. 
 
Mice. Six- to 8-week old male AhR
+/+
, AhR
-/-
, and OTII Foxp3
egfp 
mice (all on a C57Bl/6 
background) were bred and maintained in the animal research facilities at the University 
of Montana. C57Bl/6 AhR
+/+ 
were originally obtained from The Jackson Laboratories 
(Bar Harbor, ME) and bred in-house. C57Bl/6 AhR
-/- 
(B6.AhR
tm1Bra
) mice were 
generously provided by Dr. B.P. Lawrence (University of Rochester Medical College, 
Rochester, NY) and bred as previously described (Schmidt and Bradfield, 1996).  OTII 
Foxp3
egfp
 mice were kindly provided by Dr. Randolph J. Noelle (Dartmouth Medical 
School, Lebanon, NH), who originally obtained these mice from Dr. A. Rudensky 
(University of Washington School of Medicine, Seattle, WA), and bred as previously 
described (Wang et al., 2008). To verify identity of mutant mice prior to use in 
experiments, AhR
-/-
 mice and OT II Foxp3
egfp
 mice were genotyped via PCR and 
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phenotyped via flow cytometry, respectively.  The genotype of AhR
+/+
 and AhR
-/-
 mice is 
based on the presence of AhR
b
 or AhR
d
 alleles.  The AhR
+/+
 mice possess the AhR
b
 allele 
(AhR
b/b
), which is 300bp, whereas AhR
-/-
 mice possess the d allele (AhR
d/d
), which is 
260bp. AhR
+/-
 mice possess both the b and d alleles thus resulting in both the 300bp and 
260bp products. Mice were housed under specific pathogen-free conditions and 
maintained on 12 h dark/light cycles. Standard laboratory food and water were provided 
ad libitum.  All protocols for the use of animals were approved by the University of 
Montana Institutional Animal Care and Use Committee and adhered to the current 
National Institutes of Health (NIH) guidelines for animal usage. 
 
Bone marrow-derived dendritic cells (BMDCs). BMDCs were prepared as previously 
described (Bankoti et al., 2010).  Briefly, bone marrow cells were collected by flushing 
murine femurs and tibias with complete media (cRPMI) comprised of RPMI (GibcoBRL, 
Grand Island, NY) supplemented with 10% FBS (Hyclone, Logan, UT), 50 µM 
mercaptoethanol, 20 mM HEPES, 10 mM sodium pyruvate, and 50 µg/ml gentamicin 
(GibcoBRL, Grand Island, NY). Subsequent gradient centrifugation using the 
Lympholyte

-M reagent (Cedarlane Laboratories Limited, Ontario, Canada) removed red 
blood cells. The hematopoietic cells were cultured at a density of 1x10
6
 cells/ml in tissue 
culture flasks or 6-well plates in cRPMI supplemented with 30 ng/ml murine GM-CSF 
(PeproTech, Rocky Hill, NJ) and treated with AhR ligands or vehicle control. Cells were 
grown for 7 d at 37°C and 5% CO2.  Media, growth factor, and AhR ligand treatment 
were refreshed on days 3 and 5.  On day 7, non-adherent cells representing immature 
DCs were harvested and purified using anti-CD11c (N418) beads (Miltenyi Biotec, 
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Auburn, CA) and the Miltenyi AutoMACS per the manufacturer’s instructions. BMDC 
purity was verified via flow cytometry, and cells subsequently cultured were >90% 
CD11c+.  Cells were ≥95% viable as determined by Trypan blue exclusion.  
 
Flow cytometry.  Accessory molecule expression on isolated cells was determined by 
flow cytometry, as previously described (Shepherd et al., 2001).  Briefly, cells were 
washed with PAB (1% bovine serum albumin and 0.1% sodum azide in PBS). Fc block 
(BioLegend, San Diego, CA) was used to eliminate non-specific staining. Optimal 
concentrations of fluorochrome-conjugated monoclonal antibodies were used to stain 
cells for an additional 10 min on ice.  Antibodies used in these experiments included 
CD11c-APC (HL3), MHC2-PECy7 (M5/114.15.2), CD86-AlexaFluor700 (GL-1), CD80-
PE (16-10A1), CD54-Pacific Blue (YN1/1.7.4), CD40-FITC (3/23), CD4-APC (RM4-5), 
CD25-PerCPCy5.5 (PC61), and their corresponding isotype controls, all of which were 
purchased from BioLegend (San Diego, CA) or BD Biosciences (San Jose, CA). One to 
five hundred thousand events were collected using a BD FACSAria flow cytometer and 
analyzed using FACSDiva (Version 6.1.2, BD Biosciences, San Jose, CA) and FlowJo 
(Version 8.7.1, TreeStar, Inc., Ashland, OR) software programs. 
 
Cell activation and cytokine assays. Purified vehicle- or AhR ligand-treated BMDCs 
were cultured in 6-well plates at a density of 1x10
6
 cells/ml and stimulated with 1 μg/ml 
lipopolysaccharide [LPS, Escherichia coli (055:B5), Sigma-Aldrich] for 24 h. Cells were 
harvested for immunophenotypic and qRT-PCR analyses while supernatants were 
collected and evaluated for cytokine production using enzyme linked immunosorbent 
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assays (ELISAs). Levels of IL-1, IL-2, IL-6, IL-10, IL-12, IFN- and TNF- were 
measured using BD ELISA kits (BD Biosciences, San Jose, CA) per the manufacturer’s 
instructions.  Levels of nitric oxide (NO) were measured using the Griess Reagent 
System (Promega, Madison, WI) per the manufacturer’s instructions. 
 
Quantitative real-time polymerase chain reaction (qRT-PCR). RNA was isolated from 
BMDCs with Trizol reagent (Invitrogen, Carlsbad, CA) followed by RNA clean-up using 
the Total RNA Kit with optional DNase treatment (Omega Bio-Tek, Norcross, GA) 
according to the manufacturers’ instructions. First strand cDNA synthesis was performed 
using qScript cDNA Supermix (Quanta Biosciences, Gaithersburg, MD). Resulting 
cDNA was subjected to qRT-PCR using commercially obtained primers (SABiosciences, 
Frederick, MD) including aldehyde dehydrogenase 1 family, member A1 (ALDH1A1), 
aldehyde dehydrogenase 1 family, member A2 (ALDH1A2), cytochrome P450 A1 
(CYP1A1), indoleamine-2,3-dioxygenase 1 (IDO1), indoleamine-2,3-dioxygenase 2 
(IDO2), interleukin 6 (IL6), interleukin 10 (IL10), interleukin 27 (IL27), latent binding 
protein 3 (LTBP), transforming growth factor, beta 1 (TGFB1), transforming growth 
factor, beta 2 (TGFB2), and transforming growth factor, beta 3 (TGFB3). Reactions were 
performed with PerfeCTa SYBR Green Supermix (Quanta Biosciences) on an Agilent 
Technologies Stratagene Mx3005P QPCR System (Santa Clara, CA). Resulting data 
were normalized to -actin, and fold changes were calculated using the ∆∆Ct method, 
which compares threshold values of the samples of interest for a particular gene relative 
to a housekeeping gene. 
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NF-kB activity.  DMSO-, I3C-, and IO-treated BMDCs were prepared and purified, as 
described above.  Purified BMDCs (2x10
6
 cells/well) were stimulated with LPS (1 
μg/ml) for 45 min in 6-well plates.  Cells were harvested, and nuclear protein extracts 
were prepared using the Active Motif Nuclear Lysis kit (Active Motif, Carlsbad, CA).  
Protein concentrations were measured using the Bradford reagent (Bio-Rad Laboratories, 
Hercules, CA), and nuclear protein (3 μg/well) was subsequently used in the Active Motif 
TransAM colorimetric assay to evaluate the DNA binding activity of NF-B p65 and 
RelB per the manufacturer’s instructions. 
 
DC:T cell co-cultures. BMDCs were grown in the presence of the DMSO vehicle, I3C, 
or IO for 7 d and subsequently purified, as described above. BMDCs were cultured with 
1 μg/ml OVA323-339 peptide (Mimotopes, Clayton, Victoria, Australia) for 2 h and washed 
twice prior to culturing with T cells.  Spleens as well as the popliteal and brachial lymph 
nodes of OTII Foxp3
egfp
 mice were harvested, and CD4+ T cells were purified to >75% 
using a naïve CD4 T cell isolation kit (Miltenyi Biotec, Auburn, CA) and the Miltenyi 
AutoMACS per the manufacturer’s instructions. Cells were ≥95% viable as determined 
by Trypan blue exclusion. DCs and T cells were co-cultured for 3 d at a ratio of 1:5 
(DC:T cells) in 96-well plates.  On day 3, cells were harvested, evaluated via flow 
cytometry for the frequency of CD4+Foxp3+ T cells, and supernatants were collected for 
subsequent evaluation of cytokine production, as described above. 
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Statistical analyses. Data sets with multiple comparisons were evaluated by one-way 
analysis of variance (ANOVA) with Dunnett’s post-hoc test while data sets with 2 groups 
were analyzed by student’s t-test. Values of p<0.05 were considered significant. 
 
RESULTS 
Concentration-dependent effects of I3C and indirubin-3’oxime (IO) on the viability 
and proliferation of BMDCs. Since the effects of I3C and IO on DCs have not yet been 
evaluated and both compounds can trigger cell cycle arrest, the concentration-dependent 
effects on proliferation and viability of these dietary AhR ligands was initially examined 
in GM-CSF-derived BMDCs. Concentrations of I3C were based on physiologically 
relevant concentrations (reviewed in Howells et al., 2007) while IO concentrations were 
based on other published in vitro studies (reviewed in Eisenbrand et al., 2004), as the 
bioavailability of IO has not yet been determined to our knowledge. Neither compound 
affected the viability of the non-adherent, immature DCs at any concentration tested; 
however, all concentrations of I3C examined decreased DC cell numbers, the highest 
concentrations of I3C (100 μM and 200 μM) decreased cell proliferation by as much as 
60% and 97%, respectively, as indicated by decreased cell numbers (Figure 1). The 
highest concentration of IO (5 μM) also significantly decreased DC cell numbers.  
Therefore, based on the results obtained in this initial experiment demonstrating no 
cytotoxicity and slight anti-proliferative effects, concentrations of 50 μM I3C and 1 μM 
IO were selected for subsequent experiments. 
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Figure 5.1 
 
 
Figure 5.1.  Concentration-dependent effects of I3C and IO on BMDC proliferation 
and viability.  BMDCs were grown in the presence of the 0.1% DMSO vehicle control 
or various concentrations of I3C (A) and IO (B).  After 7 d, non-adherent cells were 
stained with Trypan blue to determine cell numbers and viability.  Results are 
representative of 3 separate experiments with n=3.  *indicates significance of p≤0.05. 
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Immunophenotypic changes induced by I3C and IO.  After determining non-cytotoxic 
concentrations of I3C and IO, the effects of these compounds on BMDC 
immunophenotype were evaluated via flow cytometry (Figure 2).  Both compounds 
significantly decreased the relative expression of CD11c, CD40, and CD54 on BMDCs 
while the expression of MHC class 2 (MHC2), MHC2
hi
 and CD80 was increased.  
Differential effects were observed on CD86 expression, as I3C increased the expression 
of this co-stimulatory molecule while IO decreased its expression. 
 
I3C and IO alter the LPS-induced changes in surface marker expression and cytokine 
production. DCs play critical roles in mounting appropriate immune responses to various 
pathogens and inflammatory insults; therefore, the effects of LPS stimulation on BMDCs 
treated with I3C or IO were examined.  Alterations in cell surface molecule expression 
were assessed initially (Figure 3). Both compounds inhibited the LPS-induced 
upregulation of CD11c and CD40 while enhancing the LPS-induced increase in the 
expression of MHC2 and CD80. I3C upregulated CD86 and CD54; however, IO slightly 
decreased the LPS-induced expression of both CD86 and CD54.  
The effects of I3C and IO on pro-inflammatory cytokine production following 
LPS activation in BMDCs were also assessed.  As anticipated, 1 μg/ml LPS induced the 
production of several pro-inflammatory cytokines including IL-1β, IL-6, IL-12, and TNF-
α. BMDCs exposed to I3C or IO and subsequently stimulated with LPS generally 
produced lower levels of pro-inflammatory cytokines (Figure 4).  I3C and IO decreased 
the LPS-induced production of IL-1β from 1506 pg/ml to 1040 pg/ml and 941 pg/ml, 
respectively.  This effect was also observed with the LPS-induced IL-6 production in 
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Figure 5.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2.  Alterations in BMDC phenotype following AhR ligand treatment.  
BMDCs were grown in the presence of the DMSO vehicle control, 50 μM I3C, or 1 μM 
IO for 7 d and subsequently evaluated for their relative expression (MFI) of surface 
markers via flow cytometry (numerical values are listed in the corresponding table below 
the histograms). Thin gray lines indicate isotype control, dotted black line indicate 
DMSO-treated cells, thick black lines indicate I3C-treated cells, and thick gray lines 
indicate IO-treated cells.  Arrows indicate MHC2/MHC2
hi
, CD86, CD80, CD54, and 
CD40 expression on CD11c+ cells.  Results are representative of 3 separate experiments 
with n=3. *indicates significance of p≤0.05. 
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Figure 5.3 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3.  Dietary AhR ligands alter LPS-induced changes in surface phenotype of 
BMDCs.  BMDCs were grown in the presence of the DMSO vehicle control, 50 μM I3C, 
or 1 μM IO for 7 d and purified.  The immature BMDCs were subsequently treated with 1 
μg/ml LPS for 24 h, and the immunophenotype was evaluated by flow cytometry. Results 
are representative of 3 separate experiments with n=3. #indicates significance of p≤0.05 
compared to unstimulated DMSO control, *indicates significance of p≤0.05 compared to 
LPS-stimulated DMSO control. 
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Figure 5.4 
 
 
 
Figure 5.4.  Suppression of LPS-induced pro-inflammatory cytokine production by 
I3C- and IO-treated BMDCs. BMDCs were grown in the presence of the DMSO 
vehicle control, 50 μM I3C, or 1 μM IO for 7 d and purified.  The immature BMDCs 
were subsequently treated with 1 μg/ml LPS for 24 h, and protein levels of cytokines 
present in the supernatants were measured by ELISA. Results are representative of 3 
separate experiments with n=3.  #indicates significance of p≤0.05 compared to 
unstimulated DMSO control, *indicates significance of p≤0.05 compared to LPS-
stimulated DMSO control. 
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which I3C and IO decreased IL-6 levels from 60 ng/ml to 32 ng/ml and 40 ng/ml, 
respectively.  IL-12 production decreased from 628 pg/ml to 525 pg/ml with I3C and 204 
pg/ml with IO.  This effect was also observed with TNF-α, as this cytokine was decreased 
from 5415 pg/ml to 4338 pg/ml with I3C and to 4427 pg/ml with IO.  Lastly, the LPS-
induced nitric oxide (NO) production was suppressed from 35 μM to 13 μM with I3C and 
to 21 μM with IO.  Conversely, I3C and IO increased the production of the anti-
inflammatory cytokine IL-10 after LPS stimulation from 598 pg/ml to 1211 pg/ml and 
1501 pg/ml, respectively.  Taken together, these results suggest that I3C and IO 
significantly suppress the inflammatory responsiveness of LPS-stimulated BMDCs by 
inhibiting inflammatory mediator production and promoting anti-inflammatory mediator 
production. 
 
I3C and IO induce immunoregulatory genes in BMDCs.  AhR activation in DCs results 
in the induction of regulatory genes, an effect that correlates with a DC-induced 
expansion of CD4+Foxp3+ Tregs (Bankoti et al., 2010; Quintana et al., 2010; Simones 
and Shepherd, 2011).  Thus, the expression of several key immunoregulatory genes was 
assessed in BMDCs treated with I3C or IO to further evaluate the immunosuppressive 
potential of these dietary AhR ligands (Table 1).  Without stimulation, BMDCs grown in 
the presence of I3C upregulated ALDH1A1 by 3.6 fold, CYP1A1 by 5.2 fold, IDO1 by 6.7 
fold, IDO2 by 5.7 fold, TGFB2 by 2.4 fold, and TGFB3 by 5.8 fold (Table 1A).  
Conversely, ALDH1A2 and IL27 decreased by 2.3 fold and 4.1 fold, respectively.  
Following LPS stimulation, IDO1, IDO2, IL6, TGFB2, and TGFB3 was upregulated 
while IL10, IL27, and TGFB1 decreased in I3C-treated BMDCs.  Similar trends were 
 143 
observed in IO-treated BMDCs with and without LPS stimulation (Table 1B).  In 
unstimulated cells, IO upregulated ALDH1A1 by 2.6 fold, CYP1A1 by 4.7 fold, IDO1 by 
3.1 fold, IDO2 by 3.0 fold, TGFB2 by 3.5 fold, and TGFB3 by 4.0 fold.  In LPS-activated 
cells, IDO1, IDO2, TGFB2, and TGFB3 were upregulated and ALDH1A2, IL6, and IL27 
were downregulated.  Overall, in an inflammatory environment, I3C- and IO-treated 
BMDCs increase their expression of key immunoregulatory genes and thus may possess 
the potential to suppress immune responses. 
 
AhR-dependence of I3C and IO on BMDCs.  To investigate whether the observed 
effects of I3C were dependent on the AhR, BMDCs from AhR
-/-
 mice were generated in 
the presence of I3C or IO.  Surface marker expression of unstimulated and LPS-
stimulated cells (Tables 2A and 2B) as well as cytokine production (Table 2C) was 
assessed. When AhR-deficient BMDCs were grown in the presence of I3C, changes in 
the expression of CD11c and CD54 were not observed relative to the vehicle control 
thereby indicating that the effects on these molecules were dependent on the AhR. The 
immunomodulatory effects of IO appeared to be more dependent on the AhR, as changes 
in CD11c, MHC2, CD80, and CD54 were not observed in unstimulated AhR
-/-
 BMDCs.   
LPS-activated cells revealed that the expected alterations in the expression of CD11c on 
I3C-treated BMDCs, and CD11c, MHC2, CD80 and CD54 on IO-treated BMDCs were 
not observed in cells lacking the AhR.  Additionally, suppression of many of the LPS-
induced pro-inflammatory cytokines examined was observed in AhR-deficient BMDCs 
treated with I3C (IL-1, IL-6, TNF- and NO) and IO (IL-6, IL-12 and TNF-).   
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Table 5.1.  Dietary AhR ligands induce regulatory gene expression in unstimulated and 
LPS-stimulated BMDCs
a
 
 
A.  Indole-3-carbinol (I3C) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.  Indirubin-3’-oxime (IO) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a
Purified BMDCs grown in the presence of vehicle, 50 μM I3C or 1 μM IO for 7 d were 
activated with 1 μg/ml LPS for 24 h to evaluate changes in gene transcription by qRT-
PCR.  Fold change is relevant to vehicle-treated cells and normalized to β-actin. Results 
are representative of 3 separate experiments. *indicates significance of p≤0.05 compared 
to the vehicle control.  
Gene 
Unstimulated LPS  
Fold 
change 
p-value 
Fold 
change 
p-value 
ALDH1A1 3.6* 0.008 -1.1 0.420 
ALDH1A2 -2.3* <0.001 -3.4* <0.001 
CYP1A1 5.2* 0.008 1.0 0.475 
IDO1 6.7* 0.001 13.5* <0.001 
IDO2 5.7* <0.001 5.1* <0.001 
IL6 1.3 0.328 1.5* 0.008 
IL10 -1.6 0.144 -1.6* 0.040 
IL27 -4.1* <0.001 -2.6* <0.001 
LTBP -1.2 0.324 1.2 0.139 
TGFB1 1.1 0.373 -1.3* 0.032 
TGFB2 2.4* <0.001 2.5* 0.001 
TGFB3 5.8* 0.005 1.8* 0.034 
Gene 
Unstimulated LPS  
Fold 
change 
p-value 
Fold 
change 
p-value 
ALDH1A1 2.6* 0.040 1.4 0.140 
ALDH1A2 -1.2* 0.019 -1.4* 0.016 
CYP1A1 4.7* 0.009 -1.4 0.262 
IDO1 3.1* 0.004 6.6* 0.001 
IDO2 3.0* <0.001 4.2* <0.001 
IL6 1.2 0.367 -1.3* 0.016 
IL10 -1.4 0.051 -1.2 0.262 
IL27 -3.4* <0.001 -3.1* 0.004 
LTBP 1.4 0.407 1.6* 0.011 
TGFB1 1.1 0.244 1.1 0.362 
TGFB2 3.5* 0.001 3.2* 0.001 
TGFB3 4.0* 0.027 1.7* 0.037 
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Table 5.2.  Immune modulation by I3C and IO is not entirely AhR-mediated in BMDCs
a
  
 
 A.  Immunophenotype of unstimulated cells 
 
 
B.  Immunophenotype of LPS-stimulated cells 
 
 
C.  Cytokine production following LPS stimulation 
 
 
a
AhR
+/+
 and AhR
-/-
 BMDCs were grown in the presence of vehicle, 50 μM I3C or 1 μM 
IO  and subsequently immunophenotyped (A) prior to or following activation (B) with 
LPS (1 μg/ml) for 24 h. Cytokine production was also assessed (C).  Mean fluorescence 
intensity (MFI) and protein concentrations values are shown as mean ± standard error. 
Data are representative of 2 independent experiments with n=3.  *indicates significance 
of p≤0.05 compared to DMSO control of respective cell type. 
 
Surface  
marker 
AhR
+/+
 AhR
-/-
 
DMSO I3C IO DMSO I3C IO 
CD11c 3391 ± 142 2603 ± 326* 2219 ± 312* 4611 ± 548 4822 ± 107 3992 ± 280 
MHC2 2833 ± 81 8056 ± 400* 6432 ± 255* 1970 ± 100 2912 ± 125* 2067 ± 100 
CD86 1299 ± 15 1493 ± 3* 1270 ± 10 1279 ± 5 950 ± 27*  1180 ± 31* 
CD80 1176 ± 23 1901 ± 8* 1412 ± 8* 839 ± 14 1129 ± 14* 822 ± 13 
CD54 548 ± 7 507 ± 11*  435 ± 6* 649 ± 6 630 ± 12 633 ± 10 
CD40 334 ± 72 290 ± 11* 291 ± 5* 409 ± 18  308 ± 16* 358 ± 6* 
Surface  
marker 
AhR
+/+
 AhR
-/-
 
DMSO I3C IO DMSO I3C IO 
CD11c 1950 ± 74 1702 ± 55* 1770 ± 96 2665 ± 74 2645 ± 98 2198 ± 174 
MHC2 3182 ± 37 8189 ±61* 6514 ±170* 1817 ± 11 3386 ±143* 1901 ± 71 
CD86 1433 ± 9 1787 ± 21* 1370 ± 8* 1665 ± 5 1304 ± 8* 1523 ± 25* 
CD80 1219 ± 29 3257 ± 92* 1874 ± 30* 981 ±15 1544 ± 52* 998 ± 39 
CD54 510 ± 6 545 ± 3* 439 ± 2* 583 ± 5 650 ± 12* 560 ±17 
CD40 452 ± 11 417 ± 12* 373 ± 21* 589 ± 12 497 ± 9* 499 ± 18* 
Cytokine 
AhR
+/+
 AhR
-/-
 
DMSO I3C IO DMSO I3C IO 
IL-1β (pg/ml) 1056 ± 53 813 ± 31* 992 ± 42* 1212 ± 56 862 ± 69* 1053 ± 52 
IL-6 (ng/ml) 47 ± 2 21 ± 1* 24 ± 1* 47 ± 0.3 31 ± 1.6* 36 ± 2.6* 
IL-10 (pg/ml) 598 ± 49 1211 ± 92* 1501 ± 83* 417 ± 67 127 ± 10* 543 ± 67 
IL-12 (pg/ml) 1463 ± 159 984 ± 25* 427 ± 30* 1921 ± 140 2018 ± 93 1323 ± 88* 
TNF-α (pg/ml) 5347 ± 181 5121 ± 135* 3962 ± 283* 7471 ± 603 5972 ± 280* 5040 ± 194* 
NO (μM) 9.3 ± 0.3 2.4 ± 0.5* 7.5 ± 0.8* 28 ± 1 16 ± 2* 30 ± 2 
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Conversely, the effects of I3C on IL-12 and the effects of IO on IL-1, IL-10 and NO 
were demonstrated to be dependent on the AhR. Interestingly, IL-10 production was 
decreased in LPS-stimulated, AhR
-/-
 BMDCs treated with I3C in contrast to the effects 
observed in AhR
+/+
 BMDCs. Finally, the induction of several immunoregulatory genes 
also appeared to be independent of the AhR, as significant upregulation of ALDH1A1, 
ALDH1A2, IDO1, and TGFB2 was observed in I3C and IO-treated AhR-deficient 
BMDCs (data not shown).  Thus, both I3C and IO exert effects on BMDCs by a 
mechanism that is partially, but not entirely, dependent on the AhR. 
 
I3C and IO differentially alter NF-kB signaling in BMDCs.  Because the 
immunomodulatory effects of I3C and IO on BMDCs were not entirely dependent on the 
AhR, NF-kB binding activity was evaluated since both I3C and IO can disrupt NF-kB 
signaling (Figure 5).  In unstimulated cells, both I3C and IO reduced the activity of 
nuclear NF-kB p65; however, similar effects were not observed in LPS-activated DCs.  
Conversely, there was a trend for increased basal levels of RelB following IO but not I3C 
treatment, whereas I3C, but not IO, significantly decreased the levels of RelB following 
LPS activation. 
 
I3C- and IO-treated BMDCs promote the generation of antigen-specific Tregs.  AhR-
activated immunoregulatory DCs can induce the generation of CD4+Foxp3+ Tregs 
(Quintana et al., 2010; Simones and Shepherd, 2011); therefore, the potential for dietary 
AhR ligand-treated BMDCs to induce OVA323-339-specific Tregs was investigated. 
Culturing naïve CD4+ OTII T cells for 3 days in the presence of I3C- or IO-treated, 
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OVA323-339-loaded BMDCs significantly increased the frequency of CD4+Foxp3+ T cells 
(Figure 6A). When compared to vehicle-treated BMDCs, I3C treatment increased the 
frequency of OTII Tregs by approximately 2.4-fold while IO treatment increased the 
frequency by almost 2-fold.  Cytokine production was also measured in the supernatants 
from these cultures (Figure 6B). OTII T cells cultured with IO-treated BMDCs 
significantly increased IL-2 production from 112 pg/ml to 6505 pg/ml.  I3C- and IO-
treated BMDCs decreased the production of IFN-γ in the co-cultures by approximately 
33% and 45%, respectively.  IL-10 production was also decreased by both the I3C- and 
IO-treated BMDCs when cultured with naïve OTII T cells.  
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Figure 5.5 
 
 
Figure 5.5.  I3C and IO differentially alter NF-kB signaling.  Purified I3C- and IO-
treated BMDCs were stimulated with 1 μg/ml LPS for 45 min, and nuclear protein 
extracts were subsequently prepared for evaluation of the binding activity of NF-kB p65 
(A) and RelB (B).  Results are representative of 1 experiment with n=3. #indicates 
significance of p≤0.05 compared to unstimulated vehicle control and *indicates 
significance of p≤0.05 compared to vehicle control of similarly activated samples. 
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Figure 5.6 
 
 
 Figure 5.6.  DCs treated with dietary AhR ligands increase the frequency of 
CD4+Foxp3+ Tregs and alter cytokine production.  AhR ligand-treated BMDCs and 
naïve CD4+ OTII T cells were prepared as described in the Materials and Methods. (A) 
The percent of CD4+Foxp3+ T cells is shown in the histogram. (B) Cytokine production 
of IL-2, IL-10 and IFN- was also measured from the culture supernatants as described in 
the Materials and Methods.  Results are representative of 2 separate experiments with 
n=3.  *indicates significance of p≤0.05. 
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DISCUSSION   
Modulating the fate and function of DCs has important therapeutic implications in 
the treatment of a large variety of immune-mediated diseases.  The AhR signaling 
pathway can play an important role in shaping the fate and function of DCs in immune 
and inflammatory responses.  Given that activation of the AhR generates 
immunoregulatory cells, including DCs and Tregs, it is essential to evaluate the effects of 
non-toxic AhR ligands, including agonists and antagonists, on critical cell populations in 
the immune system.  I3C and indirubin are particularly interesting dietary AhR ligands 
since they both possess potent anti-cancer properties, but currently our knowledge of 
their effects on immune cells is limited.  Therefore, in this study we investigated the 
potential of I3C and indirubin to promote immunosuppressive and anti-inflammatory 
effects via the AhR. 
Following AhR activation in DCs, several changes in cell surface molecule 
expression, cytokine production, and regulatory gene induction contribute to suppressive 
and tolerogenic immune responses.  The exogenous, prototypical ligand TCDD and the 
endogenous ligand 2-(1'H-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester 
(ITE) both decrease the expression of CD11c and upregulation of MHC2 and CD86 in 
murine BMDCs (Bankoti et al., 2010).  Alternatively, the small molecule VAF347 
decreases CD86 and HLA-DR in human DCs (Ettmayer et al., 2006) while the 
environmental contaminant benzo(a)pyrene (BaP) induces few changes in the expression 
of CD11c, MHC2, and CD86 on murine DCs (Hwang et al., 2007). Consistent with the 
results from TCDD- and ITE-treated DCs, we demonstrated that I3C and IO decreased 
the expression of CD11c, CD40, and CD54 while increasing the expression of MHC2 
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and CD80.  Decreased CD11c expression on DCs following exposure to I3C and IO 
suggests altered differentiation of these professional antigen-presenting cells.  
Furthermore, since CD40 and CD54 are critical immune molecules involved in the 
interactions of T cells with DCs, decreased expression of these markers on DCs suggests 
that their ability to successfully activate effector T cells may be defective.  Although both 
I3C and IO are AhR agonists (Miller, 1997; Guengerich et al., 2004), changes in the 
immunophenotype of BMDCs were not entirely dependent on the AhR as observed when 
using BMDCs from mice lacking the AhR.  Similarly, it has been noted that the effects of 
BaP are not entirely AhR-dependent (Hwang et al., 2007).  This is distinctly different 
than the effects of TCDD, which are entirely dependent on the AhR (Bankoti et al., 
2010).  Overall, the changes in surface marker expression on DCs treated with I3C and 
IO could be contributing to the generation of immune suppression, in part via AhR 
activation.  
Cytokines are soluble mediators that play a critical role in influencing immune 
responses.  Following activation by bacterial stimuli, such as LPS, DCs secrete many pro-
inflammatory cytokines that can promote inflammatory responses.  Consequently, we 
determined the effects I3C and IO on the LPS-induced production of inflammatory 
mediators.  In general, we found that I3C and IO suppressed the secretion of many pro-
inflammatory cytokines thereby indicating anti-inflammatory activity.  Interestingly, 
TCDD was recently shown to increase the LPS-induced production of IL-6 and TNF-α 
(Bankoti et al., 2010) whereas other AhR ligands including BaP, ITE, and VAF347 
decrease the production of pro-inflammatory cytokines (Ettmayer et al., 2006; Lawrence 
et al., 2008; Quintana et al., 2010).  Thus, I3C and IO elicit cytokine patterns much more 
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similar to readily metabolized AhR ligands than TCDD, an extremely stable and 
persistent AhR agonist. 
To further explore the immunosuppressive and anti-inflammatory properties of 
dietary AhR ligands, gene transcription was evaluated in unstimulated and LPS-activated 
BMDCs.  Both I3C and IO upregulated IDO and TGFB genes, which have important 
implications in the generation of regulatory immune cells.  Several investigators have 
demonstrated that AhR activation by TCDD in DCs induces regulatory genes that 
promote the expansion of Tregs (Mellor et al., 2004; Tas et al., 2007; Bankoti et al., 
2010; Simones and Shepherd, 2011).  Our laboratory previously reported that TCDD 
induced IDO1, IDO2, and TGFB3 in both unstimulated and LPS-stimulated BMDCs.  
Prior to activation, TCDD upregulated TGFB3 while TGFB1 and TGFB2 were 
upregulated following LPS activation (Bankoti et al., 2010). Importantly, the induction of 
IDO expression by DCs has been associated with the non-canonical NF-κB pathway (Tas 
et al., 2007; Vogel et al., 2008).  Aldehyde dehydrogenase is associated with retinoic acid 
metabolism, which has been linked to regulatory DCs that drive Treg expansion.  In our 
studies, ALDH1A1 was upregulated by both compounds while ALDH1A2 did not seem to 
have an important role in producing DCs of a regulatory phenotype.  This effect was also 
observed with the endogenous ligand ITE, as ALDH1A1 was induced in DCs possessing 
regulatory functions (Quintana et al., 2010).  Overall, upregulation of these 
immunoregulatory genes by I3C and IO suggest that these compounds have the potential 
to generate a regulatory environment that promotes the induction of regulatory T cells. 
Because DCs acquired an immunoregulatory phenotype following treatment with 
I3C or IO, we evaluated their ability to generate Tregs from naïve CD4+ T cells in an 
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antigen-specific manner.  In this study, I3C- and IO-treated BMDCs significantly 
increased the frequency of CD4+Foxp3+ T cells in vitro. These findings are consistent 
with a study that demonstrated that indirubin increased CD4+CD25+Foxp3+ T cells in 
vivo (Zhang et al., 2007).  However, in this study it was not determined if indirubin acted 
directly on the T cells or indirectly via other immune cells such as the DCs.  To date, no 
studies have reported direct and/or indirect effects of I3C on Foxp3+ Treg induction.  
TCDD, VAF347, and ITE have all been shown to increase CD4+CD25+Foxp3+ Tregs 
(Hauben et al., 2008; Quintana et al., 2010; Simones and Shepherd, 2011). ITE was 
recently demonstrated to induce Tregs both directly via effects on T cells and indirectly 
by altering DC function. Moreover, these effects in the DCs were found to be dependent 
on the generation of retinoic acid, as Foxp3+ Treg generation was blocked following the 
addition of a retinoic acid inhibitor (LE135) to the DCs (Hauben et al., 2008; Quintana et 
al., 2010; Simones and Shepherd, 2011).  On the other hand, a recent study from our 
laboratory demonstrated that DCs treated with TCDD increased the frequency of OVA-
specific, CD4+Foxp3+ Tregs in an IDO-dependent manner (Simones and Shepherd, 
2011).  Thus, based on the imunoregulatory profiles of DCs exposed to different AhR 
ligands, it is possible that Treg induction can occur through several mechanisms 
including retinoic acid, kynurenines, and/or TGF-β.  
Both I3C and indirubin have traditionally been used in anti-cancer and anti-
inflammatory applications.  To date, neither I3C nor IO has been specifically evaluated 
for their potential anti-inflammatory effects on DCs, and information regarding the 
effects of these compounds on other immune cells is also limited.  I3C has been assessed 
in vitro using the murine macrophage cell line RAW264.7 and primary murine 
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macrophages.  These studies revealed that I3C decreased the LPS-induced production of 
several inflammatory mediators, such as nitric oxide (NO) and TNF-α, which has been 
associated with decreased translocation of NF-κB into the nucleus (Chen et al., 2003; 
Tsai et al., 2010; Chang et al., 2011).  Our laboratory has recently demonstrated that I3C 
ameliorates disease severity and inflammation associated with a murine model of colitis 
(manuscript in preparation), which is consistent with our previously published work 
regarding the anti-inflammatory and immunosuppressive effects of TCDD on colitis 
(Benson and Shepherd, 2011).  The anti-inflammatory effects of indirubin have been 
considerably less studied.  Kunikata and colleagues reported that indirubin inhibited IFN-
γ production from human myelomonocytic HBL-38 cells, IL-6 production by murine 
splenocytes, and ear swelling in a murine model of delayed-type hypersensitivity 
(Kunikata et al., 2000).  Most recently, IO inhibited the LPS-induced production of NO, 
TNF-α, IL-1β, and PGE-2 by rat brain microglia cells via inhibition of NF-κB activation 
(Jung et al., 2011).  
Since suppression of NF-κB signaling has been associated with decreased 
inflammatory mediator production by both I3C and IO, it is likely that these compounds 
also interfere with NF-κB signaling to contribute to the anti-inflammatory responses we 
observed in BMDCs.  The AhR can interact with NF-kB signaling components (Ruby et 
al., 2005; Vogel et al., 2007a; Vogel et al., 2007b). Therefore, it is conceivable that I3C 
and IO may interact with the AhR and/or NF-κB in DCs to reduce their inflammatory 
responsiveness.  In this study, we demonstrated that I3C and IO decrease the binding 
activity of NF-κB p65 found in the nucleus of the BMDCs, but only I3C significantly 
decreased RelB activity following LPS activation.  Therefore, it is possible that altered 
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NF-κB signaling contributes, at least in part, to the suppression of LPS-induced 
inflammatory cytokine production in DCs.  Overall, our data suggest that both the AhR 
and NF-κB signaling pathways may contribute towards the immunoregulatory and anti-
inflammatory effects of I3C and IO in DCs.  Additional studies utilizing DRE and NF-κB 
luciferase reporter assays conducted in DCs may help delineate the contribution of these 
pathways, as most studies on these compounds to date have been conducted in cancer 
cells. For example, it was shown that 60 μM I3C decreased relative luciferase activity in 
breast cancer cells with regards to NF-κB activity (Rahman KM et al., 2004) while the 
DRE-driven luciferase of indigoids has been documented in a derivative of human 
hepatoma HepG2 cells (Guengerich et al., 2004). 
Given that the effects observed in this study were not entirely dependent on either 
the AhR or NF-κB, it is possible that other factors contributed to the observed effects, as 
IO has been reported to inhibit Src kinase activity and subsequently the phosphorylation 
of STAT3, which has been implicated as an important factor in Th17 cell differentiation 
(Nam et al., 2005; Kimura et al., 2007). AhR activation leads to the generation of Tregs 
and IO may decrease Th17 differentiation so these factors together may contribute to the 
observed immunosuppressive environment.   
It should be noted that in the acidic environment of the stomach, I3C forms the 
acid condensation product diindolylmethane (DIM).  Since I3C is rapidly metabolized 
into DIM following oral consumption, the use of I3C in cell culture experiments has been 
criticized, as it has been shown that DIM is primarily responsible for the anti-cancer and 
anti-proliferative effects in vivo. However, a recent study demonstrated that following the 
addition of I3C to cultured cells, DIM spontaneously forms and accounts for much of the 
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documented effects in vitro (Bradlow and Zeligs, 2010).  Accordingly, we expect that 
DIM also formed in our cell cultures and thereby is at least partially responsible for the 
observed effects on murine BMDCs.  
Collectively, we have demonstrated that the dietary AhR ligands I3C and IO exert 
anti-inflammatory and immunoregulatory effects on DCs in vitro.  Although both of these 
compounds bind the AhR, the effects we observed on cell surface marker expression, 
cytokine production, and gene transcription were not entirely dependent on the AhR.  
Moreover, altered NF-kB signaling pathway may be contributing to the anti-
inflammatory effects of both I3C and IO.  Since no severe adverse reactions have been 
reported in humans consuming I3C or indirubin (clinical trials reviewed in Eisenbrand et 
al., 2004; Minich and Bland, 2007), these compounds may ultimately be useful 
complementary therapeutics for treating inflammatory disorders by altering DC fate and 
function, consequently creating an immunosuppressive environment. Importantly, our 
results also suggest that the generation of regulatory DCs and T cells following exposure 
to I3C and indirubin may significantly reduce the utility of these natural products as anti-
cancer reagents. It is plausible that different metabolism occurs in vivo versus in vitro 
leading to a differential effect in animals compared to cell culture. It is also possible that 
the anti-proliferative effects of I3C/DIM on tumor cells combined with additional anti-
inflammatory and regulatory effects on the immune system may limit damage generated 
by the tumor cells permitting a more robust immune response. Therefore, focused in vivo 
studies to investigate these possibilities are warranted based on previously published 
studies and our results presented herein. 
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CHAPTER 6:  CONCLUSIONS 
 
Crohn’s disease is a multifactorial gastrointestinal disorder of unknown etiology 
that affects millions of people worldwide.  The goal of current conventional therapeutics 
is to induce and maintain remission by controlling the inflammation that causes 
symptoms. This is accomplished with five basic categories of treatments 
(aminosalicylates, corticosteroids, immunomodulators, antibiotics, and biologics) that are 
used in combination to treat patients, as corticosteroids rapidly reduce inflammation 
while immune modulators help maintain remission, for example. These medications, 
however, must be tailored to each patient and are also accompanied by severe adverse 
effects, especially with extended use.  Thus, there is a need to develop new therapeutics 
that more effectively and more safely control and possibly prevent intestinal 
inflammation. 
The aryl hydrocarbon receptor (AhR) has emerged recently as an attractive 
therapeutic target for several disease states including those that involve chronic 
inflammation.  The AhR is perhaps most recognized for mediating the toxic effects of its 
prototypical ligand 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) via events that are both 
dependent and independent of dioxin response elements (DREs).  A notable effect of 
AhR activation by TCDD is the generation of Foxp3+ regulatory T cells (Tregs), which 
potently suppress inflammation.  Due to its severe adverse effects, TCDD would not be a 
realistic therapeutic option for human diseases. Therefore, there is a need to identify AhR 
ligands that selectively block DRE-driven transcription associated with TCDD toxicity 
but still repress acute phase genes.  These selective AhR modulators ultimately have the 
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potential to be used in combination with current therapies for inflammatory diseases and 
hormone-dependent cancers since they do not exert the toxic effects associated with 
TCDD (McDougal et al., 2001; Okino et al., 2009; Murray et al., 2010; Murray et al., 
2011; Smith et al., 2011).   
Since AhR activation by various ligands can generate immunoregulatory and anti-
inflammatory effects and little is currently known about the role of the AhR in gut 
immune responses, we explored the role of AhR activation in the mucosal immune 
system and the potential for natural ligands to ameliorate intestinal inflammation without 
eliciting toxic effects.  Our central hypothesis was that that AhR agonists found in the diet 
have the potential to dampen inflammation associated with Crohn’s disease. We utilized 
a murine model of colitis to evaluate the role of the receptor in the gut and also conducted 
in vitro experiments to further investigate the mechanisms of dietary AhR ligands on 
important immune cells present the gut. The following sections highlight the primary 
conclusions from this project and future directions worth pursuing to extend the research. 
 
Dietary AhR ligands modulate intestinal inflammatory responsiveness 
The first goal of this project was to test the hypothesis that AhR activation by the 
prototypical AhR ligand TCDD would reduce the inflammation generated in a murine 
model of Crohn’s disease by promoting an immunosuppressive environment in the gut. 
We demonstrated for the first time that TCDD suppressed 2,4,6-trinitrobenzenesulfonic 
acid (TNBS)-induced intestinal inflammation, as indicated by decreased disease severity, 
decreased inflammatory mediator production, and increased Foxp3+ Tregs in colon tissue 
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(Benson and Shepherd, 2011a). Thus, the amelioration of colitis likely occurred via the 
Treg generation following AhR activation. 
Since TCDD is not a viable treatment option for Crohn’s disease patients, it is 
necessary to identify other AhR agonists lacking the toxic effects associated with TCDD. 
Indole-3-carbinol (I3C) is a natural AhR agonist present in cruciferous vegetables that 
possesses the potential to dampen inflammation (Takada et al., 2005; Kim et al., 2009; 
Tsai et al., 2010; Chang et al., 2011). We found that I3C exerted sex-specific effects on 
disease severity by dampening inflammation in female, but not male, mice (Benson and 
Shepherd, 2011c). Due to the potential crosstalk with several signaling pathways, 
complex interactions of the AhR with the estrogen receptor and/or nuclear factor-kappa B 
(NF-kB) signaling pathways are likely responsible for this effect (Ohtake et al., 2003; 
Wormke et al., 2003; Matthews et al., 2005). 
 Collectively, these in vivo studies demonstrated the importance of AhR activation 
in the gut by exerting anti-inflammatory and immunoregulatory effects.  Several 
investigators have also reported an increased frequency of Tregs following AhR 
activation, which consequently suppressed autoimmune diseases induced in mice 
including multiple sclerosis (Quintana et al., 2010), diabetes (Kerkvliet et al., 2009), and 
uveoretinitis (Zhang et al., 2010).  With respect to colitis, several ligands have been 
shown to suppress intestinal inflammation following AhR activation.  These compounds 
that activate AhR signaling include the I3C metabolite diindolylmethane (DIM) (Kim et 
al., 2009), 6-formylindolo[3,2-b]carbazole (FICZ) (Monteleone et al., 2011), and 
Lactobacillus bulgaricus OLL1181 (Takamura et al., 2011).  To our knowledge, 
however, I3C is the first documentation of an AhR ligand exerting sex-specific effects on 
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intestinal inflammation.  This suggests that effects of ligands may vary based on the 
context of inflammation in certain tissues. Moreover, I3C is a commercially available 
supplement so it could have significant implications for self-medicating patients who 
want to relieve symptoms not suppressed by conventional medicine or to relieve the 
symptoms of the medicine.  
 
Regulatory cells present in the gut are induced by natural AhR ligands 
The second primary goal of this project was to investigate the mechanism(s) by 
which dietary AhR ligands exert their effects on important immune cells found in the gut.  
Dendritic cells (DCs) constitutively express the AhR and are a critical cell population in 
the gut that maintains tolerance by promoting the expansion of Tregs. We found that I3C, 
as well as the traditional Chinese medicine component indirubin, exerted anti-
inflammatory effects via the reduction of lipopolysaccharide (LPS)-induced 
inflammatory cytokines in bone marrow-derived DCs (BMDCs). I3C and indirubin 
increased the expression of several regulatory genes including indoleamine-2,3-
dioxygenase (IDO), transforming growth factor beta (TGFB), and aldehyde 
dehydrongenase (ALDH1A). The ligand-treated BMDCs also induced Foxp3+ Tregs 
when co-cultured with antigen-specific naïve CD4+ T cells (Benson and Shepherd, 
2011b). Collectively, the results obtained demonstrate the anti-inflammatory and 
immunoregulatory effects of I3C and indirubin. 
  Several mediators, especially IDO, TGF-β, and retinoic acid, are critical for 
maintaining a regulatory environment to prevent inappropriate responses to food particles 
and commensal bacteria in the gut. In line with our in vitro findings, it was recently 
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demonstrated that immunoregulatory DCs suppressed TNBS-induced colitis, which was 
partially dependent on IDO (Hoshino et al., 2011). In fact, IDO inhibition exacerbates 
TNBS-induced colitis (Gurtner et al., 2003). Previous investigations in our laboratory 
revealed that TCDD generates regulatory DCs capable of inducing Foxp3+ Tregs in an 
IDO-dependent manner (Simones and Shepherd, 2011). Thus, it is possible that I3C or 
indirubin administered to mice would induce regulatory cells capable of suppressing 
disease severity in the gut.  Furthermore, the results obtained in DCs could also be 
extended to intestinal epithelial cells (IECs), which are AhR-expressing antigen 
presenting cells that produce protective mediators necessary to prevent inappropriate 
immune responses to food particles and commensal bacteria.  Importantly, IECs also 
condition DCs to have a regulatory phenotype via TGF-β and retinoic acid (Iliev et al., 
2009).  Taken together, natural AhR ligands induce a regulatory phenotype in DCs 
without exerting overt cytotoxicity, which is crucial to effectively dampening 
inflammation, and thus may also be effective treatment options for those afflicted with 
inflammatory bowel diseases. 
 
Future directions 
Collectively, the data generated in this project demonstrate that the AhR plays an 
important role in mediating gut immune responsiveness. Dietary AhR ligands possess the 
potential to impart regulatory and anti-inflammatory functions by acting on several cell 
populations including DCs, intestinal epithelial cells, and lymphocytes. To expand this 
research, several additional studies would better define the role of the AhR in intestinal 
immune tissue. Since the studies in this project utilized an acute model of colitis, it is 
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necessary to confirm the observed effects of AhR ligands in a chronic model of colitis, 
which is in many ways more representative of human Crohn’s disease. Another important 
avenue to pursue is the evaluation of the effects of AhR ligands in combination with 
conventional treatment (i.e. corticosteroids) that can rapidly reduce inflammation. 
Finally, one of the most fascinating topics in current research involves trying to 
understand how the gut microbiome interacts with the immune system. Thus, it would be 
useful to evaluate how AhR activation by various ligands in the gut mucosa specifically 
alters gut bacteria populations and their functions.   
In general, the most recent therapeutic approaches under development for treating 
inflammatory bowel diseases are aimed at improving mucosal barrier integrity via stem 
cells, restoring homeostasis of the gut bacteria via probiotics, and identifying vehicles 
that deliver potent therapeutics directly to the intestines (Plevy and Targan, 2011; 
Scholmerich, 2011). Selectively modulating AhR activity is a novel approach to suppress 
disease severity, and our studies provide insight into natural AhR ligands that can 
dampen intestinal inflammation by promoting an immunosuppressive environment. 
Clearly, the AhR is a promising novel therapeutic target that warrants further 
investigation for its potential to improve the function of gut mucosal immune responses.  
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APPENDIX 1 
 
Colonic gene and protein expression of aryl hydrocarbon receptor deficient mice 
 
 
OVERVIEW 
Since the aryl hydrocarbon receptor (AhR) knockout (KO) mice in the University 
of Montana laboratory animal facility were unexpectedly less sensitive to colitis, 
preliminary studies were conducted to evaluate gene and protein expression in the colons 
of naïve AhR KO mice compared to naïve AhR wild-type (WT) mice.  Since T cells play 
a critical role in mounting inappropriate immune responses in colitis, and inflammation 
causes the clinical signs of the disease, these two pathways were specifically evaluated in 
the gene expression analyses. Moreover, proteomics analyses are quite extensive so 
changes in proteins involved in these pathways were of particular interest. 
 
METHODS 
Laboratory animals.  Six to eight week old AhR
 
WT and AhR KO mice (both on the 
C57Bl/6 background) were bred and maintained in the animal research facility at the 
University of Montana. C57Bl/6 AhR
 
WT mice were originally obtained from The 
Jackson Laboratories (Bar Harbor, ME) and bred in-house. C57Bl/6 AhR KO 
(B6.AhR
tm1Bra
) mice were obtained from Dr. Paige Lawrence (University of Rochester 
Medical College, Rochester, NY) and bred as previously described (Schmidt et al., 
1996). All mice were housed under specific pathogen-free conditions and maintained on 
12 h dark/light cycles. 
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SuperArray. Three AhR WT samples and three AhR KO samples were pooled for gene 
expression analysis.  RNA and cDNA was prepared as described above. Resulting cDNA 
was subjected to the RT2 Profiler PCR Array Systems for T helper Cell Differentiation 
and NF-kB Signaling Pathway per the manufacturer’s instructions (SA Biosciences, 
Frederick, MD). Reactions were performed with PerfeCTa SYBR Green Supermix 
(Quanta Biosciences) on an Agilent Technologies Stratagene Mx3005P QPCR System 
(Santa Clara, CA).  Resulting data were analyzed using SA Bioscience’s Web-Based 
PCR Array Data Analysis tool.  
 
Proteomics.  The colonic mucosa was collected as previously described (Calpe-Berdiel et 
al., 2007). Briefly, colons were removed, washed with ice cold PBS, and opened 
longitudinally such that the mucosal layer could be lightly scraped.  Approximately 5 mg 
of mucosal tissue was assessed for protein expression, as described by Lai and colleagues 
(Lai et al., 2011).  Briefly, mucosa was solubilized, trypsinized, and fractionated via 
HPLC.  MS was used to identify and quantify peptides. Resulting data were analyzed 
using Ingenuity Systems Pathway Analysis software (Ingenuity Systems Inc., Redwood 
City, CA). 
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RESULTS 
Genes involved with Th cell differentiation and NF-kB signaling were upregulated in 
AhR KO mice.  Components of Th cell differentiation and NF-kB signaling were 
investigated by commercially available array kits. Numerous genes involved in T helper 
cell differentiation were upregulated including IL-4, IL-13, IFN-γ, and Tbx21 while only 
Ccr6 was downregulated in AhR KO mice (Table 1A).  No clear bias towards any T 
helper cell subset (ie Th1, Th2, Th17 or regulatory T cells) was observed. Moreover, 
many genes involved in the NF-kB signaling pathway were also upregulated while 
decreases in gene expression were not observed in AhR KO mice (Table 1B). Overall, 
gene expression data suggested no clear skewing of T helper cell subsets and also implied 
that KO mice may have enhanced NF-kB signaling thereby making them more 
susceptible to inflammation, which is still inconsistent with the results observed in the 
TNBS model. 
 
AhR KO mice have decreased expression of proteins involved in NF-kB signaling, 
apoptosis, and antigen presentation.  A total of 2374 proteins were identified in AhR 
WT and KO mice.  Interestingly, more proteins were downregulated than upregulated, as 
shown in Tables 2 and 3.  Of the proteins exhibiting at least a -1.5 fold change, there 
were several related to immune and inflammatory responsiveness in the gut including 
Card10, Mapk14 (p38-), Bax, Fadd, and Ctsb. There were also several immune and 
inflammatory genes upregulated including Saa1, Fkpb5, Atrn, and Ctsl; however 
increased expression of these proteins are not consistent with the decreased inflammation 
observed in AhR KO mice following TNBS administration.  Networking analyses 
performed with Ingenuity Systems software revealed that the top network with the 
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protein expression fold changes at least +/- 1.5 is cell death, cellular movement, and gene 
expression (results not shown).  There were 20 focus proteins in this network including 
Bax, Brp44L, Card10, Ctbp2, Ctsb, Eif2s2, Fadd, Hcfc1, and Pik3r6 among several 
others.  
173 
 
Table 1.  Gene expression in the colon of AhR KO mice 
 A. T helper cell differentiation  
 
 
 
 
 
 
 
B.  NF-kB signaling pathway 
 
 
 
 
 
 
 
Colon tissue from AhR WT and KO mice was homogenized in Trizol and subjected to 
qRT-PCR to assess changes in gene expression.  Genes with fold changes +/- 2.0 relative 
to WT mice are shown in the table.  Data are representative of one experiment in which 
tissue from three mice were pooled for each group. 
  
Gene Fold Change Gene Fold Change Gene Fold Change 
Cacna1f 3.24 Ifng 16.40 Il2ra 4.10 
Ccl7 2.42 Il12b 5.26 Il4 2.98 
Ccr3 3.22 Il12rb2 7.39 Il5 3.85 
Ccr6 -2.25 Il13 4.04 Il9 7.19 
Csf2 4.04 Il18r1 2.31 Myb 2.11 
Fasl 27.40 Il18rap 9.49 Nr4a3 2.31 
Gata3 4.52 Il1r1l 3.13 Stat1 2.26 
Gata4 4.13 Il2 16.52 Stat4 4.58 
Havcr2 2.04 Il21 19.51 Tbx21 2.18 
Icos 3.55     
Gene Fold Change Gene Fold Change Gene Fold Change 
Atf2 2.55 Fos2 2.68 Ripk2 2.68 
Casp1 2.75 Htr2b 2.99 Stat1 2.31 
Casp8 2.60 Ifng 12.04 Tlr6 2.35 
Ccl2 2.45 Il10 5.46 Tlr7 4.63 
Csf2 7.62 Il1a 5.50 Tlr8 3.48 
Csf3 5.58 Il1b 4.26 Tnf 2.10 
Egr1 2.17 Il6 24.59 Tnfsf14 4.68 
Fasl 12.47 Nlrp12 13.09   
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Table 2.  Downregulated protein expression in AhR KO mice 
 
Protein Fold Change p-value 
Card10 Caspase recruitment domain-containing protein 10 -4.5 0.1 
Eml5 Echinoderm microtubule-associated protein-like 5 -2.9 0.2 
Bphl Valacyclovir hydrolase -2.7 0.05 
Mptx Mucosal pentraxin -2.4 0.2 
Plbd1 Phospholipase B-like 1 -2.3 0.08 
Rab5b RAB5B, member RAS oncogene family -2.2 0.3 
Hmbs Porphobilinogen deaminase, Isoform 2 -2.1 0.09 
Ctbp2 C-terminal binding protein 2 -2.1 0.2 
Ccdc109a Coiled-coil domain-containing protein 109A -2.1 0.1 
Srrm1 Serine/arginine repetitive matrix protein 1, Isoform 2 -2.0 0.01 
Eif2s2 Eukaryotic translation initiation factor 2, subunit 2 (beta) -2.0 0.04 
Dhrs11 Dehydrogenase/reductase SDR family member 11 -2.0 0.04 
Bax Apoptosis regulator BAX -2.0 0.01 
Col6a3 Collagen alpha-3(VI) chain -1.9 0.3 
Ttll13 Tubulin polyglutamylase TTLL13 -1.9 0.01 
Sec13 Protein SEC13 homolog -1.9 0.08 
Sema6a Semaphorin-6A, Isoform 2 -1.9 0.05 
Hdhd2 
Haloacid dehalogenase-like hydrolase domain-
containing protein 2 
-1.9 0.05 
Msh2 DNA mismatch repair protein Msh2 -1.9 0.03 
Clpp 
Putative ATP-dependent Clp protease proteolytic 
subunit, mitochondrial 
-1.8 0.06 
Npepl1 Aminopeptidase NPEPL1 -1.8 0.1 
Wwp2 NEDD4-like E3 ubiquitin-protein ligase WWP2 -1.8 0.2 
Tmem43 Transmembrane protein 43 -1.7 0.2 
Rbm3 Rbm3 protein -1.7 0.2 
Pik3r6 
Phosphoinositide 3-kinase regulatory subunit 6, Isoform 
2 
-1.7 0.09 
Cbara1 Calcium uptake protein 1, mitochondrial -1.7 0.09 
Rpl7A Ribosomal protein L7A -1.6 0.4 
S100a11 Protein S100-A11 -1.6 0.3 
Cask Peripheral plasma membrane protein CASK -1.6 0.5 
Pcdh1 Protocadherin 1 -1.6 0.1 
Sacm1l Phosphatidylinositide phosphatase SAC1 -1.6 0.4 
Mtnd4 NADH-ubiquinone oxidoreductase chain 4 -1.6 0.2 
Ndufb7 
NADH dehydrogenase [ubiquinone] 1 beta subcomplex 
subunit 7 
-1.6 0.2 
Parp3 NAD+ ADP-ribosyltransferase 3 PARP-3 -1.6 0.3 
Ttc39a Tetratricopeptide repeat protein 39A, Isoform 2 -1.6 0.06 
Phactr4 Phosphatase and actin regulator 4, Isoform 2 -1.6 0.3 
Hcfc1 Host cell factor 1 -1.6 0.06 
Gm10093 Histone deacetylase -1.6 0.1 
Gcn1l1 GCN1 general control of amino-acid synthesis 1-like 1 -1.6 0.03 
175 
 
Ndufaf1 
Complex I intermediate-associated protein 30, 
mitochondrial 
-1.6 0.5 
Brp44l Brain protein 44-like -1.6 0.3 
Nars Asparaginyl-tRNA synthetase, cytoplasmic -1.6 0.2 
Gm12597 Alpha-interferon -1.6 0.3 
Smpdl3a Acid sphingomyelinase-like phosphodiesterase 3a -1.6 0.3 
Acss2 Acetyl-coenzyme A synthetase, cytoplasmic -1.6 0,2 
Tmem14c Transmembrane protein 14C -1.5 0.4 
Slc35c2 Slc35c2 protein -1.5 0.3 
Shank1 SH3 and multiple ankyrin repeat domains protein 1 -1.5 0.2 
Rab11fip1 Rab11 family-interacting protein 1 -1.5 0.02 
Fadd Protein FADD -1.5 0.1 
Pfdn5 Prefoldin subunit 5 -1.5 0.2 
Mtx2 Metaxin 2 -1.5 0.2 
Mapk14 Mitogen-activated protein kinase 14, Isoform 3 -1.5 0.2 
Ppp1r12a Protein phosphatase 1 regulatory subunit 12A, Isoform 2 -1.5 0.1 
Picalm 
Phosphatidylinositol-binding clathrin assembly protein, 
Isoform 2 
-1.5 0.1 
Carkd 
Carbohydrate kinase domain-containing protein, Isoform 
2 
-1.5 0.3 
Ppip5k1 
Inositol hexakisphosphate and diphosphoinositol-
pentakisphosphate kinase 1 
-1.5 0.06 
Ccdc47 Coiled-coil domain containing 47 -1.5 0.2 
Coq3 Coenzyme Q3 homolog methyltransferase -1.5 0.3 
Ctsb Cathepsin B -1.5 0.2 
Rpl31 60S ribosomal protein L31 -1.5 0.04 
 
 
 
Colonic mucosa from naïve AhR WT and KO mice were analyzed for protein expression, 
as described in Materials and Methods.  Fold changes of  -1.5 compared to WT mice are 
listed in the table. Results are representative of one experiment with n=3. 
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Table 3.  Upregulated protein expression in AhR KO mice 
 
 
 
Colonic mucosa from naïve AhR WT and KO mice were analyzed for protein expression, 
as described in Materials and Methods.  Fold changes of  +1.5 compared to WT mice 
are listed in the table. Results are representative of one experiment with n=3. 
 
 
 
 
Protein Fold Change p-value 
Gapdh Glyceraldehyde-3-phosphate dehydrogenase 1.5 0.3 
Saa1 Serum amyloid A protein 1.5 0.4 
Reep5 Receptor expression-enhancing protein 5 1.5 0.3 
Rab27b RAB27b, member RAS oncogene family 1.5 0.2 
Ndufa7 
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex 
subunit 7 
1.5 0.3 
Obscn Obscurin, Isoform 3 1.5 0.3 
Fkbp5 FK506 binding protein 5 1.5 0.3 
Col5a3 Collagen type V alpha 3 chain 1.5 0.3 
Cc2d2a Coiled-coil and C2 domain-containing protein 2A 1.5 0.3 
Clns1a Chloride channel, nucleotide-sensitive, 1A 1.5 0.3 
Cisd1 CDGSH iron-sulfur domain-containing protein 1 1.5 0.5 
Atrn Attractin 1.5 0.04 
Rpl28 60S ribosomal protein L28 1.5 0.2 
Prkaa1 5'-AMP-activated protein kinase catalytic subunit alpha-1 1.5 0.1 
Psmd9 26S proteasome non-ATPase regulatory subunit 9 1.5 0.3 
Snrpd2 Small nuclear ribonucleoprotein Sm D2 1.5 0.1 
Kcnc3 Potassium voltage-gated channel subfamily C member 3 1.5 0.2 
Ube2d2 Ubiquitin carrier protein 1.5 0.3 
Rangap1 Ran GTPase-activating protein 1 1.5 0.2 
Snrpd2 Small nuclear ribonucleoprotein Sm D2 1.6 0.1 
Mlec Malectin 1.6 0.2 
Cmas N-acylneuraminate cytidylyltransferase, Isoform 2 1.6 0.2 
Hdgf Hepatoma-derived growth factor 1.6 0.1 
Ctsl Cathepsin L 1.6 0.006 
Ist1 IST1 homolog 1.6 0.2 
Nme1 Nucleoside diphosphate kinase (Fragment) 1.7 0.2 
Sh3bgrl3 SH3 domain-binding glutamic acid-rich-like protein 3 1.8 0.04 
Mt1 Metallothionein-1 1.8 0.2 
Pgm3 Phosphoacetylglucosamine mutase 2.1 0.06 
Rps11 40S ribosomal protein S11 2.5 0.1 
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DISCUSSION 
Since our results in both AhR WT and KO mice were quite different than the 
published data, we further investigated the gut of naïve AhR KO mice for factors that 
may contribute the unexpected immune response in TNBS colitis.  Thus, we screened 
gene expression of T helper cell differentiation and NF-kB signaling components.  Gene 
expression data did not indicate an increase in a specific T helper cell subset and actually 
indicated heightened NF-kB signaling response.  Again, these results are consistent with 
the literature in that an exacerbated disease state would be expected in AhR KO mice 
during colitis, which is not what we observed in TNBS-treated colitic mice.   
Proteomic analyses, however, revealed decreased expression of many proteins 
involved in NF-kB signaling, apoptosis, and antigen presentation.  The proteins involved 
in these physiologic pathways have important roles in the intestinal immune system, so 
their decreased expression may at least partially account for the decreased disease 
severity observed in AhR KO mice treated with TNBS.  Dampening NF-kB signaling via 
Card10 and Mapk14 can decrease inflammation.  Since increased gene expression of NF-
kB signaling components was observed, this could be indicative of a compensatory 
mechanism of increasing gene expression due to decreased response to stimuli.  
Decreased apoptosis via Bax and Fadd has been reported to have a protective effect in 
intestinal epithelial cells (IECs), as increased apoptosis in IECs affects barrier integrity 
thereby exacerbating colitis.  In Crohn’s disease patients, apoptotic rates of IECs are 
increased from 2% to 5%, which enables luminal antigens to enter mucosal tissue 
(Schulzke et al., 2006).  Moreover, anti-TNF therapy decreases apoptosis and restores 
epithelial barrier integrity (Zeissig et al., 2004).  Since the TNBS model of colitis 
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revolves around TNBS binding colonic proteins prior to recognition by the immune 
system, decreased antigen presentation would dampen the ensuing immune insult 
typically caused by TNBS.  However, it must be emphasized that protein expression was 
evaluated in whole mucosa and not specific cell populations. Thus, the results may not 
accurately reflect what is occurring in each cell population that can alter immune 
responsiveness in the gut. 
The data presented in Appendix 1 is preliminary so future studies could be 
conducted to confirm these results.  It is also expected that by extending these analyses 
into TNBS-treated AhR WT and AhR KO mice we may be better able to understand how 
gene and protein expression is changed in the context of this potent inflammatory 
stimulus. Ultimately this data could help delineate specific pathways responsible for the 
decreased inflammation observed in our AhR KO mice. 
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